
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

37231000
1481
10.1038/s41392-023-01481-w
Review Article
The blood–brain barrier: Structure, regulation and drug delivery
http://orcid.org/0000-0002-2176-2691
Wu Di wudichem@zju.edu.cn

12
http://orcid.org/0000-0002-5152-0079
Chen Qi 1
Chen Xiaojie 1
Han Feng 3
http://orcid.org/0000-0003-4755-9357
Chen Zhong chenzhong@zju.edu.cn

1
http://orcid.org/0000-0002-1350-2961
Wang Yi wang-yi@zju.edu.cn

12
1 https://ror.org/04epb4p87 grid.268505.c 0000 0000 8744 8924 Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, 310053 Hangzhou, China
2 https://ror.org/0491qs096 grid.495377.b Zhejiang Rehabilitation Medical Center, The Third Affiliated Hospital of Zhejiang Chinese Medical University, 310053 Hangzhou, China
3 https://ror.org/059gcgy73 grid.89957.3a 0000 0000 9255 8984 Key Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing Medical University, Nanjing, China
25 5 2023
25 5 2023
2023
8 21730 11 2022
19 4 2023
27 4 2023
© The Author(s) 2023
2023
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Blood–brain barrier (BBB) is a natural protective membrane that prevents central nervous system (CNS) from toxins and pathogens in blood. However, the presence of BBB complicates the pharmacotherapy for CNS disorders as the most chemical drugs and biopharmaceuticals have been impeded to enter the brain. Insufficient drug delivery into the brain leads to low therapeutic efficacy as well as aggravated side effects due to the accumulation in other organs and tissues. Recent breakthrough in materials science and nanotechnology provides a library of advanced materials with customized structure and property serving as a powerful toolkit for targeted drug delivery. In-depth research in the field of anatomical and pathological study on brain and BBB further facilitates the development of brain-targeted strategies for enhanced BBB crossing. In this review, the physiological structure and different cells contributing to this barrier are summarized. Various emerging strategies for permeability regulation and BBB crossing including passive transcytosis, intranasal administration, ligands conjugation, membrane coating, stimuli-triggered BBB disruption, and other strategies to overcome BBB obstacle are highlighted. Versatile drug delivery systems ranging from organic, inorganic, and biologics-derived materials with their synthesis procedures and unique physio-chemical properties are summarized and analyzed. This review aims to provide an up-to-date and comprehensive guideline for researchers in diverse fields, offering perspectives on further development of brain-targeted drug delivery system.

Subject terms

Drug delivery
Neurological disorders
https://doi.org/10.13039/501100004731 Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LD22H310003 LD22H310003 LD22H310003 LD22H310003 Wu Di Chen Qi Chen Xiaojie Wang Yi https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 82003666 Wu Di National Foundation of Zhejiang Provinceissue-copyright-statement© West China Hospital, Sichuan University 2023
==== Body
pmcIntroduction

Blood–brain barrier (BBB) is a semi-permeable barrier encompassing microvasculature of central nervous system (CNS). In the capillaries, the wedged endothelial cells line in the interior vessels forming extensive tight junctions.1–3 Together with an ensemble of receptors, transporters, efflux pumps and other cellular components, the barrier takes control of entrance and expulsion of the molecules in vascular compartment to the brain. The intact BBB impedes the influx of most blood-borne substances from entering the brain. But it should be noted that at meantime of brain protection, BBB also excludes more than 98% of small-molecule drugs and all macromolecular therapeutics from access to the brain.4,5 The tight gap allows only passive diffusion of lipid-soluble drugs at a molecular weight lower than 400-600 Da. Increasing lipophilicity of the therapeutic agents is a feasible method to improve the BBB permeability. For example, Crizotinib, an oral selective small-molecular tyrosine kinase inhibitor, is an effective anti-cancer medicine but with poor activity against brain tumor metastases due to its low BBB penetration.6 Structural modification of conjugation of a fluoroethyl moiety increases the lipophilicity of Crizotinib and results in enhanced brain permeability.7 However, increasing lipophilicity is not a universal strategy as it may inhibit the biological activity of drugs of interest. Further, therapeutic drugs with high liposolubility have longer retention and duration of action in non-target peripheral organs, causing considerable side effects. In addition, due to the presence of P-glycoprotein (referred to as multidrug resistance associated membrane protein), drugs could be transported back into the blood by ATP-dependent efflux pumps.8,9 Thus, it is urging to address the issue of brain-targeted therapeutics by developing effective and safe delivery strategies.

Spurred by recent development of materials science and nanotechnology, various strategies for regulation of BBB permeability were developed as well as a library of brain-targeted drug delivery systems. Transport routes of the drug molecules across the BBB occurs via the pathways including paracellular and transcellular diffusion, receptor-mediated transcytosis, cell-mediated transcytosis, transporter-mediated transcytosis, and adsorptive mediated transcytosis (Fig. 1a).10 Many efforts have been made in response to each process of the drug transportation, which have also been accompanied by reviews of latest progress in this field, but most of literature emphasize the BBB breakdown in specific brain disorders,11–14 or give a general review of delivery strategies concentrating on the barrier physiology.15,16 On the basis of these strategies, functional materials with small size, tailored architecture and therapeutic motifs that facilitate the targeted drug delivery are widely engineered. They can be constructed by using a wide range of substrates including organic (e.g., liposomes, micelles, hydrogels, etc.),17–19 inorganic (e.g., metal/metal oxide particles, silica nanoparticles, quantum dots, etc.),20,21 and biomass-derived materials (e.g., exosomes, cells, bacteria, etc.).22–24 Improved performance of brain-targeted drug delivery was proved thanks to these materials with obvious advantages including non-invasive delivery, high drug loading, good biocompatibility, prolonged blood circulation, and importantly brain targeting effect. Over the past few years, we have witnessed the booming advances in exploiting materials science and nanotechnology in brain-targeted drug delivery. Brain disorder therapy utilizing tailored systems has been a benefactor of this emergence, yet a timely and comprehensive review is lacking. In the light of excellent performance of BBB crossing strategies for enhanced drug delivery, we will first summarize the structure and different cells contributing to the integrity of BBB (Fig. 1b). Further, main BBB crossing strategies derived are highlighted with relevant transcytosis mechanisms as well as their interactions at barrier interface (Fig. 1c). Specifically, we addressed the issues of different pathways from passive transcytosis, intranasal administration, ligands conjugation for brain targeting, membrane coating for brain targeting, to stimuli-mediated BBB disruption. Then, the updated progress of customized materials was overviewed and how they were fabricated and utilized for the treatment of brain disorders was summarized (Fig. 1d). The discussion of potential translational trials and the remaining challenging in this field will also be presented. This review will be of great interest to those working in materials science, nanotechnology, and especially to those in biomedical engineering and translational medicine, which will not only serve as an up-to-date compilation of achievements in this area, but also provide a generalized guideline for BBB regulation and rational design of targeted drug delivery systems.Fig. 1 Strategies and materials for BBB regulation and brain-targeted drug delivery. a Schematic diagram of different mechanisms for BBB crossing. b Schematic diagram of BBB structure. c Engineered materials for brain-targeted drug delivery. d Various non-invasive strategies for BBB crossing

BBB structure and physiology

Anatomical structure of the BBB

The existence of the BBB was first found by Paul Ehrlich and proved by Edwin Goldmann.25,26 BBB is a spacious, multicellular, and dynamic semi-permeable membrane that isolates the foreign substances in the blood from the CNS.27 The presence of BBB avoids the brain from damage by keeping a stable environment.28,29 But it also limits the drugs that enter into the CNS for treating brain diseases such as neurodegenerative diseases and brain cancer.30,31 Capillaries are the major site of the BBB. Because the neural cell is close to a capillary no further than 25 µm, passaging the BBB for drug delivery is a favored route when compared to another by-passed route which is relatively longer.32 This case pushes researchers to develop effective strategies to regulate BBB permeability and targeted delivery systems to overcome the BBB limits. Some reviews have discussed the BBB recognition which is one of the key steps for enhanced brain-targeted delivery.33–35 For a deeper understating of the interaction between delivery systems and the brain, how the BBB is constructed should be clarified.

From the physiological point of view, endothelial cells, astroglia, pericytes, and junctional complexes including tight junctions and adherens junctions compose the BBB basically.36–39 In this section, we focus on the five constituents mentioned above and others are not covered here.

Endothelial cells

Endothelial cells are considered as the BBB’s core anatomical structure for lining the cerebral blood vessels and interacting with different types of cells in the CNS.40,41 The endothelial cells in the BBB differ from peripheral endothelial cells in morphology and function.42,43 The barrier performance is not the innate properties of endothelial cells.44,45 For morphology, the endothelial cells in the BBB are fastened by both tight junctions and adherens junctions, resulting in distinct lumenal and abluminal membrane compartments.46 They further present with no fenestrations, also known as small transcellular pores, which greatly limit free diffusion and the rapid exchange of molecules between brain tissue and blood.47 Besides, the amounts of mitochondria in endothelial cells in the BBB are higher than in peripheral endothelial cells, which means more energy is needed for transport.48,49 For function, first, they display a net negative surface charge, refusing to accept negatively charged compounds, as well as quite low degrees of leukocyte adhesion molecules, hampering the entry of the number of immune cells.50–52 Second, they show designated transporters for regulating the inflow and outflow of specific substrates.53 Third, they show a restriction on the number of transcellular vesicles through the vessel wall due to the high transendothelial electrical resistance.54,55 Because of the existence of the local environment, endothelial cells can together form and maintain the BBB.

Astrocytes

Astrocytes, also known as astroglia, are the most numerous glial cells, expressing polarized and complex morphology, which are heterogeneous throughout the brain.56 In tradition, they are divided into two categories, that one is protoplasmic which locates in the well-vascularized gray matter, and the other one is fibrous which locates in the less vascular white matter.57–59 Their end feet link them with the basement membrane, via the binding of a set of proteins (aquaporin IV and the dystroglycan-dystrophin complex) with the proteoglycan agrin.60,61 In the CNS, they play a major role in dynamic signaling such as clearing waste, tuning brain blood flow, regulating vascular function, ion hemostasis and balancing neuroimmune responses.62–66 However, the exact role of astrocytes in BBB function is still controversial.67–69 Some studies considered astrocytes can arise barrier behaviors in cerebral, other endothelial cells, and related epithelial, while other studies thought the BBB goes first before the appearance of astrocytes. In this regard, there is no doubt that the BBB exists primarily through the coordination between cells, and astrocytes are a type of neural cells that together with pericytes surround blood vessels in the brain, serving as the interface between neurons and endothelial cells.70,71 Moreover, for invertebrates that lack a vascularized circulatory system, astrocytes are the main components of the barrier separating humoral fluids from the CNS.72

Pericytes

Pericytes are mural cells presenting at intervals along the walls of the capillary blood vessels.73 They are embedded in the basement membrane and lie abluminal to the endothelial cells.74 The length that pericytes covering the CNS endothelium approaches 100%.75 It should be noted that pericytes are central to the neurovascular unit function.76–78 Because of the physical apposition, pericytes and endothelial cells are in close communicate with each other. For example, the PDGF-B signaling pathway is one such communication.79,80 Endothelial cells secrete the PDGF-B to bind PDGFRβ on pericytes, which recruits pericytes to blood vessels.81,82 In turn, pericytes also can release signaling factors to affect endothelial cells by determining the numbers of tight junctions and polarizing the end feet of astrocytes.83 If the amounts of pericytes reduce, the tight junctions between endothelial cells will also be reduced.84 Except for modulating and maintaining the BBB, pericytes also have functions in adjusting cerebral blood flow, vascular development and maintenance, and neuroinflammation.85–87

Tight junctions

In the BBB, tight junctions are the main functional components in sustaining the permeability barrier and controlling tissue homeostasis.88–91 They are also known as occluding junctions or zonulae occludes which can restrict the cross of hydrophilic molecules and macromolecules.92 They reside between endothelial cells, seal the interendothelial cleft, and work as gates and fences to limit paracellular permeability and the lateral diffusion of integral membrane proteins and lipids, thus maintaining cell polarization.93,94 There are many transmembrane and cytoplasmic proteins involved in forming tight junctions. Claudins and occludins that situate in two-cell contacts are the major tight junction proteins.95,96 Claudins display essential barrier function and occludins ensure the tightness of the tight junctions.97 Tricellulin and the lipolysis-stimulated lipoprotein receptor that reside in three-cell contacts are also the major tight junction proteins.98,99 Besides, more like junction adhesion molecules, calcium/calmodulin-dependent serine protein kinase, monoclonal antibody 7H6, and heterotrimeric G protein also contribute to the constitution of tight junctions.100–103 Junction adhesion molecules mediate the early attachment in the BBB developmental processes.104,105 Kinase-like proteins modulate the blood–brain barrier permeability.106 Interactions among these proteins provide physical support for the complex of tight junctions.107 Downregulation of tight junction-related proteins will loss of the BBB phenotype.108

Adherens junctions

Adherens junction is extra crucial for the BBB structural integrity and appropriate assembly of proteins of tight junctions.109,110 At cellular interfaces, they build spatially, chemically, and mechanically discrete microdomains.111 In common with tight junctions, adherens junctions are linked to the cytoskeleton and consisted of transmembrane and cytoplasmic plaque proteins.112,113 Vascular endothelial-cadherin, scaffolding proteins catenins, scaffolding proteins p120, plakoprotein are the main components of adherens junctions.114,115 Vascular endothelial-cadherin primarily is associated with cell-to-cell adhesion.116,117 It is a homo-dimeric transmembrane protein whose extracellular domain can connect with the other same molecules of neighboring endothelial cells in the paracellular cleft, and the cytoplasmic domain can interact with the actin filaments via scaffolding proteins.2 In the meantime, catenins, p120, plakoprotein are responsible for supporting physics and regulating junctions by forming a bridge that interacts with zonula occludens-1 (tight junctions proteins) and the actin filaments.118,119 Besides, other proteins, such as platelet and endothelial cell adhesion molecule 1, CD99, and nectin, have been reported that might be related to the adherens junction.120–122 Totally, adherens junctions are fundamental for the integrity of BBB, any change of adherens junctions may disrupt inter-endothelial cell connections.123

Physiology of the BBB

The existence of BBB provides a controlled microenvironment by regulating the exchange of ions and molecules between the bloodstream and brain tissue. Numerous studies have revealed the physiological functions of the BBB such as brain protection. In addition to physical restriction of the potentially harmful substances, the BBB also plays multiple roles in maintaining homeostasis,124,125 facilitating transport of the essential molecules,126 regulating inflammation127,128 and so forth. The BBB maintains the brain homeostasis by regulating the specific ions channels and transporters. For example, Na+, K+, Ca2+, Cl− are the major ions in the CNS, which should be kept at an optimal level for neural and synaptic signaling functions. These ions are asymmetrically distributed between luminal and abluminal membranes, of which efflux and influx were mainly dependent on the ion transporters on BBB. For example, the influx of Na+ and the efflux of K+ are regulated by abluminal Na-K-ATPase against the concentration gradient for maintenance of the electrochemical gradient across the cell membrane.129 Meanwhile, cotransporters such as NKCC1 regulate the ion balance by transporting Na+, K+, Cl−.130 The dysfunction of the ion transporters may induce the pathological alterations. Other BBB transporters such as solute carriers and ATP-binding case families control the transport of other essential molecules, metabolites and nutrients, maintaining the brain homeostasis.131 Intriguingly, pathways through the junctional complex or across the cells actively that participate in transport of ions, nutrients and other molecules could also be potential routes for drug delivery, which is discussed in detail in Section 3.1.

Strategies for BBB regulation and crossing

Brain tumors, cerebrovascular diseases, and neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis, are serious CNS diseases.132 However, therapies for these challenging diseases are limited, because of the lack of effective methods, to enable drugs surpass natural protective hindrances to maintain homeostasis within the brain for preventing the entry of drug molecules to the CNS.133 A number of drugs are routinely administrated by invasive strategies for the management of these diseases and symptom control. For instance, intrathecal drug administration is a typical method for drug delivery into the entire ventricular system without passing through the BBB.134,135 It has been approved to deliver anti-sense oligonucleotides for the treatment of spinal muscular atrophy.136 Other invasive strategies including convection-enhanced delivery,137,138 intracranial implantation,139,140 and deep-brain stimulation were developed for brain drug delivery.141,142 Recent development of microneedle and polymeric wafers with minimal invasiveness provides sustained drug release for CNS disease management which circumvent the BBB.143–146 But the potential risks from brain exposure and damage of these invasive strategies limited their applications for long-term use. In order to efficiently deliver drugs into the brain with safety and precision, various non-invasive strategies to overcome BBB have been exploited. These strategies include BBB penetration via passive transcytosis, intranasal administration, ligands conjugation, membrane coating, and the BBB disruption using light, focused ultrasound, biochemical reagents, and radiation.

Passive transcytosis

Passive transcytosis, also known as non-specific transfers, has two possible routes across the microvascular endothelial layer, via paracellular and transcellular.147

The paracellular pathway is the principal route blocked by the tight junctions of cell gaps, restricting ions, polar solutes, and most macromolecules.148 But the tight junctions are not perfect, small and soluble substances could sufficiently cross through the paracellular pathway.149 Typically, BBB is destroyed in some brain diseases. One strategy for therapeutics to use the paracellular pathway is by downregulating the expression of tight junction proteins. For example, a modulator called minoxidil sulfate (MS) that anchored the potassium channel, enhances shipping by attenuating the tight junction proteins.150 Zhou et al. developed brain tumor-targeting ligand-modified nanoparticles named CTX-mHph2-III-62%, inside which co-encapsulation of three modulators, minoxidil, lexiscan, and NECA.151 If without further engineering, the ability of terpolymer III-62% to penetrate the BBB is limited. Through co-encapsulation, such nanoparticles could release BBB modulators in the local tumor site, which adjust the permeability of BBB in the paracellular pathway to ensure more nanoparticles in the same area. Besides, Han et al. developed M@H-NPs using hyaluronic acid-based nanoparticles to load minoxidil, which can target brain metastatic tumors.152 Hyaluronic acid can specially target cell surface receptor CD44, which is highly expressed in breast cancer.153 With the help of the CD44 target and MS boost, M@H-NPs could penetrate blood–brain tumor barrier (BTB), internalizing into brain metastatic tumor cells (BMTCs), blunting drug efflux at BMTCs, and producing effective treatment which can extend the median survival time in breast cancer brain metastases models.

The transcellular pathway is the preferable route for carriers to enter and transport therapeutic compounds, when compared to the paracellular pathway. In brief, the molecules can partition into the cellular membranes from the top to the bottom lateral side through carrier-mediated and receptor-mediated transcytosis.154 In particular, lipophilic carriers and some other known carrier systems like cationic amino acids are mainly transported via the transcellular pathway. For instance, Allan et al. showed targeting is possible in intracerebral hemorrhage (ICH) using lipid nanoparticles.155 They fabricated a liposome HSPC:CHOL: DSPE-PEG2000 and injected them into ICH mice. Brain liposome accumulation was measured via radioisotope and optical detection methods, in order to investigate the kinetics of the liposome across the brain. From their results, after injection, the entry of liposome amounts peaked at 3 h and 48 h, which provided evidence that by utilizing transcellular pathways, liposomes can gather at the lesion site through self-diffusion. Gu et al. modified OX26 antibody to the surface of PEGylated cationic lipid nanoparticles to load baicalin, which was known as OX26-PEG-CSLN.156 OX26-PEG-CSLN not only can deliver drugs across BBB but also can adjust the changes of extracellular amino acids. OX26-PEG-CSLN showed a stronger effect than the baicalin solution., which might be attributed to the more enhanced ability to penetrate the BBB and prolong the valid time of the drugs.

The tightness of the BBB precludes the entrance of most pharmaceuticals into the brain via passive transcytosis, except for hydrophilic compounds which have a mass lower than 150 Da and highly hydrophobic compounds which have a mass lower than 400–600 Da.157,158 For this reason, if passive transcytosis is demanded to realize the delivery of the drugs at higher molecular weight, some strategies to enhance the BBB permeability or break BBB temporarily will be desired.

Intranasal administration

Intranasal administration is a non-invasive route, allowing rapid brain targeting from nose to brain, when compared to direct injection by intraventricular and intraparenchymal into brain tissue.159 Except for those cleared drug molecules by mucociliary clearance, the remains of drugs entered the nasal cavity via neuronal pathway and systemic circulation. As depicted in Fig. 2a, the perineural and perivascular regions of the olfactory and trigeminal nerves are major contributors to the process of the target after intranasal administration. There are three nose-to-brain pathways: (1) Olfactory nerve-olfactory bulb-brain; (2) Trigeminal nerve-brain; and (3) Lungs/ Gastrointestinal tract-blood–brain.160 Among them, (1) and (2) are the major routes through neuronal pathways while (3) is the minor route through the systemic circulation. Specifically, (1) is the shortest and most direct route. It has been used advantageously to deliver drugs at high speed. It was possible to complete the delivery within the time window of 1.5-6 h, and even the route via olfactory epithelial cells takes only a few minutes.161 (2) is also a direct route of drug delivery, because the trigeminal nerve locates in not only the respiratory region but also the olfactory region. The trigeminal nerve has three branches, each of them joined to the brain stem and olfactory bulb, mainly liable for sensating pain and temperature.162 (3) is an indirect route connected to the systemic circulation involving the gastrointestinal and respiratory systems. It belongs to systematic circulation, which may cause extensive drug metabolism. To sum up, the amount of indirect delivery of drugs, when compared to direct delivery, is probably less, due to unexpected elimination in the body.Fig. 2 Intranasal administration allows rapid brain targeting from nose to brain. a Schematic illustration of the routes from the nasal cavity to the brain. b Transmission electron microscopy and structure schematic images of LENK nanoparticles. c The change of concentration of LENK in the olfactory bulb and cerebrum after the administration of nanopeptide or as the peptide alone. b, c Reproduced with permission. Copyright 2017, Elsevier. d Dynamics of fluorescence in rat trigeminal nerve. e Fluorescence intensity in the trigeminal nerve. f CSF concentration of Alexa-dextran. g Dynamics of MPEGePCLeTat complex in brain tissue. Reproduced with permission. d–g Reproduced with permission. Copyright 2013, Elsevier

Intranasal drug delivery systems, as one of the important brain-targeted systems, possess the ability to pass through the BBB using above discussed nose-to-brain pathways. Uchegbu et al. constructed a nano-peptitde with a 30–60 nm particle size, encapsulating leucine5-enkephalin hydrochloride (LENK), and proved this nanoparticle was able to transport LENK through intranasal administration (Fig. 2b, c).163 The results presented that after administered, LENK was found in the olfactory bulb, but into the brain it was hard to find them. But using the formulations of nanoparticles, the brain distribution of LENK was facilitated, with no peripheral exposure, and within the thalamus and cortex, nanoparticle localization can be observed. Similarly, in another study, Seta et al. developed nano micelles MPEG-PCL-Tat for intranasal administration using a cell-penetrating peptide (Tat), who is derived from HIV, to modify nano micelles, which were comprised of polyethylene glycol-polycaprolactone polymers (Fig. 2d–g).164 Functionally, this system played an important role to deliver siRNA to the brain. The authors harvested nasal olfactory mucosa or olfactory bulb, and prepared frozen samples of that, demonstrating the pathway of nucleic acid transfer using the system, focusing on the major nose-to-brain pathways involving olfactory nerve and trigeminal nerve.

Due to the unique anatomical relationship between the CNS and the nasal cavity, relatively quick along with easy access for nanodrugs to the brain could be realized via intranasal administration. However, there are also some limitations, including the difference in the shape of respective nasal cavities, the exact dosing of intranasal drugs, the mucociliary elimination, and the drainage to the pharynx or to the lower part.165 Moreover, the health status of the body also needs to think, otherwise, maybe someone occurs conditions such as allergies or colds, which is not suited for intranasal administration. It appears the outcomes of delivery by the nasal route differ widely between the studies.166 Thus, the nasal route to deliver drugs into the brain is rather immature and more high-quality drug delivery systems should note to solve the above-motioned limitations.

Ligands conjugation for brain targeting

Ligands conjugation is an active targeting strategy using ligands that have high specificity toward the receptor expressed on the brain endothelial cells.167 As shown in Fig. 3a, here we take transferrin receptors, insulin receptors, low-density lipoprotein receptors, and folate receptors as examples.Fig. 3 Ligands conjugation is an active targeting strategy using ligands that have high specificity toward the receptor on the endothelial cells of the brain. a Schematic illustration of receptor-mediated drug delivery using ligands conjugated nanoparticles to the brain. b The MRI images of the brain of glioma-bearing mouse. The photo and micrograph image of glioma which was removed from U87-MG glioma nude mice. c Real-time imaging of the U87-MG glioma nude mice. b, c Reproduced with permission. Copyright 2020, Ivyspring International Publisher. d Microscopic visualization of nanoconjugates after permeating the BBB. Scale bar: 20 μm. Reproduced with permission. Copyright 2022, American Chemical Society. e Biodistribution results of NIR-797-labeled NP-5N and NP-5N-FRα-FA in ICR mice. Reproduced with permission. Copyright 2019, American Chemical Society

Transferrin receptor as a glycoprotein, has two subunits of 90 kDa linked by a disulfide bridge, participating in the transcytosis of cellular iron by each subunit is capable of binding to one molecule of transferrin.168 There have been a lot of studies undertaken using transferrin ligands. Rao et al. formulated a di-block polymer of Poly-lactic-co-glycolic acid (PLGA) and hetero bi-functional COOH-PEG-NH2, embedded with an imidazotetrazine alkylating agent (TMZ), and conjugated to a ligand (polysorbate-80/transferrin) and a stem cell targeting moiety (anti-nestin antibody).169 Such nanocomposites having targeting ligands could deliver TMZ to intracerebral glioblastoma xenografts and present favorable pharmacokinetics and anti-cancer potential. Qi et al. used RI7217, a monoclonal antibody from mouse, which shows high selectivity and sensitivity for the transferrin receptor, to modify long-circulating liposomes (Fig. 3b, c).170 In their research, hCMEC/D3 cells and U87-MG glioma cells were used to evaluate the uptake and mechanism of the targeted liposomes, and intracranial U87-MG glioma was used to test the capacity of the targeted liposomes to cross the BBB and anti-tumor. They concluded that RI7217 antibody decoration is a promising strategy to make a drug delivery system towards brains at the end. Xie et al. optimized dual-mediated liposomes with transferrin and cell-penetrating peptide.171 Firstly, in order to construct the rational dual-mediated liposomes, they screened the different PEG molecular weight which is used for connecting transferrin and cell-penetrating peptide (CPP) with liposomes and the densities of ligands. Then, they evaluated the permeability for the BBB of the liposomes to confirm the role of transferrin, and the behaviors of cellular internalization and lysosomal escape to confirm the role of CPP. Meanwhile, nude mice were used as models to trace Tf-CPP-SSL in vivo, demonstrating this drug delivery system performed well in brain targeting and prolonged circulation. However, it should be noted that ligands could not be easily separated from the transferrin receptor and the internalization by endo/lysosomes also compromised the detaching. For this reason, Gao and his group developed a series of nanoplatforms on the basis of acidic cleavable ligand modification.172,173 For example, acid-sensitive imine linker (DAK) was conjugated with D-T7 peptide on the nanoparticle surface, which would break up in acidic environment, facilitating the endo/lysosomal escape.174 The system was demonstrated to have significant BBB transcytosis enhancement and was employed for further use in the treatment of autism spectrum disorder. Such responsive strategy mitigates the defects of transferrin receptor-mediated transcytosis.

Insulin receptors are highly expressed in the brain, not only in the hypothalamus, olfactory bulb, hippocampus, and striatum, but also in cerebral cortex, and cerebellum.175 Insulin could bind to the α-subunits of insulin receptors which locate outside of the cells, inducing the β-subunits which locate in the inside of the cells dimerization and autophosphorylation.176 When compared to insulin, insulin-like growth factor 1 (IGF1) showed relative lower binding affinity to insulin receptors.177 Similar intracellular signaling pathways could be initiated by both insulin and IGF1 receptors. Jörg et al. employed human serum albumin (HSA) nanoparticles to couple insulin or an anti-insulin receptor monoclonal antibody covalently.178 They used loperamide as delivered drugs inside HSA and evaluated the potential of loperamide across the BBB. Loperamide-loaded and insulin-modified HSA presented an increase in size because of the existence of insulin agglomeration on the surface, demonstrating the successful preparation of such insulin-targeting nanoparticles using NHS-PEG-MAL5000 crosslinker. After being injected through the tails of ICR (CD-1) mice, the NP showed significant antinociceptive effects which means loperamide was able to be transported across BBB. Frey II et al. investigated the delivery of IGF1 to CNS, confirming they reached CNS target sites of rats by administering a mixture of [125I]-labeled IGF1.179 The results from high-resolution phosphor imaging autoradiography established the specific binding of IGF1 and binding sites. Further, they proved IGF1 could activate different signaling pathways in diverse CNS areas.

Low-density lipoprotein receptor-related protein (LRP) as a transmembrane glycoprotein can mediate the uptake of cholesterol-rich low-density lipoprotein, including cholesterol, tocopherol, and Apos.180 The family of LRP has a lot of members, such as LRP-1, low-density lipoprotein (LDL) receptor-related protein 1B, megalin/LRP-2, apolipoprotein E receptor 2, sortilin-related receptor, LRP-5, and LRP-6.33 Previously, our group has reported an angiopep-2 (a dual-targeting ligand towards LRP-1) modified nanogel for targeted delivery of anti-epileptic drugs.181,182 The brain accumulation of electro-responsive nanogels was significantly improved by the functionalization. Interestingly, although the mechanism remains to be explored, the nanogel was found to distribute at temporal lobe which is the common brain region of epileptic focus. Chung et al. synthesized nanoparticles conjugated with angiopep-2 which have core-shell structure, to target and treat glioma.183 They proved the decoration of angiopep-2 can improve selective glioma targeting for the amounts of cellular uptake of nanoparticles by C6 glioma cells were higher than that by L929 fibroblasts. Besides, when to contrast the control group, intravenous injection of these angiopep-2 decorated nanoparticles could achieve a 10-fold diminution in tumor volume. Holler and co-wokers reported six peptide vectors were attached to a poly(β-l-malic acid)-trileucine polymer (Fig. 3d).184 These peptides could act the specific targeting function, aiming at low-density lipoprotein receptor-related protein-1, transferrin receptor, bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex. They studied the ability of nanoconjugates to cross the BBB extensively, including tumor-bearing brains, Alzheimer’s disease-like brains, and healthy brains. What’s more, they conducted molecular mechanisms about regulating cross-talks between transcytosis pathways.

Folate receptors, high-affinity receptors, could mediate the cell uptake of folate or folic acid (FA), anticipating DNA synthesis and nutrient provision.185 They are in relatively common use in the design of drug delivery systems. Zhang et al. demonstrated a grapefruit-derived nanovector (GNV) coated with folic acid to carry miR17 for treating the GL-26 brain tumors which is one kind of the folate receptor-positive tumors.186 They found GNV reduces the toxicity of the polyethylenimine, which was used for the load of RNA, and FA-GNVs show better targeting behavior than GNVs with rapid movement into the brain within 1.5 h. Shu et al. constructed a folate-modified polymeric micellar delivery system using the thin-film hydration method.187 The delivery drug was pterostilbene (Pt) and the main structure of this system was contributed by mPEG-PCL. Compared to free Pt/mPEG-PCL, FA-Pt/mPEG-PCL showed enhanced toxicity toward folate receptors-overexpressing A172 cells, which proves folate anticipated in the condensation of Pt in A172 cells through folate receptor-mediated route. Additionally, in vivo, they analyzed the BBB penetration value and drug targeting index, illustrating the developed delivery system had great potential for brain delivery. Sosnik et al. produced poly(ethylene glycol)-b-poly(ε-caprolactone) block polymers and functioned them in the edge with folate receptor alpha (FRα) and FA (Fig. 3e).188 Modified nanoparticles showed better compatibility and greater internalized extent by primary human choroid plexus epithelial cells. After intravenous administration, the biodistribution of unmodified nanoparticles and FRα-FA-modified nanoparticles was tested. As results showed from the systemic circulation, the introduction of FRα and FA to the surface of nanoparticles promote brain accumulation.

Membrane coating for brain targeting

Recently, cell membranes as a new root of materials have gained wide focus. They have unique characteristics coming from their parent cells, including the natural functionalities and transmitting information networks that could conquer many obstacles confronted in vivo.23 Thanks to the multiple molecular interactions (hydrogen binding, electrostatic interaction, π interaction, etc.) and specific receptor recognition, between the membranes and potential substrates, the membranes of interest could be serve as the outer layer of the delivery systems.189–191 For this reason, many drug delivery systems based on different cells’ membrane coating, such as red cell membrane, brain tumor cell membrane, immune cell membrane, and so on, could endow the brain targeting abilities (Fig. 4a).192–194Fig. 4 Cell membranes donate drug delivery systems with the brain targeting abilities. a Schematic illustration of examples of cell membrane coating strategies. b The fluorescence images of orthotopic U87-Luc glioblastoma tumor. c In vivo pharmacokinetics. d Quantification in different organs and tumor of (doxorubicin) DOX accumulation. b–d Reproduced with permission. Copyright 2018, Wiley-VCH. e The analysis of PD-1 levels on different phenotypes of macrophages. f The analysis of the PD-1+ cell ratio in different types of macrophages. g The fluorescence images pictured in groups of PLGA/DiR and PD-1-MM@PLGA/DiR. h Immunohistochemistry staining images. Scale bar: left 1 mm; right 50 μm. e–h Reproduced with permission. Copyright 2022, American Chemical Society. i Schematic illustration of the process of NK@AIEdots to inhibit the growth of the brain tumor. Reproduced with permission. Copyright 2020, American Chemical Society

Red blood cells, or erythrocytes, have been exploited as delivery systems due to the advantages of prolonging the life span of drugs in circulation and preventing drugs from immune clearance for many years.195 They are easy to obtain and have uniformed size and shape. CD47 proteins rich on the red cell membrane ensure red cell membrane-coated systems can circulate almost 100–120 days without being cleared by macrophages.196 Lu et al. used a facile method of avidin-biotin chemistry to modify the red blood cell membrane with CDX peptide, which shows high bond towards nicotinic acetylcholine receptors.197 They demonstrated successful preparation of the modified blood cell membrane-coated systems and loading of DOX. And they verified the red cell membrane coating could improve the circulation time of the systems and locate them close to tumor vessels. Both targeting and therapeutic efficiency studies in cells and in animals illustrated that red blood cell membrane-peptide-coated systems not only had the capability to traverse the BBB, displaying exceptional brain targeting effect, but also could release DOX and prolong the survival of mice. Shi’s group developed a biomimetic nanoparticles by modifying angiopep-2 to the surface of red blood cell membranes to camouflage polymer which was pH-sensitive and coload with anti-cancer drug DOX and BBB regulator lexiscan (Fig. 4b–d).198 The system with low immunogenicity and systemic toxicity improved blood cycle time and tumor accumulation in U87MG glioblastoma tumor-bearing nude mice.

Brain tumor cell membrane, originated from brain tumor cells, tend to have homotypic targeting, long-time circulation, and BBB crossing abilities.199 Specific membrane proteins, such as focal adhesion proteins, integrin, focal adhesion kinase, and ras homologous family proteins, contribute to the functions of brain tumor cell membrane-coated systems.200 Liu et al. fabricated lanthanide-doped nanoparticles with the coating of brain tumor cell membrane, which can be used for brain tumor visualization and surgical navigation in the window from 1500 nm to 1700 nm in near-infrared-IIb.201 Because of the existence of the cell membrane from the brain tumor, this nanoparticle could easily home to the tumor site. They compared the particle with indocyanine green which is a clinically approved imaging agent, and discovered this particle had a superior resolution with lower background signals, offering a clear view of the location of the tumor.

Immune cell membranes, like their mother immune cells, are a promising choice for constructing drug delivery systems, showing great biocompatibility and unnoticeable adverse effects to normal cells.202

Macrophages play important part in the physiological microenvironment and the polarization of their phenotypes affects tumor progression and metastasis directly. In response to neuroinflammation, macrophages could be activated into anti-inflammatory state, serving as protectors digesting cell debris and pathogens, as well as releasing anti-inflammatory factors and activating other immune cells. Thus, the macrophage-based strategy for drug delivery harnesses the prolonged circulation time, abundant surface receptors, and active targeting ability of macrophages under specific phenotype.203 Wang et al. enhanced programmed cell death-1 expression on macrophage membranes and coated them onto rapamycin (RAPA)-loaded PLGA core to fabricate a novel nano-platform (PD-1-MM@PLGA/RAPA) (Fig. 4e-h).204 Macrophage membranes help the nano-platform to travel across the BBB in response to multiple chemokines. Programmed cell death-1 expression on macrophage membranes optimized the efficacy of immunotherapy, due to the PD-1/PD-L1 signal axis blockade. RAPA, as model drug, could induce cancer cell death and complement immunotherapy. This novel nano-platform provided an anti-glioblastoma multiforme (GBM) strategy through the combination of chemotherapy and immunotherapy. Their results showed more tumor-infiltrating immune-stimulatory cells, especially CD8+ cytotoxic T-lymphocyte, were recruited and triggered the release of anti-tumor cytokines, magnifying the anti-tumor effect. Sun et al. attached rabies virus glycoprotein and triphenylphosphine cation molecules on the macrophages membrane and coated them to solid lipid nanoparticles (SLNs), constructing RVG/TPP-MASLNs for delivering natural antioxidants Genistein (GS) to neuronal mitochondria which is a new curative target for Alzheimer’s disease.205 The MA membranes provided RVG/TPP-MASLNs with favorable biocompatibility and reticuloendothelial system evasion behaviors. In addition, the combination of MA membranes and functional ligands endowed RVG/TPP-MASLNs with the capabilities for double targeting including neuronal targeting and mitochondria targeting.

Neutrophils are the main type of white blood cells defensing against the pathogens and could migrate from circulation to injured brain region by crossing the BBB. Upon recruitment, the membrane adhesion proteins such as intercellular adhesion molecule-1 on endothelial cells are up-regulated, and the proteins including integrin β2, macrophage-1 antigen, and lymphocyte function-associated antigen 1 are overexpressed on the neutrophil membrane, together facilitating the transmigration.206 Chen et al. proposed a “nanobuffer”, (LA-NM-NP/CBD), that has a clear structure.201 The inner core consists of PLGA nanoparticles and reactive oxygen species (ROS)-scavenging cannabidiol (CBD). The neutrophil membrane serves as the shell to orient to the infarct core while α-lipoic acid (LA) serves as the corona to scavenge ROS. They used LA-NM-NP/CBD to change the adverse environment of the brain and take care of the salvageable penumbra for the therapy of ischemic stroke.

Natural killer (NK) cells are large granular lymphocytes and can naturally undergo immunosurveillance of diseased/stressed cells.207 With the assistance of inhibitory and activating receptors on the cell surface such as LAF-1 and VLA-4, they could efficient target specific cells, providing the potential of brain-targeted delivery. They can directly bind to cancer cells via receptors and kill them without prior sensitization. Tang and co-workers developed nanorobots by coating an aggregation-induced emission-active polymeric endoskeleton with a membrane from NK cells to mimic NK cells (Fig. 4i).208 The mechanistic studies demonstrated that receptors from NK cells to the surface of the nanorobots, play a major duty in BBB traversing and tumor identification. Besides, with help of a laser, the AIE-active conjugated polymer could be a tight junction modulator, helping to disrupt the tight junction and making this nanorobot cross the BBB easier.

External stimuli-mediated BBB disruption

To regulate the BBB permeability, external stimuli-mediated BBB disruption based on the energy conversion materials has been widely explored. Such strategies can be manipulated with various external stimulations, such as light, ultrasound, electroacupuncture, etc.

Light has been widely used due to its advantages, such as spatiotemporal precision, minimized scattering and domestic nonlinear absorption.27 As mentioned in the above chapter, light could help to open the BBB, inducing specific changes in the integrity of BBB. This phenomenon is temporary and could recover. In 1990, Eggert et al. investigated the Nd:YAG laser irradiation.209 They found laser irradiation immediately caused BBB breakdown which looked to be associated with structural damaged regions of brain microvessels. Besides, it suggested that laser-induced BBB abnormality or impairment is monophasic. After irradiation, the BBB dysfunction peaked at 2 h and persisted for 24 h approximately. However, the effects on brain from the irradiation is highly dependent on power intensity, irradiation time and distance between laser source and targeted area, which in all contributed to the temperature elevation. Thanks to the development of temperature measurement technology, researchers are able to monitor the temperature in a non-contact manner. Among all, near-infrared light (NIR) at the wavelength from 700 to 1600 nm has attracted great attention in this field due to its deep tissue penetration.210–212 In recent studies, NIR irradiation for BBB permeability regulation was applied under infrared thermal monitoring and the head temperature was kept lower than 43 °C. At this power intensity, the irradiation caused negligible brain damage confirmed by histological staining.213,214 The reduced transendothelial electrical resistance of cellular monolayer induced by irradiation could recover within 10 min.215 In 2011, Choi et al. reported without compromising vascular integrity, the ultrashort pulsed laser could induce transient leakage of blood plasma.216 They combined the ultrashort pulsed laser with a systemic injection to deliver target molecules to brain cortex and different other tissues. This strategy allowed invasive local delivery to an extremely small extent. In 2018, Guo and co-workers demonstrated that 2D black phosphorus nanosheets that possess excellent photothermal effects can be a new neuroprotective platform to selectively capture Cu2+ for treating neurodegenerative disorders.214 Under near-infrared irradiation, local hyperthermia for five minutes with the temperature at 41–43 °C increased the generation of tiny mechanical waves thus increasing the BBB permeability. Their results showed that the power density of light could be kept over 37% of the original value and the depth could be ~1.3–2.6 mm for the mouse brain. In addition, they studied the risk of cerebral thrombosis using nuclear magnetic resonance imaging and found no obvious cerebral thrombosis, which means the black phosphorus nanosheets have great potential in future clinical applications. In 2019, Wang and co-workers also designed black phosphorus nanosheets-based drug delivery system for loading with the antidepressant drug, Fluoxetine.217 They conducted the release ability of fluoxetine and proved 90% of the drugs could be released under 30 min light irradiation. For in vivo studies, they reported, with near-infrared irradiation, the local temperature was kept at 41–43 °C for five minutes. Finally, they compared free fluoxetine and black phosphorus nanosheets loaded fluoxetine and got the conclusion that black phosphorus nanosheets loaded fluoxetine shorted the therapy time of depression with the help of light. In 2021, Qin et al. modulated BBB by using light boost of molecular targeted nanoparticles, the synthesized gold nanoparticles, which were conjugated with the antibody BV11.218 Their results showed after light stimulation of BV11 modified gold nanoparticles, tight junctions of BBB ameliorated, allowing particles like macromolecules and virus to cross. Brain microvasculature and parenchyma were also examined. There were no obvious disruptions in vast dynamics or neuronal injury. Recently, an electro-responsive dopamine-pyrrole hybrid system that improved the delivery efficiency of anti-epileptic drugs by improving the cross of BBB via the combination of receptor-mediated transcytosis and photothermal conversion of NIR were reported.215 This system was smart for epilepsy pharmacotherapy, showing enhanced conductivity and sensitivity in various seizure models, including acute seizure, continuous seizure, and spontaneous seizure. The authors realized two hours sustained and 30 s rapid release of phenytoin and reduced drug dosage.

Ultrasound is a technique that can noninvasively focus deep into the body using an ultrasound field.219 They are mechanical or elastic vibrations in a medium of a frequency above the range of human hearing (18–20 kHz).220 Since the 1940s, ultrasound has been noted for non-invasive ablation in the brain.221 For ultrasonic BBB disruption, varied sonication parameters can cause different impacts, including the threshold pressure, the magnitude, and the drug quantity for delivering.222 In recent years, gas-filled microbubble has emerged as a contrast agent in conjunction with ultrasound for opening the BBB in an image-guided and targeted manner, ensuring the local delivery of drugs.223 Qin et al. constructed a microbubble delivery system, fixing quercetin-modified sulfur nanoparticles.224 In combination with ultrasound, this system could accumulate in the brain and promote drug delivery because of the transient opening of the BBB. Moreover, Qc@SNPs-MB effectively treated Alzheimer’s disease by protecting nerve cells and reducing endoplasmic reticulum stress which comes from oxidative stress, inflammatory response, calcium homeostasis imbalance, and neuronal apoptosis. Price’s group utilized gas-filled microbubbles for the selective transfection of endothelial cells of the cerebral vasculature.225 The negative mCherry plasmid was conjugated to cationic microbubbles. Such microbubbles have good stability. Their method through the oscillating of microbubbles under the ultrasound field could implement the transport of the gene product beyond the blood vessels without breaking the tight junctions and disrupting the BBB. To be noted, one highlight of this study is the experiments on cell identification and enrichment of whole-brain tissue samples, demonstrating their strategy achieved around 90% cell specificity of selective transfection with no extra use of a cell-specific promoter.

Electroacupuncture is a widely accepted complementary therapy through stimulating acupoints, although there is limited supporting information in modern anatomical studies.226 Studies found that electroacupuncture stimulation at certain parameters could improve the permeability of the BBB.227 Lin and co-workers found the Baihui and Shuigou acupoints are ideal regions to use for electroacupuncture for 40 min to open BBB.228 However, research on the application of nanomaterials in synergy with electroacupuncture in the brain has not yet been found. We believe there will be improvements in this cross-field in the future.

Other non-invasive strategies

Besides the widely used strategies that have been discussed before, among which active strategies for BBB regulation and crossing are summarized in Table 1, there are more strategies that people used to achieve the intention of brain-targeted drug delivery (Fig. 5a).Table 1 Active strategies for BBB regulation and crossing

Strategy	Material/technique	Advantage	Specificity	Refs.	
Ligands conjugation	Transferrin	High specificity	Affinity to transferrin receptor	169,171	
RI7217	High selectivity and sensitivity	Affinity to transferrin receptor	170	
Acidic cleavable ligand-modified peptide	Facilitating the endo/lysosomal escape	Affinity to transferrin receptor	172–174	
Insulin or anti-insulin receptor monoclonal antibody	Highly expressed	Affinity to insulin receptor	178	
IGF1	Activate different signaling pathways in diverse CNS areas	Affinity to IGF1 receptor	179	
Angiopep-2	High BBB transcytosis capacity	Affinity to LDL receptor	181–183	
Six peptide vector	Muti-specific targeting function	Affinity to low-density LRP-1, transferrin receptor, bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex	184	
Folate	Compatibility and internalized extent	Affinity to folate receptor	186–188	
Membrane coating	Red cell membrane	Long circulation and preventing from immune clearance	Affinity to CD47 proteins receptor	195–198	
Brain tumor cell membrane	Homotypic targeting and long-time circulation	Affinity to focal adhesion proteins, integrin, focal adhesion kinase, and RHO family protein	199–201	
Macrophage membrane	Favorable biocompatibility and RES evasion behavior	Polarization of their phenotypes affects brain tumor progression and metastasis	204,205	
Neutrophil membrane	Pass across tissues and walls of veins	Affinity to infarct core and inflammatory cytokine	201	
Natural killer cell membrane	Directly bind to cancer cells via receptors and kill them without prior sensitization	Naturally undergo immunosurveillance of diseased/stressed cells	207,208	
External stimulation	Light (NIR)	Minimized scattering, domestic nonlinear absorption, and deep tissue penetration.	Help to open the BBB, inducing specific changes in the integrity of BBB	209,213–218	
Gas-filled microbubble/Focused ultrasound	Deep tissue penetration.	Non-invasive ablation	219–225	
Electroacupuncture	Improve the BBB permeability	Stimulating acupoints	226–228	
Biochemical reagents	Adjust the penetration	Shrink the endothelial cells of the brain	229,230	
Other active strategies	AAVs	High efficiency	Specific molecules identified on the luminal surface of the BBB	231,233–236	
Bacteria	Act as antigens	Target and penetrate	237,238	
Redox-sensitive systems and cytokine-mediated system	Responsive and sensitive	Developed for oxidative stress and the pro-inflammatory state	239–244	

Fig. 5 Other strategies can achieve the intention of brain-targeted drug delivery. a Schematic illustration of examples of other strategies. b Fluorescence images using in vivo imaging system of isolated brains. c Schematic illustration of the weight drop-induced TBI model. d Time points of physically invaded BBB was studied. e Schematic illustration of the isolation of primary neuronal cells from mouse embryos. b–e Reproduced with permission. Copyright 2020, American Association for the Advancement of Science. f Ex vivo fluorescence images of primary organs of glioma-bearing mice. g Confocal images and corresponding fluorescence intensity of 3D tumor microspheres. f, g Reproduced with permission. Copyright 2022, Nature Publishing Group. h Evaluation of general toxicity, kidney function and liver function over time. Reproduced with permission. Copyright 2022, American Association for the Advancement of Science

Agents, such as metals, polysorbate-80 (PS-80), etc., are used to shrink the endothelial cells of the brain.229 Using this treatment, various drug delivery systems could bypass BBB. However, it has serious disadvantages, for example, compromising the integrity of BBB and further leading unwanted exogenous agents, including blood components, neurotoxic, and xenobiotics, to accumulate in cerebral tissue. For short, it is a non-patient-friendly method that may cause injury to the CNS. Joshi et al. reported a PLGA-based with different surface coatings platforms used for brain delivery of siRNA to treat traumatic brain injury (TBI; Fig. 5b–e).230 They tried a nonionic surfactant PS-80 coating among their formulations and proved drug delivery across BBB could be promoted by interacting with lipoprotein receptors. They euthanized mice after injection and extracted brains for observing the fluorescence signals labeled nanoparticles. PS-80 nanoparticles showed significantly superior fluorescence signals than other formulations. They pointed out in their manuscript that although the joint modulation of surface chemistry and PS-80 density, is a useful tool to adjust BBB penetration, functional or behavior evaluations, for instance, cell death, neuroinflammation, or larger animal models, are lacking in the study. Hence, biosafety and performance in clinical may still have questions.

AAVs, presenting targeting ligands, could interact with specific molecules identified on the luminal surface of the BBB.231 The integrity of BBB could be breached by the intrinsic properties of the pathogens.232 Directed evolution and capsid engineering have been developed to engineer a number of BBB-crossing AAVs.233 Among the AAV family, a natural AAV9 capsid variant which was isolated from human liver tissue, has the ability to bypass BBB, becoming a star capsid for drug delivery into CNS.234 After intravenous injection, AAV9 mainly enriches the brain and liver.235 Bei et al. reported a rational design of two AAV9 variants for brain drug delivery.236 Confirmed by rodent and primate models, the variants prepared by insertion of cell-penetrating peptide enhanced both BBB transcytosis and cellular transduction. The authors claimed that these variants not only displayed increased BBB crossing, but also of greater importance maintained the neurotropism, paving the translational potential of neurological disorders treatment.

Bacteria can go through the BBB and infect phagocytes.237 Researchers have proved the feasibility of adopting bacteria to build drug delivery systems to resist central nervous system diseases. For glioblastoma photothermal immunotherapy, Sun et al. developed a ‘Trojan bacteria’ consisting of two types of bacteria (Fig. 5f, g).238 They demonstrated that intravenously injected Trojan bacteria system could target and penetrate glioblastoma. The confocal images showed that 3D tumor microspheres could be penetrated with a depth of around 260 μm. With the help of a laser, bacterial cells and the adjacent tumor cells could be destructed by the heat from irradiation. The debris from bacteria and tumor cells also can act as antigens to promote cancer immunotherapy.

BBB is also modulated by redox-sensitive systems and cytokine-mediated systems. The former is mainly developed for oxidative stress, which is the similarity between brain disease.239 The latter is mainly developed for the pro-inflammatory state, which is a common state in a number of CNS pathologies.240 Oxidative stress is incited by an imbalance of oxidants.241 These oxidants can further impact a variety of signaling pathways associated with pathological processes, resulting in BBB dysfunction eventually.242 Redox-sensitive systems could be designed in response to the high level of oxidants, for example, Kong et al. reviewed the related developments in nervine.243 They discussed the choice of ROS-responsive functional groups, including sulfides, selenide, ferrocene, amino acrylate, etc. Meanwhile, the pro-inflammatory state, a result of local oxidative stress, stimulates many cytokines, such as IL-1 and TNF-α. Thus, conducting cytokine-mediated systems is an optional method. Veiseh et al. reported a cytokine delivery platform as interleukin-2-producing cytokine factory organized with polymer and ARPE-19 cells which can be clinically translatable (Fig. 5h).244 They conducted this robust platform in peritoneal tumors in ovarian and colorectal mouse models and considered it could be addressed in other cancers including brain cancer. They found no significant deviations from healthy ranges using complete blood count and blood chemistry analysis, showing this system was well tolerated in nonhuman primates.

Engineered brain-targeted drug delivery systems

To fight against the BBB, a growing number of advanced materials and technologies have been developed for enhanced brain-targeted drug delivery in CNS disorder treatment. By using the passive and/or active strategies for BBB regulation and crossing in a controlled and non-invasive manner, various drug delivery systems are engineered to facilitate the brain-targeted delivery of specific therapeutics including small-molecule drugs, proteins, genes, and other biopharmaceutics. Due to the requirement of both delivery efficiency and safety, the majority of drug delivery systems with the ability to cross BBB are designed at a nanoscale level with tailored chemical composition and surface properties (Table 2). Since the approval of DOX in liposomes (Doxil) for anti-cancer treatment nearly three decades ago, increasing numbers of drug delivery systems are studied in clinical trials and some formulations for enhanced drug delivery have entered to clinic.245–247Table 2 Brain-targeted drug delivery systems engineered by various material types

Material type	Size (nm)	Representative delivery cargo	Refs.	
Liposome	50–500	cisplatin, curcumin, DOX, erlotinib, obidoxime, paclitaxel, plasmid β-galactosidase	254,255,257,258,260,383,384	
Micelle	2–300	curcumin, temozolomide, resveratrol, siRNA, RAPA	268–270,385,386	
Polymeric nanoparticle	<200	enzyme, Epothilone B, memantine, Schisantherin A	264,387–389	
Nanogel	50–300	DOX, harmine, insulin, thymidine analog, teriflunomide	272,273,275–277	
Gold nanoparticle	2–80	cisplatin, DOX, insulin, lacosamide, quercetin, siRNA	290,295,296,298,390–392	
Carbon nanotube	20–200	DOX	393,394	
Graphene (oxide)	20–1000; thickness: <5	plasmid DNA, puerarin, ruthenium carbonyl clusters	313,395	
Graphene quantum dot	<20	docetaxel	318	
Iron oxide nanoparticle	10–300	cisplatin, paclitaxel, siRNA	332,333	
Mesoporous silica nanoparticle	20–300; pore size: 2–50	berberine, docetaxel, DOX, leptin, monophosphate, pioglitazone, paclitaxel, siRNA, trastuzumab	341,343,345–347,396	
Biomimetic system	40–200	a-CTLA-4, a-PD-1, chlorin e6, coumarin 6, CPPO, curcumin, dopamine, DOX, glucose polymer, human Mucin 1 protein, indocyanine green, methotrexate, monoclonal antibodies, mRNA, phosphatase, proteins, siRNA, succinobucol	238,359,360,365–367,369,397–406	
Black phosphorus	3–250; thickness: <20	DOX, matrine, paeoniflorin	371,407,408	

Liposomal formulations

Liposomes are the first generation of drug delivery systems and have been widely used since their discovery in 1965.248 They are composed of one or more lipid bilayers and hollow aqueous compartment, which endow them with loading versatility for both hydrophobic and hydrophilic therapeutic agents.249 Together with high biocompatibility, biodegradability and its intrinsic capability of BBB crossing, liposomes are considered as one of the most successful delivery systems with a great potential in translational medicine. In the past decade, research on liposomes has further substantially increased along with the advance of materials engineering and nanotechnology.250 Various types of functionalization strategies have been involved for the development of liposomal delivery system such as brain/tumor-targeting delivery, controlled drug release, imaging-guided delivery, etc.251 These strategies facilitate the development of liposomal formulations to improve brain-specific delivery.

Brain-targeted delivery of the liposomes could be enhanced by modification of targeting ligands including polymers, peptides, antibodies, and aptamers.252 For example, Zhan et al. functionalized liposomal surface with amyloid-β-derived peptide which has a highly specific binding affinity towards plasm apolipoproteins, giving a protein corona-modified liposomal system. Significant enhancement of the brain distribution of DOX-loaded liposomes as well as higher anti-tumor efficacy were found.253 Quan et al. developed transferrin receptor aptamer-functionalized liposomes to deliver acetylcholinesterase reactivator in brain (Fig. 6a).254 Compared with non-targeting liposomes, this functionalized system has higher BBB penetration efficiency confirmed by both in vitro BBB model and in vivo biodistribution study. Conjugation of brain-targeting peptide is also proved to be an effective method to improve the brain accumulation. Zhang et al. used RVG29, a 29 amino-acid peptide derived from rabies virus glycoprotein, as a targeting ligand in the liposome-based delivery system for treatment of Parkinson’s disease.254 But it begs for the question that how can targeting ligand-modified liposomes bypass through the BBB via receptor-mediated transcytosis. To give a vivid description, Lauritzen et al. characterized all steps of the liposome delivery routes into brain by using transferrin receptor-targeted liposomal nanoparticles as a model system.255 They revealed that post-capillary venules is the key site for transcytosis-mediated brain entry of nanoparticles.Fig. 6 Liposomal formulations and polymeric materials for brain-targeted drug delivery. a Schematic illustration of synthesis of Apt-LP-LuH-6 liposomes and the structure characterization. Reproduced with permission. Copyright 2021, Elsevier. b Small-molecule-loaded ultrasound-controlled liposomal nanocarrier. Reproduced with permission. Copyright 2020, Nature Publishing Group. c Schematic illustration of synthesis of micelles by nanoprecipitation. Reproduced with permission. Copyright 2019, American Association for the Advancement of Science. d Schematic illustration of nanoprecipitation of peptide-modified PLGA and GALC CLEAs for the generation of enzyme delivery system. Reproduced with permission. Copyright 2021, Nature Publishing Group

For brain tumor treatment in particular, the systems are required to have a capability of both BBB crossing and tumor targeting.256 Thus, dual targeting strategy in liposome functionalization becomes a possible solution for drug delivery in brain tumor therapy. For instance, a GBM-specific cell-penetrating peptide and an anti-GBM antibody were simultaneously anchored onto the liposome surface, giving the ability of BBB penetration.257 By incorporation of superparamagnetic iron oxide nanoparticles (SPIONs) and DOX, the liposomes displayed a thermo-responsive drug release in an alternating magnetic field. Another example of dual functionalized liposomes was achieved by Singh’s group.258 Surface modification of transferrin and a cell-penetrating peptide was performed. Their liposome system thus showed around 12 and 3.3-fold increases of two chemotherapeutics (DOX and erlotinib) delivery, respectively compared to the free drugs. These strategies confirmed that ligand modification for BBB and tumor targeting could largely improve the drug delivery for brain tumor treatment. Interestingly, the liposome without any targeting ligands conjugation could also serve as an external stimuli-controlled nanosystem for brain-targeted drug delivery. As shown in Fig. 6b, Yanik et al. prepared drug-loaded liposomes tethered to lipid microbubbles containing perfluorobutane gas core.259 By applying two-component aggregation and uncaging focused ultrasound sequences at different stages, the drug-loaded liposomes could aggregate locally first and then uncage the cargo responsively to achieve high target specificity. The released drugs can cross the intact BBB without compromising the integrity.

Recently, some new types of liposomes with unique structures were reported for enhanced therapy of CNS diseases. Gomes et al. proposed a concept of exosome-like liposomes to overcome the limitations of large size and low productivity. A lipid film including DODAP (1,2-dioleoyl-3-dimethylammonium-propane) and DPPC (dipalmitoylphosphatidylcholine) was introduced in the preparation of the liposomes, giving the bilayer similar to the outer membrane of exosome.260 More liposome-based biomimetic nanomaterials for drug delivery will be emphasized in section 4.7.

Polymeric drug delivery systems

Polymeric materials for brain-targeted delivery refer an extensive number of drug delivery systems.261 They have shown potentials in pre-clinical study in different animal models of CNS diseases demonstrating attractive properties for drug delivery including controlled drug release, cellular targeting and uptake, and the ability to avoid phagocytosis of reticuloendothelial system. PLGA is a typical Food and Drug Administration (FDA)-approved polymer used for the formulation of delivery systems in biomedicine.262 PLGA-based delivery system is qualified to encapsulate a wide range of therapeutic cargos including small-molecule drugs, genes, proteins, vaccines, ensuring high bioavailability by protecting them from degradation. The PLGA assembles without any functionalization have a high distribution up to 16.4% in the brain and can keep at the level for at least seven days.263 Moreover, the possibility of surface decoration of targeting ligands could further promote their penetration of biological barriers. A typical example was reported by Cecchini et al., demonstrating that PLGA polymers conjugated with different targeting peptides could be used for enzyme therapy of brain disorders such as Krabbe disease (Fig. 6c).264

Amphiphilic polymers are known for their advantage of self-assembly into micelles which has a hydrophobic core and a hydrophilic shell at a size of 2–300 nm. Such architecture thus enables high loading capacity and prolonged blood circulation of therapeutic agents, and its efficient accumulation in brain lesions. We recently proposed a micelle-based drug delivery nanosystem for febrile seizure control.265 The designed copolymer of poly(acrylamide coacrylonitrile)-methoxy polyethylene glycolsuccinimidyl carbonate could self-assemble into defined micelles. Because of the incomplete development of BBB in mice pups, the micelles could quickly accumulate in neonatal brain as early as five minutes. Anti-inflammatory small-molecular inhibitor CZL-80 was chosen as a model drug. After micelle encapsulation, therapeutic window of the drugs was significantly increased to at least 4 hours, whereas 20 min for injection of CZL-80 alone. Importantly, the nano-engineered micelle is gifted for an upper critical solution temperature of 39 °C, showing a thermos-sensitive drug release mechanism for on-demand therapy. To combat against drug-resistant gliomas, Saltzman et al. prepared a reduction-responsive polymeric nanoparticle for co-delivery of oxaliplatin (the third-generation platinum anti-cancer drug) and 56MESS (a cationic platinum DNA intercalator) (Fig. 6d).266 Oxaliplatin and 56MESS were encapsulated inside the nanoparticles through hydrophobic interaction and electrostatic complexation, respectively. Higher level of glutathione (GSH) in tumor reductive microenvironment could trigger the drug release due to the rupture of disulfide bonds in polymer backbones. The authors claimed that by using convection-enhanced delivery, the drugs could traverse the BBB and accumulate at the glioma region. Another case of micelle-based drug delivery system for CNS disease treatment without any brain-targeted functionalization was reported by Jiang’s group.267 They developed an microthrombus-targeted micelle-based system for ischemia stroke therapy. Due to the pathologically damaged BBB, microthrombus-targeted micelle could penetrate BBB efficiently and promoted RAPA delivery via hydrophobic interactions. These micelles are assembled by ROS-responsive and fibrin-binding polymer, giving extended drug retention and ROS-triggered drug release for neuroinflammation regulation. Micelle-based delivery systems is also effective in the treatment of those diseases with intact BBB structure. A brain and microglia dual targeting nanosystem was constructed by an targeting peptide derived from β-amyloid protein and ROS-responsive amphiphilic polymer.268 By mimicking the unregulated Aβ transportation, the micelles could target the Alzheimer’s disease microenvironment and release the model drug curcumin in response to excessive ROS generation in Alzheimer’s disease. Similar micelle-based strategies with surface modification of targeting ligands were performed for the synergistic chemotherapy of glioma,269 gene therapy of Alzheimer’s disease,270 and traumatic brain injury.230

Nanogel is formulated by three-dimensional crosslink of functional polymers and has a network capable of efficient drug encapsulation.271 Tunable properties such as deformability, nanoscale size and high hydrophilicity make nanogel a candidate for nose-to-brain delivery. Di Carlo et al. manufactured a poly(N-vinyl pyrrolidone)-based nanogel by e-beam irradiation and evidenced this nanogel-based system could provide nose-to-brain delivery of insulin.272 Compared with free insulin administration, the drug levels in the anterior and cerebellar regions were significantly increased within 60 minutes. The authors indicated this improvement could be resulted from intranasal delivery via olfactory and trigeminal nerve pathways. Another polymeric nanogel delivery system of teriflunomide-loaded lipid-based carbopol-gellan gum in situ gel was reported by Kokare and co-wokers.273 By balancing the interactions of gelling agents, mucoadhesive agents, the nanogel was formulated with lipophilic medicine and achieved two-fold enhancement of drug permeability. The same group further developed paliperidone palmitate poloxamer-guar gum nanogel for schizophrenia treatment by nasal delivery directly to the brain bypassing the BBB.274 Wang et al. fabricated calcium ions-triggered harmine in situ nanogel through coupling homogenization and spray-drying technology.275 The bioavailability of harmine administrated by nanogel was found to be 25-fold higher than that by oral administration. At the meantime, incorporation of brain targeting motifs allows nanogel transcytosis across the BBB for brain-targeted drug delivery. Morgenroth reported nanogel-based carrier for the intracellular delivery of radiophamaceuticals to brain tumor cells by functionalization of ligands of diphtheria toxin receptor overexpressed in abnormal cerebral blood vessels.276 The crosslinked network also contained matrix metalloproteinase substrate, permitting protease responsive drug release. Cell membrane-mimicked nanogel is another typical nanocarrier for BBB crossing. For example, Yu and his group utilized phosphorylcholine nanogels for enhanced GBM chemotherapy.277 The phosphorylcholine polymer exhibited long-lasting circulation and achieved higher accumulation in brain tumor tissue, serving as an effective tool for BBB crossing.

There are other polymers-enabled delivery platforms that have been proved for successful brain-targeted delivery including semiconducting polymers, polysaccharides, gelatin and other synthetic or natural polymers.278–282 Further investigations on bioavailability, degradability, and bio-interactions of polymers in vivo will facilitate the development in this field.

Gold nanomaterials

Gold nanomaterials have a number of distinctive advantages over drug delivery for brain diseases.283,284 Inert surface chemistry of gold allows limited interactions at nano-bio interface and consequently leads to high cellular and tissue compatibility. They could enter the brain by crossing the brain endothelium in a size-dependent manner. In addition, it is comparatively simple to synthesize the gold nanomaterials with tailored structure and defined size. Although only smaller size (<10 nm) gold nanoparticles after intravenous injection was observed to be distributed in the brain slice.285 Sub-100-nm gold nanoparticles can extravasate through the damaged BBB under some pathological circumstance such as brain tumor, cerebral stroke, brain injury and epilepsy. Moreover, gold nanomaterials could be traced by using computed tomography imaging for imaging-guided therapy, evaluating their biodistribution and accumulation in the brain.286,287 A variety of applications based on gold nanoparticles have developed for brain disorders treatment thanks to their excellent properties. For example, some gold nanoparticles that have higher absorbance at near infrared biowindow are potential nanogents for photothermal therapy of brain tumor.288 In this section, we will focus on the discussion of the design and synthesis of gold nanomaterials-based delivery systems.

Functional ligands or drugs can be stably anchored onto the gold surface via gold-thiol bonding for enhanced drug delivery.289 Popovtzer developed insulin-coated gold nanoparticles as endogenous BBB transport system for delivering therapeutics into the brain regions, rich in insulin receptors.290 Prior to the modification, thiol-mPEG-COOH copolymer was attached onto the gold nanoparticles via gold-thiol interaction, leaving carboxylic groups for further EDC/NHS conjugation with insulin. They also proved the 20 nm of gold nanoparticles showed highest accumulation in the brain compared with 50 nm and 70 nm nanoparticles. Another example of maze tetrapeptide-anchored gold nanoparticles was confirmed by Guo’s group.291 The thiolated biomolecules were anchored onto the nanoparticle surface, achieving brain-targeted delivery and neuroprotection to prevent Alzheimer’s disease. As mentioned, the gold-thiol interaction between gold nanoparticles and functional ligand enabled a simple and effective strategy for nanoparticles functionalization.

More recently, chiral gold nanoparticles have received attention in both nanotechnology and biomedicine.292,293 Tang and co-workers firstly revealed that the BBB penetration of gold nanoparticles is clearly affected by their chirality (Fig. 7a, b).294 It is known that GSH transporters at high level in the brain promoted the BBB permeability of GSH-capped nanoparticles. In this work, the authors indicated that the D-GSH-stabilized gold nanoparticles at 3.3 nm (D3.3) possessed higher brain distribution compared to its enantiomer (L-GSH-stabilized nanoparticles, L3.3). Together with a larger binding affinity towards amyloid-β of D3.3, the introduction of chiral ligands endowed the nanoparticles with improved rescue of behavioral impairments in Alzheimer’s disease. This study undoubtfully provides a deeper understanding of nanotechnology-enabled BBB crossing by ligand functionalization.Fig. 7 Gold nanomaterials and carbon materials for brain-targeted drug delivery. a Simulated structures of Aβ17-36 with L- and b D-GSH-coated Au (111) surface obtained from molecular docking simulation. Reproduced with permission. Copyright 2020, Nature Publishing Group. c Schematic illustration of synthesis and d TEM images of mazindol-B6 peptide-PCB-S-curcumin-siRNA (MBPCS) and intermediate products. Reproduced with permission. Copyright 2019, Royal Society of Chemistry. e Structures and reactivity of the various nuclearities of Ru-CO clusters on GO, and f FTIR spectra of 1Ru-and 11Ru-CO. Reproduced with permission. Copyright 2018, Wiley-VCH. g Schematic illustration of synthesis of drug-loaded graphene quantum dots (GQD-D) and Cetuximab-labeled red blood cell membrane-coated GQD-D anchored inside the nanosponge (Ct-RBC@GQD-D/NS) and h their TEM images. Reproduced with permission. Copyright 2019, American Chemical Society

Gold nanoparticle-based drug delivery systems in unconventional structure other than sphere particle have been designed for enhanced brain-targeted delivery. For example, a switchable nanoplatform for co-delivery of gene and chemical drugs was nano-fabricated by Zhang and his team (Fig. 7c, d).295 The modification of nanoparticles with B6 peptide, mazindol, β-thiother ester bonded-copolymer endowed the nanosystem with brain targeting ability, high affinity towards dopaminergic neurons, and ROS-response drug release, respectively. It significantly improved the targeted delivery of curcumin and small interfering RNA to accomplish a synergistic delivery overcoming the issue of Parkinson’s disease. Interestingly, the levodopa attached on the gold surface provides a Fe3+-enabled assembly in neurons for enhanced computed tomography. Microenvironment-mediated switching between self-assembly and disassembly by gold nanoparticles was developed for brain tumor treatment. The endogenous factors in brain tumor such as low pH and higher GSH could triggered the transition of assembly–disassembly state to improve theranostic efficacy.296,297 Moreover, hybrid nanoparticles that are composed of gold and other materials inherited the intrinsic properties of each component. Bimetallic nanoparticles (gold and palladium) modified with quercetin could serve as a potential inducer for the therapy of Alzheimer’s disease.298

Currently, some gold nanomaterials-based systems are undergoing pre-clinical and clinical trials. The limitations and strengths of these systems should be further investigated and summarized, provide a guidebook for the community. Comparative studies are required to explore the effects of shape, size, surface charge, and other factors on nano-bio interactions. In addition to the BBB crossing, research on the biodistribution and elimination of gold nanomaterials in the brain should be continued.

Carbon materials

Carbon materials including carbon dots (CDs), carbon nanotubes (CNTs), graphene, and graphene oxide have been considered as promising agents for biomedical applications.299–301 They are evolving as functional materials not only for drug delivery but also, in parallel, for imaging, diagnosis and other treatments while proving negligible side effects.302–305

CDs have been exploited as biocompatible nanocarriers for brain-targeted drug delivery due to their tunable properties, photostability, small size, and facial synthesis.306 Leblanc et al. successively reported the development of two CDs-based nanocarriers to treat glioblastoma brain tumor and Alzheimer’s disease.307,308 The CDs for brain tumor treatment were conjugated with transferrin, epirubicin, temozolomide via EDC/NHS reactions with carboxylic groups on CDs surface. And the CDs for Alzheimer’s disease treatment were fabricated by an ultrasonication-mediated strategy, producing amphiphilic yellow-emissive particles at a size of 3 nm. Such CDs with amphiphilicity could cross the BBB through passive fusion.

Graphene oxide (GO) and reduced GO (rGO) are two representative graphene-based materials.309 They were well known for their electro-mobility, and photothermal properties, high specific surface area, giving them great potentials in targeted drug delivery. Drug molecules could be conveniently loaded into graphene-based delivery system via non-covalent interactions (π-π stacking, hydrophobic interactions, hydrogen bonding, and electrostatic interactions).310 Further, the -OH and -COOH groups of GO and rGO provides a feasibility to conjugate with targeted molecules and material matrix. Interestingly, the graphene-based materials themselves have the potential therapeutic effects in treatment of CNS disorders. They have been used to inhibit misfolding and aggregation of amyloid-β protein. By loading dauricine, a dibenzyl tetrahydroisoquinoline alkaloid that alleviates brain inflammation, GO sheets were verified to possess the therapeutic effects for Alzheimer’s disease.311 In addition to small-molecule drugs, clusters such as RuII(CO)2 species could be absorbed onto GO (Fig. 7e, f).312 Under photothermal activation, carbon dioxide was released for the treatment of vascular diseases, like stroke remediation. Obviously, conjugation of functional ligands has been explored to facilitate the BBB transcytosis of graphene-based materials, such as lactoferrin, porphyrin, and transferrin.313–316 Physico-chemical properties such as size and surface charge also have impact on BBB penetration efficiency of GO and rGO.309 Graphene quantum dots at a size range from 2 to 4 nm have higher BBB permeability than GO at a size from 5 to 20 nm, indicating the crucial role of particle size in brain drug delivery.317 Due to the small size, graphene quantum dots could be encapsulated onto mesoporous nanostructure and mediate the theranostic penetrative delivery of drug and photolytics (Fig. 7g, h).318 her engineering of cell membrane onto the hybrid particles prolongated the blood circulation, leading to enhanced accumulation at brain tumors.

CNTs can been divided into two types, namely single-walled CNTs (SWCNTs) and multi-walled CNTs (MWCNTs) depending on the inner graphene layers. Unique surface chemistry and walled structure of CNTs permit drug loading and polymer conjugation for targeted delivery to brains.319 The CNTs for drug delivery were usually modified with functional groups such as -NH2 or -COOH, providing reactive sites. Raza developed PEGylated CNTs after -NH2 modification for delivery of mangiferin, a potential anti-cancer drug as a nanomedicine for brain tumor.320 Carboxylated SWCNTs were utilized for brain delivery of levodopa for the treatment of Parkinson’s disease.321 Chen et al. combined a mixture of brain targeting peptide, glioma targeting and polyethyleneimine with carboxylated MWCNTs to form nanomedicine for orthotopic brain tumors.322 The therapeutic agents could be loaded within the systems via either covalent conjugation or non-covalent bonding. However, it remains public concern for human health as exposure of CNTs may cause cytotoxicity in CNS,323,324 and more toxicological profiles are needed before they can be applied in clinical trials.

Iron oxide nanoparticles

Iron oxide nanoparticles (IONPs) are a class of widely used nanomaterials for biomedical applications including drug delivery, bioimaging, hyperthermia therapy, and magnetic separation.325–327 Magnetite (Fe3O4), hematite (α-Fe2O3) and maghemite (γ-Fe2O3) are three common IONPs, in which Fe3O4 nanoparticles received great interests. Of importance, customized IONPs with different size, shape, morphology, and surface chemistry could be synthesized in a controlled manner. Typically, administration of unmodified IONPs does not permit brain-targeted delivery. Their accumulation pattern in organs of rodent models was revealed as follows: spleen > blood > liver > kidney > lungs > heart > testis > brain.328 Covalent conjugation of targeting ligands, and/or polymeric materials such as PEG chains, carboxymethyl cellulose, dextran could distinctively facilitate the transport of IONPs across the BBB.329–331

Spherical IONPs or SPIONs could serve as carriers for brain-targeted delivery. For instance, IONPs synthesized by a mixture of L-aspartic acid, FeCl3·6H2O, and FeCl2·4H2O could be functionalized with carboxylic groups, paclitaxel, PEG polymer chain, and GSH step by step.332 The as-synthesized particles were proved to pass through the BBB with shuttle peptide and deliver the drug molecules into brain. Ni and co-authors fabricated brain-targeted IONPs for co-delivery of GSH peroxidase 4 and cisplatin for gene-chemotherapy.333 The small interfering RNA and the chemical drugs were loaded via EDC/NHS reaction and direct absorption, respectively. Small size IONPs were sometimes used as therapeutic agents other than the carriers. Guo developed an ultrasound-responsive nanoparticle for thrombolysis, by assembly of PLGA and targeting peptide dual-modified nanoparticles onto perfluorohexane nanodroplet (Fig. 8a–d).334 In another report, SPIONs, quantum dots, cilengitide were integrated into one nanoplatform, giving liposomal formulation for imaging-guided therapy. The hydrophilic cilengitide was encapsulated in the aqueous core, whereas SPIONs and quantum dots were concealed inside the lipid membrane. The SPIONs and the quantum dots used in the formulation have a size of ~20 nm and ~8 nm, respectively, and the hydrodynamic diameter of the final liposome was determined to be ~100 nm. The authors claimed the size change could promote the passive targeting via leaking vasculature (7–150 nm) and meanwhile prevent homogenous leakage of SPIONs into normal tissues.335Fig. 8 Iron oxide nanoparticles, silica nanomaterials, biomimetic nanomaterials and Cas9/RNA nanoparticles for brain-targeted drug delivery. a Schematic illustration of synthesis of Fe3O4 nanoparticles-PLGA-perfluorohexane (PFH) nanoparticles with CREKA peptides and b, c representative TEM images of Fe3O4-PLGA-PFH-CREKA and PLGA-PFH-CREKA nanoparticles, and d their elemental mapping results. Reproduced with permission. Copyright 2019, American Chemical Society. e Schematic illustration of synthesis of HA-MMSN-1F12 nanoparticles and f particle size and g TEM images of HA-MMSN and HA-MMSN-1F12 nanoparticles. Reproduced with permission. Copyright 2022, Ivyspring International Publisher. h Schematic illustration of synthesis of cell membrane-coated nanostructures and its targeted synergistic therapy of glioblastoma. Reproduced with permission. Copyright 2022, Nature Publishing Group. i Schematic illustration of synthesis of CRISPR-Cas9 nanocapsules and j their TEM images and k size distribution. Reproduced with permission. Copyright 2022, American Association for the Advancement of Science

Recently, IONPs with tailored structures or multi-component IONPs-based particles were developed for brain diseases. Zhou et al. provided gallic acid-coated magnetic nanoclovers for targeted delivery of nanomedicine to brain tumors.336 The clover-shaped nanoparticle was synthesized by a mixture of CoFe-oleate, oleic acid, and oleyl alcohol after an elongated reaction time. The authors indicated that these nanoclovers have greater heat induction efficiency than common IONPs, leading to enhanced magnetic hyperthermia-chemotherapy combination for brain tumor treatment. Paulmurugan and co-workers synthesized polyfunctional gold-iron oxide nanostars for microRNA delivery to combat against glioblastoma.337 The gold-iron oxide nanostars could be obtained by consecutive seed and growth steps, giving a uniform size distribution of around 34 nm. Further coating of hybrid polymer (β-cyclodextrin-chitosan) and decoration of PEG-T7 peptide enabled efficient cargo loading and brain tumor targeting.

IONPs are widely used in the clinic for diagnostic and/or prognostic applications. The development of IONPs-based drug delivery system enabled trackable delivery and imaging-guided therapy. Recent advances of magnetotherapy offer a new opportunity for combined therapy. Thus, future work on the construction of multi-functional nanoplatform, as well as the study on how to balance the interactions between each component for optimized efficacy should be conducted.

Silica nanomaterials

Silica nanoparticles are a type of stable, low toxic, and nanostructured bioceramics contributing their superlative properties and uses to biomedicine. Mesoporous silica nanoparticles (MSNs) characterized by ordered distribution of mesopores at a pore size between 2 and 50 nm with high pore volume and surface area are ideal candidates of starting biomaterials, particularly as drug carrier.338,339 The presence of silanol groups at particle surface enables the production of multifunctional derivatives of MSNs system for targeted drug delivery in the treatment of brain diseases.

There are mainly two strategies to fabricate MSNs-based delivery system for BBB crossing. First, MSNs can be employed as a drug delivery system by direct drug absorption and surface ligand functionalization. Chen et al. conjugated cRGD peptide with the MSNs and simultaneously load antineoplastic DOX by mixing.340 They found that such system exhibited strong permeability across the BBB and then could induce cancer cells apoptosis by releasing drugs. The transport capability of MSNs at the sizes of 20, 40, and 80 nm were evaluated by the authors and were calculated to be 44.0%, 59.2%, and 38.6%, respectively, which were all higher than that of free drugs (32.8%), indicating a size-dependent penetration mechanism. Gómez-Ruiz and co-workers prepared a MSNs-based nanoplatform for delivery of a cocktail of agents (leptin and pioglitazone) to fight against amyotrophic lateral sclerosis.341 Leptin, a polypeptide hormone possessing neuroprotective effects, was conjugated with -NH2 of MSNs through EDC/NHS coupling, and pioglitazone, an anti-inflammatory agent, was loaded through adsorption. The surface area and the pore volume before and after the drug loading were determined to be 853 m2/g and 0.73 cm3/g, 512 m2/g and 0.47 cm3/g, respectively. These results demonstrated successful incorporation of both agents. Other nanoplatforms using iRGD peptide,342 lactoferrin,343 lipoic acid,344 Angiopep-2,345 lipid bilayer,346 as targeting ligands also demonstrated efficient drug loading and BBB crossing of MSNs-based delivery systems.

Moreover, MSNs were used as core substrates for further materials growth, or as the carrier shell coating on other functional nanostructures including those particles mentioned above. For example, a core-shell particle system was constructed by polymerization of tetraethyl orthosilicate grafting on magnetic Fe3O4 nanoparticles for both drug delivery and magnetic resonance imaging. Afterwards, the drug-loaded Fe3O4@MSNs particles were wrapped up by activated neutrophils, producing a biomimetic theranostic platform. The authors claimed the neutrophils not only have the native ability of BBB crossing, but also could act as “living” delivery system targeting inflammatory regions for maximizing the drug bioavailability.347 Similar magnetic core-shell particles were developed by Luo and co-workers (Fig. 8e–g).348 The Fe3O4@MSNs particles were modified with both amyloid-β antibody (1F12) and CD44-targeting ligand (hyaluronic acid). Thus, after BBB penetration enabled by hyaluronic acid, the particles could specifically remove amyloid-β oligomers. In their work, the particles size had a hydrodynamic size ranging from 413 to 478 nm which is not an ideal particle size for BBB crossing. However, the authors successfully settled the problem by conjugation of CD44-targeting ligand with MSNs. Karathanasis demonstrated the BBB permeability of Fe3O4@MSNs modified with NH2-PEG polymer and fibronectin-targeting peptide CREKA. Thanks to the magnetic cores, external low-power radiofrequency field could facilitate deep penetration of drugs across blood–brain tumor interface.349

Unique properties of silica nanomaterials have made them ideal candidates to be used as drug carriers. In particular, the superior surface chemistry and structural feature of the materials distinctively improve the drug loading capacity. Thus, efficient and standardized production protocols of silica materials should be developed to achieve reproducibility.

Biomimetic drug delivery systems

Engineered materials could exert their therapeutic benefits in drug delivery as an enormous quantity of nanoparticles with customized physio-chemical properties according to the requirement in disease treatment. In the past decade, camouflaged drug delivery systems that using biomimetic materials were developed to traverse BBB for brain-targeted drug delivery.350–352 The earliest work can be traced back to twelve years ago that Zhang’s group demonstrate an erythrocyte membrane-camouflaged polymeric nanoparticle for drug delivery.353 Since then, in addition to membrane-enabled technology, alternative strategies including biomacromolecule-enabled strategy,354 exosome-mediated carrier,355 virus-inspired synthesis,356 extracellular vesicles bionic method,357 and bacteria bionic strategy358 have been adopted in preparation of custom-build nanocarriers. In terms of the synthesis process, the biomimetic nanomaterials for brain delivery can generally be categorized into two strategies, namely bottom-up and top-down strategies.

The bottom-up strategy for particle construction mainly includes the use of a massive number of targeting ligands derived from living systems. From small molecules, short peptides, nuclei acids, to various functional proteins, researchers have created a toolbox of targeting ligands for nanoparticles decoration. In addition to direct conjugation to nanoparticles that have been mentioned in previous sections, targeting ligands are also able to assemble into the nanostructures in assistance with polymers to accomplish the goals of targeted drug delivery. A synthetic protein nanoparticle assembled by HSA, cell-penetrating peptide (iRGD), reactive macromer (OEG) and siRNA against STAT3, a key factor related to tumor progression, was engineered by Lahann.359 Under the treatment of electrohydrodynamic jetting, the OEG macromer polymerized and covalently interacted with the lysine residues from albumin, giving nanoparticles at an average size of 115 nm. In vitro and in vivo study evidenced the BBB crossing and tumor accumulation of the protein-mediated nanoparticles. To improve the BBB permeability of cytotoxic T-lymphocyte associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) for immunotherapy of brain glioma, Ljubimova and co-workers described a nanoscale immunoconjugate system.360 The immunoconjugate was obtained by covalently attaching antibodies (a-CTLA-4 IgG2b, or a-PD-1 IgG) to poly(β-L-malic acid) polymers, with pre-conjugation of anti-mouse transferrin receptor antibody, and trileucine. Some natural cell membranes such as exosomes without any functionalization have ability to cross the BBB.335,361 The delivery efficiency is mainly dependent on the lipid membrane and the active proteins which mediate the internalization between exosomes and target cells. In addition, some exosomes improved the drug delivery efficiency by increasing the BBB membrane fluidity. Interestingly, some natural exosomes not only could penetrate BBB, but also accumulate at brain tumor site362 or inflammatory region,363 serving as dual targeted delivery systems.

Biomimetic nanomaterials developed with top-down cell-engineered approach inherited complexity of their source cells, bypassing cumbersome synthesis process for particle construction. Cellular internalization and cell membrane coating as typical top-down strategies endow the nanoparticles with bionic communications with biological entities including membrane fusion, cell tropism, immune evasion, cell-cell recognition, which in all contributes to targeted drug delivery. Researchers have reported a variety of biomimetic nanomedicines by engineering whole cells for synthesis of whole-cell-based systems, and parts of cells for semi-biological biomimetic systems. Zhang developed a neutrophil-mediated drug delivery system by anti-cancer drug encapsulation into cationic liposomes, followed by internalization by tumor-associated neutrophils.364 The camouflaged delivery system maintained the physiological features, which could efficiently traverse BBB and migrate to inflammatory sites such as tumor parenchyma. Interestingly, the internalization by leukocytes could complete in vivo. Qin et al. prepared cRGD-modified liposomes and demonstrated their enhanced uptake by monocytes and neutrophils in vivo due to the high and specific binding affinity.365 As known, leukocytes are promptly recruited when neuroinflammation occurs in brain disorders. This cell-mediated delivery strategy could thus facilitate the migration of drug-loaded liposomes across BBB in vivo. Thanks to the homotypic recognition of membrane components, cell membrane coating is an alternative method to fabricate biomimetic delivery system. For example, cell membrane harvested from glioma U251 cells was used as a chaperon to increase brain tumor targeting of delivery system (Fig. 8h).366 The self-assembly nanoparticles composed of hemoglobin, lactate oxidase, chlorin e6, and chemiluminescence reagent were co-extruded with tumor cell membranes to produce membrane-coated nanoparticles. Such system displayed efficient BBB penetration and tumor-targeting capability. In some cases, due to similar amphiphilicity between cell membrane and liposome, the functional proteins from the membranes could be inserted inside the liposomal bilayer after protein fusion, generating proteolipid nanoparticles. Zheng et al. prepared biomimetic proteolipid nanoparticles by embedding glioma cell membrane proteins into indocyanine green-loaded liposomes.367 Unlike membrane-coated polymeric “hard” nanoparticles such as PLGA nanoparticles, these membrane-camouflaged nanoparticles were proved to be “soft” and the active proteins were easy to be inserted. Further study on platelet-camouflaged delivery system also confirmed the enhanced drug delivery in multiple tumor models including glioma, which was enabled by platelet membrane proteins.368 Such delivery systems largely improved the drug accumulation in brain tumor via homologous binding mechanism. To further optimize the membrane-mediated delivery with region-specific targeting, biomimetic systems could be labeled by targeting ligands via covalent or non-covalent conjugations. Ren and co-authors modified the exosome-based system with LDL peptide by simply co-incubation.369 The high binding affinity of the peptide and LDL receptor promoted the BBB penetration, glioma distribution and cellular uptake. Similar strategy was performed in a delivery system for brain tumor treatment by using conjugation of T7 peptide.339

Other materials

In addition to the aforementioned nanomaterials, development of biotechnology and materials engineering offers other opportunities for BBB crossing. Black phosphorus (BP) is two-dimensional layered semiconducting material with high drug loading capacity, efficient photothermal conversion, and satisfactory biocompatibility.370 Chen prepared a BP-based delivery system consisted of brain targeting peptide lactoferrin and Paeoniflorin-loaded BP nanosheets.371 Elevated BBB permeability of the system was observed due to a combination of lactoferrin-mediated BBB transcytosis and photothermal effects. Some examples of metal or metal oxide-based materials (e.g., MnO2, MgO, TiO2) have been exploiting in carrier construction by taking advantages of their catalytic effects and imaging functions.372–375 More recently, variants of the AAV have been investigated for its potential use for BBB penetration. Nanocapsules containing single CRISPR-Cas9 and GSH-sensitive polymeric shell for glioblastoma gene therapy were designed by Shi and co-workers (Fig. 8i–k).376 The particle core of Cas9/sgRNA complexes were decorated with positively charged polymer via electrostatic interactions, as the particle size increased from 17 nm for naked Cas9/sgRNA to 31 nm.

Conclusion and perspectives

BBB is a natural barrier protecting the brain from the entrance of toxins and pathogens. However, intact BBB consisted of endothelial cells and tight junctions impedes the brain permeability of therapeutic agents, which largely comprises their therapeutic efficacy of CNS diseases. Along with the rapid development of materials science and nanotechnology, various strategies for BBB regulation and crossing have been developed and engineered delivery systems with unique physio-chemical properties and multifunctional motifs were prepared for enhanced drug delivery via different BBB crossing pathways. This review introduced the basic information of BBB structure and physiology and discussed the different strategies to enhance BBB crossing in detail as well as the bypassing routes and mechanisms. Recent progress of various types of drug delivery systems and their distinguishing attributes for BBB crossing were summarized. The engineered drug delivery systems with appropriate physio-chemical properties, multi-functional modules, and good biocompatibility guaranteed excellent performance of BBB penetration for enhanced drug delivery.

Although extensive achievements have been made in this community with several FDA-approved trials, there is still a long way to go from clinical popularization and translational application. More efforts on both development of materials engineering and biomedicine are needed to bridge the gap. We list some pointel aspects for future research as following: (1) More appropriate in vitro and in vivo models for evaluation of BBB permeability. Currently, cell monolayer model (e.g., Transwell model) was widely used to verify the BBB crossing and calculate the penetration efficiency. Yet, a compliant three-dimensional BBB model is more preferred to investigate the role of blood flow and drug transport in BBB maintenance. Recent advances in 3D printing technology may provide an alternative approach to in vitro BBB study;377,378 (2) Targeted delivery with better spatial and temporal precision. Although abovementioned strategies provide means to improve brain targeting, none of them could complete brain region-specific delivery, which is crucial for treatment of brain disorders. Strategy of targeting ligand functionalization significantly relies on the receptor expression, and stimuli-triggered BBB disruption has limited resolution. Drug release in a time-controlled manner would also be highly favored. Treatment of paroxysmal disorders such as epilepsy required timely drug release. (3) Safety issues should be addressed before clinical translation. In addition to conventional acute and chronic toxicity evaluation in cellular, organ, tissue, and system levels, studies on distribution and metabolic fate of nanomaterials in a long-term period should be conducted. Even though most literature claimed satisfactory biocompatibility in their reports, toxicological studies on organic and inorganic drug delivery systems revealed neurotoxicity and inflammatory damages in the brain.379–381 Researches on integrity and function of BBB at molecular level after non-invasive regulation should also be performed to verify the biosafety. (4) The interactions between drug delivery systems, cargo drug molecules, and cells should be identified. A deeper understanding of complex interactions and computational modeling, including machine learning algorithms,382 could provide complementary insight on empirical design of drug delivery system. (5) Scalability and reproducibility should be guaranteed. New methodologies for carrier construction and drug loading will facilitate their practical uses. (6) In addition to drug delivery, a combinational delivery of other agents such as imaging probes and biosensors is anticipated to improve the therapeutic efficacy by fabricating theranostic nanoplatforms. Targeted drug delivery is a multi-disciplinary study involving biotechnology, chemistry, material science and medicine. Considered the promising results that shown in this field, we envision that further continuous interdisciplinary cooperation will build a broader platform for enhanced BBB crossing for the treatment of brain diseases in the future.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (82273861, 82003666, 82022071), Natural Science Foundation of Zhejiang Province (LD22H310003, LQ23H300001), and Young Elite Scientists Sponsorship Program by CAST (YESS20220139). Schematic illustrations in Figs. 1, 2a, 3a, 4a, and 5a are created with BioRender.com.

Author contributions

Y.W., Z.C., and D.W. conceived this review. D.W. and Q.C. wrote the manuscript. Y.W. revised the manuscript, and other authors discussed and commented on the review. All authors have read and approved the article.

Competing interests

The authors declare no competing interests.

These authors contributed equally: Di Wu, Qi Chen
==== Refs
References

1. Abbott NJ Blood–brain barrier structure and function and the challenges for CNS drug delivery J. Inherit. Metab. Dis. 2013 36 437 449 23609350
Abbott, N. J. Blood–brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis. 36, 437–449 (2013).23609350
2. Abbott NJ Patabendige AAK Dolman DEM Yusof SR Begley DJ Structure and function of the blood–brain barrier Neurobiol. Dis. 2010 37 13 25 19664713
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R. & Begley, D. J. Structure and function of the blood–brain barrier. Neurobiol. Dis. 37, 13–25 (2010).19664713
3. Ballabh P Braun A Nedergaard M The blood–brain barrier: an overview: Structure, regulation, and clinical implications Neurobiol. Dis. 2004 16 1 13 15207256
Ballabh, P., Braun, A. & Nedergaard, M. The blood–brain barrier: an overview: Structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1–13 (2004).15207256
4. Pandit R Chen L Götz J The blood-brain barrier: physiology and strategies for drug delivery Adv. Drug Deliv. Rev. 2020 165-166 1 14 31790711
Pandit, R., Chen, L. & Götz, J. The blood-brain barrier: physiology and strategies for drug delivery. Adv. Drug Deliv. Rev. 165-166, 1–14 (2020).31790711
5. Banks WA From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery Nat. Rev. Drug Discov. 2016 15 275 292 26794270
Banks, W. A. From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery. Nat. Rev. Drug Discov. 15, 275–292 (2016).26794270
6. Shaw AT Yasothan U Kirkpatrick P Crizotinib Nat. Rev. Drug Discov. 2011 10 897 898 22129984
Shaw, A. T., Yasothan, U. & Kirkpatrick, P. Crizotinib. Nat. Rev. Drug Discov. 10, 897–898 (2011).22129984
7. Alauddin MM Radaram B Rao Y Yang P Piwnica-Worms D Novel derivatives of anaplastic lymphoma kinase inhibitors: synthesis, radiolabeling and preliminary biological studies on crizotinib and alectinib analogues Cancer Res. 2019 79 10 10
Alauddin, M. M., Radaram, B., Rao, Y., Yang, P. & Piwnica-Worms, D. Novel derivatives of anaplastic lymphoma kinase inhibitors: synthesis, radiolabeling and preliminary biological studies on crizotinib and alectinib analogues. Cancer Res. 79, 10–10 (2019).
8. Fromm MF Importance of P-glycoprotein at blood–tissue barriers Trends Pharmacol. Sci. 2004 25 423 429 15276711
Fromm, M. F. Importance of P-glycoprotein at blood–tissue barriers. Trends Pharmacol. Sci. 25, 423–429 (2004).15276711
9. Endicott JA Ling V The biochemistry of P-glycoprotein-mediated multidrug resistance Annu. Rev. Biochem. 1989 58 137 171 2570548
Endicott, J. A. & Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58, 137–171 (1989).2570548
10. Choudhari M Evolving new-age strategies to transport therapeutics across the blood-brain-barrier Int. J. Pharm. 2021 599 120351 33545286
Choudhari, M. et al. Evolving new-age strategies to transport therapeutics across the blood-brain-barrier. Int. J. Pharm. 599, 120351 (2021).33545286
11. Sweeney MD Sagare AP Zlokovic BV Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders Nat. Rev. Neurol. 2018 14 133 150 29377008
Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133–150 (2018).29377008
12. Arvanitis CD Ferraro GB Jain RK The blood–brain barrier and blood–tumour barrier in brain tumours and metastases Nat. Rev. Cancer 2020 20 26 41 31601988
Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26–41 (2020).31601988
13. Tang W Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics Chem. Soc. Rev. 2019 48 2967 3014 31089607
Tang, W. et al. Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem. Soc. Rev. 48, 2967–3014 (2019).31089607
14. D’Souza A Dave KM Stetler RA S. Manickam D Targeting the blood-brain barrier for the delivery of stroke therapies Adv. Drug Deliv. Rev. 2021 171 332 351 33497734
D’Souza, A., Dave, K. M., Stetler, R. A. & S. Manickam, D. Targeting the blood-brain barrier for the delivery of stroke therapies. Adv. Drug Deliv. Rev. 171, 332–351 (2021).33497734
15. Terstappen GC Meyer AH Bell RD Zhang W Strategies for delivering therapeutics across the blood–brain barrier Nat. Rev. Drug Discov. 2021 20 362 383 33649582
Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood–brain barrier. Nat. Rev. Drug Discov. 20, 362–383 (2021).33649582
16. Zhao Z Ukidve A Kim J Mitragotri S Targeting strategies for tissue-specific drug delivery Cell 2020 181 151 167 32243788
Zhao, Z., Ukidve, A., Kim, J. & Mitragotri, S. Targeting strategies for tissue-specific drug delivery. Cell 181, 151–167 (2020).32243788
17. Liu Y Castro Bravo KM Liu J Targeted liposomal drug delivery: a nanoscience and biophysical perspective Nanoscale Horiz. 2021 6 78 94 33400747
Liu, Y., Castro Bravo, K. M. & Liu, J. Targeted liposomal drug delivery: a nanoscience and biophysical perspective. Nanoscale Horiz. 6, 78–94 (2021).33400747
18. Hwang D Ramsey JD Kabanov AV Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval Adv. Drug Deliv. Rev. 2020 156 80 118 32980449
Hwang, D., Ramsey, J. D. & Kabanov, A. V. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. Adv. Drug Deliv. Rev. 156, 80–118 (2020).32980449
19. Wang H Chen Q Zhou S Carbon-based hybrid nanogels: a synergistic nanoplatform for combined biosensing, bioimaging, and responsive drug delivery Chem. Soc. Rev. 2018 47 4198 4232 29667656
Wang, H., Chen, Q. & Zhou, S. Carbon-based hybrid nanogels: a synergistic nanoplatform for combined biosensing, bioimaging, and responsive drug delivery. Chem. Soc. Rev. 47, 4198–4232 (2018).29667656
20. Mitchell MJ Engineering precision nanoparticles for drug delivery Nat. Rev. Drug Discov. 2021 20 101 124 33277608
Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021).33277608
21. Zou Y Huang B Cao L Deng Y Su J Tailored mesoporous inorganic biomaterials: assembly, functionalization, and drug delivery engineering Adv. Mater. 2021 33 2005215
Zou, Y., Huang, B., Cao, L., Deng, Y. & Su, J. Tailored mesoporous inorganic biomaterials: assembly, functionalization, and drug delivery engineering. Adv. Mater. 33, 2005215 (2021).
22. Wu F Liu J Decorated bacteria and the application in drug delivery Adv. Drug Deliv. Rev. 2022 188 114443 35817214
Wu, F. & Liu, J. Decorated bacteria and the application in drug delivery. Adv. Drug Deliv. Rev. 188, 114443 (2022).35817214
23. Le QV Lee J Lee H Shim G Oh YK Cell membrane-derived vesicles for delivery of therapeutic agents Acta Pharm. Sin. B 2021 11 2096 2113 34522579
Le, Q. V., Lee, J., Lee, H., Shim, G. & Oh, Y. K. Cell membrane-derived vesicles for delivery of therapeutic agents. Acta Pharm. Sin. B 11, 2096–2113 (2021).34522579
24. Liang Y Duan L Lu J Xia J Engineering exosomes for targeted drug delivery Theranostics 2021 11 3183 3195 33537081
Liang, Y., Duan, L., Lu, J. & Xia, J. Engineering exosomes for targeted drug delivery. Theranostics 11, 3183–3195 (2021).33537081
25. Bentivoglio M Kristensson K Tryps and trips: cell trafficking across the 100-year-old blood–brain barrier Trends Neurosci. 2014 37 325 333 24780507
Bentivoglio, M. & Kristensson, K. Tryps and trips: cell trafficking across the 100-year-old blood–brain barrier. Trends Neurosci. 37, 325–333 (2014).24780507
26. Liebner S Czupalla CJ Wolburg H Current concepts of blood-brain barrier development Int. J. Dev. Biol. 2011 55 467 476 21769778
Liebner, S., Czupalla, C. J. & Wolburg, H. Current concepts of blood-brain barrier development. Int. J. Dev. Biol. 55, 467–476 (2011).21769778
27. Upton DH Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy Theranostics 2022 12 4734 4752 35832071
Upton, D. H. et al. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics 12, 4734–4752 (2022).35832071
28. Harati R Villégier A-S Banks WA Mabondzo A Susceptibility of juvenile and adult blood–brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity J. Neuroinflammation 2012 9 273 23253775
Harati, R., Villégier, A.-S., Banks, W. A. & Mabondzo, A. Susceptibility of juvenile and adult blood–brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity. J. Neuroinflammation 9, 273 (2012).23253775
29. Cai Z Role of blood-brain barrier in Alzheimer’s disease J. Alzheimers Dis. 2018 63 1223 1234 29782323
Cai, Z. et al. Role of blood-brain barrier in Alzheimer’s disease. J. Alzheimers Dis. 63, 1223–1234 (2018).29782323
30. Eichler AF The biology of brain metastases-translation to new therapies Nat. Rev. Clin. Oncol. 2011 8 344 356 21487419
Eichler, A. F. et al. The biology of brain metastases-translation to new therapies. Nat. Rev. Clin. Oncol. 8, 344–356 (2011).21487419
31. Saraiva C Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases J. Control. Release 2016 235 34 47 27208862
Saraiva, C. et al. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J. Control. Release 235, 34–47 (2016).27208862
32. Greene C Campbell M Tight junction modulation of the blood brain barrier: CNS delivery of small molecules Tissue Barriers 2016 4 e1138017 27141420
Greene, C. & Campbell, M. Tight junction modulation of the blood brain barrier: CNS delivery of small molecules. Tissue Barriers 4, e1138017 (2016).27141420
33. Ruan S Zhou Y Jiang X Gao H Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release Adv. Sci. 2021 8 2004025
Ruan, S., Zhou, Y., Jiang, X. & Gao, H. Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release. Adv. Sci. 8, 2004025 (2021).
34. Zheng M Tuning the elasticity of polymersomes for brain tumor targeting Adv. Sci. 2021 8 e2102001
Zheng, M. et al. Tuning the elasticity of polymersomes for brain tumor targeting. Adv. Sci. 8, e2102001 (2021).
35. Song Y Hu C Fu Y Gao H Modulating the blood–brain tumor barrier for improving drug delivery efficiency and efficacy VIEW 2022 3 20200129
Song, Y., Hu, C., Fu, Y. & Gao, H. Modulating the blood–brain tumor barrier for improving drug delivery efficiency and efficacy. VIEW 3, 20200129 (2022).
36. Begley DJ Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol. Ther. 2004 104 29 45 15500907
Begley, D. J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104, 29–45 (2004).15500907
37. Zhou Y Peng Z Seven ES Leblanc RM Crossing the blood-brain barrier with nanoparticles J. Control. Release 2018 270 290 303 29269142
Zhou, Y., Peng, Z., Seven, E. S. & Leblanc, R. M. Crossing the blood-brain barrier with nanoparticles. J. Control. Release 270, 290–303 (2018).29269142
38. Kadry H Noorani B Cucullo L A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity Fluids Barriers CNS 2020 17 69 33208141
Kadry, H., Noorani, B. & Cucullo, L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17, 69 (2020).33208141
39. Xie J Shen Z Anraku Y Kataoka K Chen X Nanomaterial-based blood-brain-barrier (BBB) crossing strategies Biomaterials 2019 224 119491 31546096
Xie, J., Shen, Z., Anraku, Y., Kataoka, K. & Chen, X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 224, 119491 (2019).31546096
40. Daneman R Prat A The blood-brain barrier CSH Perspect. Biol. 2015 7 a020412
Daneman, R. & Prat, A. The blood-brain barrier. CSH Perspect. Biol. 7, a020412 (2015).
41. Zhang T Li W Meng G Wang P Liao W Strategies for transporting nanoparticles across the blood-brain barrier Biomater. Sci. 2016 4 219 229 26646694
Zhang, T., Li, W., Meng, G., Wang, P. & Liao, W. Strategies for transporting nanoparticles across the blood-brain barrier. Biomater. Sci. 4, 219–229 (2016).26646694
42. Reese TS Karnovsky MJ Fine structural localization of a blood-brain barrier to exogenous peroxidase J. Cell Biol. 1967 34 207 217 6033532
Reese, T. S. & Karnovsky, M. J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34, 207–217 (1967).6033532
43. Westergaard E Brightman MW Transport of proteins across normal cerebral arterioles J. Comp. Neurol. 1973 152 17 44 4765853
Westergaard, E. & Brightman, M. W. Transport of proteins across normal cerebral arterioles. J. Comp. Neurol. 152, 17–44 (1973).4765853
44. Langen UH Ayloo S Gu C Development and cell biology of the blood-brain barrier Annu. Rev. Cell Dev. Bi. 2019 35 591 613
Langen, U. H., Ayloo, S. & Gu, C. Development and cell biology of the blood-brain barrier. Annu. Rev. Cell Dev. Bi. 35, 591–613 (2019).
45. Lippmann ES Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells Nat. Biotechnol. 2012 30 783 791 22729031
Lippmann, E. S. et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat. Biotechnol. 30, 783–791 (2012).22729031
46. Betz AL Firth JA Goldstein GW Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells Brain Res. 1980 192 17 28 6103738
Betz, A. L., Firth, J. A. & Goldstein, G. W. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res. 192, 17–28 (1980).6103738
47. Alhadidi Q Bin Sayeed MS Shah ZA The interplay between cofilin and phospho-cofilin: Its role in maintaining blood brain barrier integrity CNS Neurol. Disord. -Drug Targets 2017 16 279 290 28124604
Alhadidi, Q., Bin Sayeed, M. S. & Shah, Z. A. The interplay between cofilin and phospho-cofilin: Its role in maintaining blood brain barrier integrity. CNS Neurol. Disord. -Drug Targets 16, 279–290 (2017).28124604
48. Oldendorf WH Cornford ME Brown WJ The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat Ann. Neurol. 1977 1 409 417 617259
Oldendorf, W. H., Cornford, M. E. & Brown, W. J. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann. Neurol. 1, 409–417 (1977).617259
49. Li X Cerium oxide nanoparticles with antioxidative neurorestoration for ischemic stroke Biomaterials 2022 291 121904 36403323
Li, X. et al. Cerium oxide nanoparticles with antioxidative neurorestoration for ischemic stroke. Biomaterials 291, 121904 (2022).36403323
50. Rössler K Expression of leucocyte adhesion molecules at the human blood-brain barrier (BBB) J. Neurosci. Res. 1992 31 365 374 1374132
Rössler, K. et al. Expression of leucocyte adhesion molecules at the human blood-brain barrier (BBB). J. Neurosci. Res. 31, 365–374 (1992).1374132
51. Santa-Maria AR Flow induces barrier and glycocalyx-related genes and negative surface charge in a lab-on-a-chip human blood-brain barrier model J. Cereb. Blood Flow Metab. 2021 41 2201 2215 33563079
Santa-Maria, A. R. et al. Flow induces barrier and glycocalyx-related genes and negative surface charge in a lab-on-a-chip human blood-brain barrier model. J. Cereb. Blood Flow Metab. 41, 2201–2215 (2021).33563079
52. Zhao Y The role of ferroptosis in blood-brain barrier injury Cell. Mol. Neurobiol. 2023 43 223 236 35106665
Zhao, Y. et al. The role of ferroptosis in blood-brain barrier injury. Cell. Mol. Neurobiol. 43, 223–236 (2023).35106665
53. Chu C Li J Boado RJ Pardridge WM Blood-brain barrier genomics and cloning of a novel organic anion transporter J. Cereb. Blood Flow Metab. 2008 28 291 301 17667996
Chu, C., Li, J., Boado, R. J. & Pardridge, W. M. Blood-brain barrier genomics and cloning of a novel organic anion transporter. J. Cereb. Blood Flow Metab. 28, 291–301 (2008).17667996
54. Tietz S Engelhardt B Brain barriers: Crosstalk between complex tight junctions and adherens junctions J. Cell Biol. 2015 209 493 506 26008742
Tietz, S. & Engelhardt, B. Brain barriers: Crosstalk between complex tight junctions and adherens junctions. J. Cell Biol. 209, 493–506 (2015).26008742
55. Wilhelm I Fazakas C Krizbai IA In vitro models of the blood-brain barrier Acta Neurobiol. Exp. (Warsz.) 2011 71 113 128 21499332
Wilhelm, I., Fazakas, C. & Krizbai, I. A. In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. (Warsz.) 71, 113–128 (2011).21499332
56. Yao S Astrocytic lactate dehydrogenase A regulates neuronal excitability and depressive-like behaviors through lactate homeostasis in mice Nat. Commun. 2023 14 729 36759610
Yao, S. et al. Astrocytic lactate dehydrogenase A regulates neuronal excitability and depressive-like behaviors through lactate homeostasis in mice. Nat. Commun. 14, 729 (2023).36759610
57. Sofroniew MV Vinters HV Astrocytes: biology and pathology Acta Neuropathol. 2010 119 7 35 20012068
Sofroniew, M. V. & Vinters, H. V. Astrocytes: biology and pathology. Acta Neuropathol. 119, 7–35 (2010).20012068
58. Mazumder AG Julé AM Cullen PF Sun D Astrocyte heterogeneity within white matter tracts and a unique subpopulation of optic nerve head astrocytes iScience 2022 25 105568 36465110
Mazumder, A. G., Julé, A. M., Cullen, P. F. & Sun, D. Astrocyte heterogeneity within white matter tracts and a unique subpopulation of optic nerve head astrocytes. iScience 25, 105568 (2022).36465110
59. Mayo F Aquaporin-4 expression switches from white to gray matter regions during postnatal development of the central nervous system Int. J. Mol. Sci. 2023 24 3048 36769371
Mayo, F. et al. Aquaporin-4 expression switches from white to gray matter regions during postnatal development of the central nervous system. Int. J. Mol. Sci. 24, 3048 (2023).36769371
60. Nagelhus EA Ottersen OP Physiological roles of aquaporin-4 in brain Physiol. Rev. 2013 93 1543 1562 24137016
Nagelhus, E. A. & Ottersen, O. P. Physiological roles of aquaporin-4 in brain. Physiol. Rev. 93, 1543–1562 (2013).24137016
61. Kim DY CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury J. Mol. Med. 2020 98 875 886 32415357
Kim, D. Y. et al. CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury. J. Mol. Med. 98, 875–886 (2020).32415357
62. Zhou X Glymphatic system in the central nervous system, a novel therapeutic direction against brain edema after stroke Front. Aging Neurosci. 2021 13 698036 34421575
Zhou, X. et al. Glymphatic system in the central nervous system, a novel therapeutic direction against brain edema after stroke. Front. Aging Neurosci. 13, 698036 (2021).34421575
63. Ahmadpour N Kantroo M Stobart JL Extracellular calcium influx pathways in astrocyte calcium microdomain physiology Biomolecules 2021 11 1467 34680100
Ahmadpour, N., Kantroo, M. & Stobart, J. L. Extracellular calcium influx pathways in astrocyte calcium microdomain physiology. Biomolecules 11, 1467 (2021).34680100
64. Abbott NJ Rönnbäck L Hansson E Astrocyte-endothelial interactions at the blood-brain barrier Nat. Rev. Neurosci. 2006 7 41 53 16371949
Abbott, N. J., Rönnbäck, L. & Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41–53 (2006).16371949
65. McConnell HL Mishra A Cells of the blood-brain barrier: an overview of the neurovascular unit in health and disease Methods Mol. Biol. 2022 2492 3 24 35733036
McConnell, H. L. & Mishra, A. Cells of the blood-brain barrier: an overview of the neurovascular unit in health and disease. Methods Mol. Biol. 2492, 3–24 (2022).35733036
66. Zhao J Activated astrocytes attenuate neocortical seizures in rodent models through driving Na+-K+-ATPase Nat. Commun. 2022 13 7136 36414629
Zhao, J. et al. Activated astrocytes attenuate neocortical seizures in rodent models through driving Na+-K+-ATPase. Nat. Commun. 13, 7136 (2022).36414629
67. Savidge TC Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione Gastroenterology 2007 132 1344 1358 17408650
Savidge, T. C. et al. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology 132, 1344–1358 (2007).17408650
68. Saunders NR Ek CJ Habgood MD Dziegielewska KM Barriers in the brain: a renaissance? Trends Neurosci. 2008 31 279 286 18471905
Saunders, N. R., Ek, C. J., Habgood, M. D. & Dziegielewska, K. M. Barriers in the brain: a renaissance? Trends Neurosci. 31, 279–286 (2008).18471905
69. Araya R BMP signaling through BMPRIA in astrocytes is essential for proper cerebral angiogenesis and formation of the blood-brain-barrier Mol. Cell. Neurosci. 2008 38 417 430 18501628
Araya, R. et al. BMP signaling through BMPRIA in astrocytes is essential for proper cerebral angiogenesis and formation of the blood-brain-barrier. Mol. Cell. Neurosci. 38, 417–430 (2008).18501628
70. Zhao Z Nelson AR Betsholtz C Zlokovic BV Establishment and dysfunction of the blood-brain barrier Cell 2015 163 1064 1078 26590417
Zhao, Z., Nelson, A. R., Betsholtz, C. & Zlokovic, B. V. Establishment and dysfunction of the blood-brain barrier. Cell 163, 1064–1078 (2015).26590417
71. Schurhoff N Toborek M Circadian rhythms in the blood-brain barrier: impact on neurological disorders and stress responses Mol. Brain 2023 16 5 36635730
Schurhoff, N. & Toborek, M. Circadian rhythms in the blood-brain barrier: impact on neurological disorders and stress responses. Mol. Brain 16, 5 (2023).36635730
72. Bhasiin K Heintz O Colodner KJ Optimization and technical considerations for the dye-exclusion protocol used to assess blood-brain barrier integrity in adult drosophila melanogaster Int. J. Mol. Sci. 2023 24 1886 36768206
Bhasiin, K., Heintz, O. & Colodner, K. J. Optimization and technical considerations for the dye-exclusion protocol used to assess blood-brain barrier integrity in adult drosophila melanogaster. Int. J. Mol. Sci. 24, 1886 (2023).36768206
73. Daneman R Zhou L Kebede AA Barres BA Pericytes are required for blood-brain barrier integrity during embryogenesis Nature 2010 468 562 566 20944625
Daneman, R., Zhou, L., Kebede, A. A. & Barres, B. A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468, 562–566 (2010).20944625
74. Frank RN Turczyn TJ Das A Pericyte coverage of retinal and cerebral capillaries Invest. Ophthalmol. Vis. Sci. 1990 31 999 1007 2354923
Frank, R. N., Turczyn, T. J. & Das, A. Pericyte coverage of retinal and cerebral capillaries. Invest. Ophthalmol. Vis. Sci. 31, 999–1007 (1990).2354923
75. Armulik A Mäe M Betsholtz C Pericytes and the blood-brain barrier: recent advances and implications for the delivery of CNS therapy Ther. Deliv. 2011 2 419 422 22826851
Armulik, A., Mäe, M. & Betsholtz, C. Pericytes and the blood-brain barrier: recent advances and implications for the delivery of CNS therapy. Ther. Deliv. 2, 419–422 (2011).22826851
76. Brown LS Pericytes and neurovascular function in the healthy and diseased brain Front. Cell. Neurosci. 2019 13 282 31316352
Brown, L. S. et al. Pericytes and neurovascular function in the healthy and diseased brain. Front. Cell. Neurosci. 13, 282 (2019).31316352
77. Liao K Niu F Hu G Buch S Morphine-mediated release of astrocyte-derived extracellular vesicle miR-23a induces loss of pericyte coverage at the blood-brain barrier: Implications for neuroinflammation Front. Cell Dev. Biol. 2022 10 984375 36478740
Liao, K., Niu, F., Hu, G. & Buch, S. Morphine-mediated release of astrocyte-derived extracellular vesicle miR-23a induces loss of pericyte coverage at the blood-brain barrier: Implications for neuroinflammation. Front. Cell Dev. Biol. 10, 984375 (2022).36478740
78. Goncalves A Antonetti DA Transgenic animal models to explore and modulate the blood brain and blood retinal barriers of the CNS Fluids Barriers CNS 2022 19 86 36320068
Goncalves, A. & Antonetti, D. A. Transgenic animal models to explore and modulate the blood brain and blood retinal barriers of the CNS. Fluids Barriers CNS 19, 86 (2022).36320068
79. Jeske R Albo J Marzano M Bejoy J Li Y Engineering brain-specific pericytes from human pluripotent stem cells Tissue Eng. Part B-Rev. 2020 26 367 382 32571167
Jeske, R., Albo, J., Marzano, M., Bejoy, J. & Li, Y. Engineering brain-specific pericytes from human pluripotent stem cells. Tissue Eng. Part B-Rev. 26, 367–382 (2020).32571167
80. Hellström M Kalén M Lindahl P Abramsson A Betsholtz C Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse Development 1999 126 3047 3055 10375497
Hellström, M., Kalén, M., Lindahl, P., Abramsson, A. & Betsholtz, C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126, 3047–3055 (1999).10375497
81. Tillie R A switch from cell-associated to soluble PDGF-B protects against atherosclerosis, despite driving extramedullary hematopoiesis Cells 2021 10 1746 34359916
Tillie, R. et al. A switch from cell-associated to soluble PDGF-B protects against atherosclerosis, despite driving extramedullary hematopoiesis. Cells 10, 1746 (2021).34359916
82. Lindahl P Johansson BR Levéen P Betsholtz C Pericyte loss and microaneurysm formation in PDGF-B-deficient mice Science 1997 277 242 245 9211853
Lindahl, P., Johansson, B. R., Levéen, P. & Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242–245 (1997).9211853
83. Armulik A Pericytes regulate the blood-brain barrier Nature 2010 468 557 561 20944627
Armulik, A. et al. Pericytes regulate the blood-brain barrier. Nature 468, 557–561 (2010).20944627
84. Sengillo JD Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer’s disease Brain Pathol. 2013 23 303 310 23126372
Sengillo, J. D. et al. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer’s disease. Brain Pathol. 23, 303–310 (2013).23126372
85. Attwell D Mishra A Hall CN O’Farrell FM Dalkara T What is a pericyte? J. Cereb. Blood Flow Metab. 2016 36 451 455 26661200
Attwell, D., Mishra, A., Hall, C. N., O’Farrell, F. M. & Dalkara, T. What is a pericyte? J. Cereb. Blood Flow Metab. 36, 451–455 (2016).26661200
86. Ribatti D Nico B Crivellato E The role of pericytes in angiogenesis Int. J. Dev. Biol. 2011 55 261 268 21710434
Ribatti, D., Nico, B. & Crivellato, E. The role of pericytes in angiogenesis. Int. J. Dev. Biol. 55, 261–268 (2011).21710434
87. Rustenhoven J Jansson D Smyth LC Dragunow M Brain pericytes as mediators of neuroinflammation Trends Pharmacol. Sci. 2017 38 291 304 28017362
Rustenhoven, J., Jansson, D., Smyth, L. C. & Dragunow, M. Brain pericytes as mediators of neuroinflammation. Trends Pharmacol. Sci. 38, 291–304 (2017).28017362
88. Luissint AC Artus C Glacial F Ganeshamoorthy K Couraud PO Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation Fluids Barriers CNS 2012 9 23 23140302
Luissint, A. C., Artus, C., Glacial, F., Ganeshamoorthy, K. & Couraud, P. O. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9, 23 (2012).23140302
89. Anderson JM Van Itallie CM Physiology and function of the tight junction CSH Perspect. Biol. 2009 1 a002584
Anderson, J. M. & Van Itallie, C. M. Physiology and function of the tight junction. CSH Perspect. Biol. 1, a002584 (2009).
90. Dong X Current strategies for brain drug delivery Theranostics 2018 8 1481 1493 29556336
Dong, X. Current strategies for brain drug delivery. Theranostics 8, 1481–1493 (2018).29556336
91. Ahlawat J Nanocarriers as potential drug delivery candidates for overcoming the blood-brain barrier: challenges and possibilities ACS Omega 2020 5 12583 12595 32548442
Ahlawat, J. et al. Nanocarriers as potential drug delivery candidates for overcoming the blood-brain barrier: challenges and possibilities. ACS Omega 5, 12583–12595 (2020).32548442
92. Gumbiner B Structure, biochemistry, and assembly of epithelial tight junctions Am. J. Physiol. 1987 253 C749 C758 3322036
Gumbiner, B. Structure, biochemistry, and assembly of epithelial tight junctions. Am. J. Physiol. 253, C749–C758 (1987).3322036
93. Gumbiner BM Breaking through the tight junction barrier J. Cell Biol. 1993 123 1631 1633 8276885
Gumbiner, B. M. Breaking through the tight junction barrier. J. Cell Biol. 123, 1631–1633 (1993).8276885
94. Tsukita S Furuse M Itoh M Multifunctional strands in tight junctions Nat. Rev. Mol. Cell Biol. 2001 2 285 293 11283726
Tsukita, S., Furuse, M. & Itoh, M. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2, 285–293 (2001).11283726
95. Haseloff RF Dithmer S Winkler L Wolburg H Blasig IE Transmembrane proteins of the tight junctions at the blood-brain barrier: structural and functional aspects Semin. Cell Dev. Biol. 2015 38 16 25 25433243
Haseloff, R. F., Dithmer, S., Winkler, L., Wolburg, H. & Blasig, I. E. Transmembrane proteins of the tight junctions at the blood-brain barrier: structural and functional aspects. Semin. Cell Dev. Biol. 38, 16–25 (2015).25433243
96. Furuse M Occludin: a novel integral membrane protein localizing at tight junctions J. Cell Biol. 1993 123 1777 1788 8276896
Furuse, M. et al. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell Biol. 123, 1777–1788 (1993).8276896
97. Persidsky Y Ramirez SH Haorah J Kanmogne GD Blood-brain barrier: structural components and function under physiologic and pathologic conditions J. Neuroimmune Pharmacol. 2006 1 223 236 18040800
Persidsky, Y., Ramirez, S. H., Haorah, J. & Kanmogne, G. D. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1, 223–236 (2006).18040800
98. Ikenouchi J Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells J. Cell Biol. 2005 171 939 945 16365161
Ikenouchi, J. et al. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J. Cell Biol. 171, 939–945 (2005).16365161
99. Kojima T Expression of tricellulin in epithelial cells and non-epithelial cells Histol. Histopathol. 2013 28 1383 1392 24101385
Kojima, T. et al. Expression of tricellulin in epithelial cells and non-epithelial cells. Histol. Histopathol. 28, 1383–1392 (2013).24101385
100. Ebnet K Junctional adhesion molecules (JAMs): cell adhesion receptors with pleiotropic functions in cell physiology and development Physiol. Rev. 2017 97 1529 1554 28931565
Ebnet, K. Junctional adhesion molecules (JAMs): cell adhesion receptors with pleiotropic functions in cell physiology and development. Physiol. Rev. 97, 1529–1554 (2017).28931565
101. Chan Y Yi-Zhi-Fang-Dai formula exerts a protective effect on the injury of tight junction scaffold proteins in vitro and in vivo by mediating autophagy through regulation of the RAGE/CaMKKβ/AMPK/mTOR Pathway Biol. Pharm. Bull. 2020 43 1847 1858 33268702
Chan, Y. et al. Yi-Zhi-Fang-Dai formula exerts a protective effect on the injury of tight junction scaffold proteins in vitro and in vivo by mediating autophagy through regulation of the RAGE/CaMKKβ/AMPK/mTOR Pathway. Biol. Pharm. Bull. 43, 1847–1858 (2020).33268702
102. Zhong Y Monoclonal antibody 7H6 reacts with a novel tight junction-associated protein distinct from ZO-1, cingulin and ZO-2 J. Cell Biol. 1993 120 477 483 8421059
Zhong, Y. et al. Monoclonal antibody 7H6 reacts with a novel tight junction-associated protein distinct from ZO-1, cingulin and ZO-2. J. Cell Biol. 120, 477–483 (1993).8421059
103. Tajes M The blood-brain barrier: structure, function and therapeutic approaches to cross it Mol. Membr. Biol. 2014 31 152 167 25046533
Tajes, M. et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol. Membr. Biol. 31, 152–167 (2014).25046533
104. Liebner S Functional morphology of the blood-brain barrier in health and disease Acta Neuropathol. 2018 135 311 336 29411111
Liebner, S. et al. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 135, 311–336 (2018).29411111
105. Teleanu DM Chircov C Grumezescu AM Volceanov A Teleanu RI Blood-brain delivery methods using nanotechnology Pharmaceutics 2018 10 269 30544966
Teleanu, D. M., Chircov, C., Grumezescu, A. M., Volceanov, A. & Teleanu, R. I. Blood-brain delivery methods using nanotechnology. Pharmaceutics 10, 269 (2018).30544966
106. Willis CL Meske DS Davis TP Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation J. Cereb. Blood Flow Metab. 2010 30 1847 1859 20700133
Willis, C. L., Meske, D. S. & Davis, T. P. Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation. J. Cereb. Blood Flow Metab. 30, 1847–1859 (2010).20700133
107. Keep RF Brain endothelial cell junctions after cerebral hemorrhage: Changes, mechanisms and therapeutic targets J. Cereb. Blood Flow Metab. 2018 38 1255 1275 29737222
Keep, R. F. et al. Brain endothelial cell junctions after cerebral hemorrhage: Changes, mechanisms and therapeutic targets. J. Cereb. Blood Flow Metab. 38, 1255–1275 (2018).29737222
108. Krol S Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier Chem. Rev. 2013 113 1877 1903 23157552
Krol, S. et al. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem. Rev. 113, 1877–1903 (2013).23157552
109. Cai N Roflumilast, a cyclic nucleotide phosphodiesterase 4 inhibitor, protects against cerebrovascular endothelial injury following cerebral ischemia/reperfusion by activating the Notch1/Hes1 pathway Eur. J. Pharmacol. 2022 926 175027 35569548
Cai, N. et al. Roflumilast, a cyclic nucleotide phosphodiesterase 4 inhibitor, protects against cerebrovascular endothelial injury following cerebral ischemia/reperfusion by activating the Notch1/Hes1 pathway. Eur. J. Pharmacol. 926, 175027 (2022).35569548
110. Zhao Y Factors influencing the blood-brain barrier permeability Brain Res. 2022 1788 147937 35568085
Zhao, Y. et al. Factors influencing the blood-brain barrier permeability. Brain Res. 1788, 147937 (2022).35568085
111. Kwak M Adherens junctions organize size-selective proteolytic hotspots critical for Notch signalling Nat. Cell Biol. 2022 24 1739 1753 36456828
Kwak, M. et al. Adherens junctions organize size-selective proteolytic hotspots critical for Notch signalling. Nat. Cell Biol. 24, 1739–1753 (2022).36456828
112. Malinova TS Huveneers S Sensing of cytoskeletal forces by asymmetric adherens junctions Trends Cell Biol. 2018 28 328 341 29195724
Malinova, T. S. & Huveneers, S. Sensing of cytoskeletal forces by asymmetric adherens junctions. Trends Cell Biol. 28, 328–341 (2018).29195724
113. Stamatovic SM Johnson AM Keep RF Andjelkovic AV Junctional proteins of the blood-brain barrier: New insights into function and dysfunction Tissue Barriers 2016 4 e1154641 27141427
Stamatovic, S. M., Johnson, A. M., Keep, R. F. & Andjelkovic, A. V. Junctional proteins of the blood-brain barrier: New insights into function and dysfunction. Tissue Barriers 4, e1154641 (2016).27141427
114. Shen D Metformin preserves VE-cadherin in choroid plexus and attenuates hydrocephalus via VEGF/VEGFR2/p-Src in an intraventricular hemorrhage rat model Int. J. Mol. Sci. 2022 23 8552 35955686
Shen, D. et al. Metformin preserves VE-cadherin in choroid plexus and attenuates hydrocephalus via VEGF/VEGFR2/p-Src in an intraventricular hemorrhage rat model. Int. J. Mol. Sci. 23, 8552 (2022).35955686
115. Gioelli N Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability Nat. Commun. 2022 13 4188 35858913
Gioelli, N. et al. Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability. Nat. Commun. 13, 4188 (2022).35858913
116. Ali J Liao F Martens E Muller WA Vascular endothelial cadherin (VE-cadherin): cloning and role in endothelial cell-cell adhesion Microcirculation 1997 4 267 277 9219219
Ali, J., Liao, F., Martens, E. & Muller, W. A. Vascular endothelial cadherin (VE-cadherin): cloning and role in endothelial cell-cell adhesion. Microcirculation 4, 267–277 (1997).9219219
117. Rho SS Ando K Fukuhara S Dynamic regulation of vascular permeability by vascular endothelial cadherin-mediated endothelial cell-cell junctions J. Nippon Med. Sch. 2017 84 148 159 28978894
Rho, S. S., Ando, K. & Fukuhara, S. Dynamic regulation of vascular permeability by vascular endothelial cadherin-mediated endothelial cell-cell junctions. J. Nippon Med. Sch. 84, 148–159 (2017).28978894
118. Kuo WT Odenwald MA Turner JR Zuo L Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival Ann. N. Y. Acad. Sci. 2022 1514 21 33 35580994
Kuo, W. T., Odenwald, M. A., Turner, J. R. & Zuo, L. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival. Ann. N. Y. Acad. Sci. 1514, 21–33 (2022).35580994
119. Liang J PEDF protects endothelial barrier integrity during acute myocardial infarction via 67LR Int. J. Mol. Sci. 2023 24 2787 36769107
Liang, J. et al. PEDF protects endothelial barrier integrity during acute myocardial infarction via 67LR. Int. J. Mol. Sci. 24, 2787 (2023).36769107
120. Brandtner AK Lehner GF Pircher A Feistritzer C Joannidis M Differential procoagulatory response of microvascular, arterial and venous endothelial cells upon inflammation in vitro Thromb. Res. 2021 205 70 80 34265605
Brandtner, A. K., Lehner, G. F., Pircher, A., Feistritzer, C. & Joannidis, M. Differential procoagulatory response of microvascular, arterial and venous endothelial cells upon inflammation in vitro. Thromb. Res. 205, 70–80 (2021).34265605
121. Zucchini C CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity Oncogene 2014 33 1912 1921 23644663
Zucchini, C. et al. CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene 33, 1912–1921 (2014).23644663
122. Dash S Duraivelan K Samanta D Cadherin-mediated host-pathogen interactions Cell. Microbiol. 2021 23 e13316 33543826
Dash, S., Duraivelan, K. & Samanta, D. Cadherin-mediated host-pathogen interactions. Cell. Microbiol. 23, e13316 (2021).33543826
123. Turowski P Kenny BA The blood-brain barrier and methamphetamine: open sesame? Front. Neurosci. 2015 9 156 25999807
Turowski, P. & Kenny, B. A. The blood-brain barrier and methamphetamine: open sesame? Front. Neurosci. 9, 156 (2015).25999807
124. Segarra M Aburto MR Acker-Palmer A Blood-brain barrier dynamics to maintain brain homeostasis Trends Neurosci. 2021 44 393 405 33423792
Segarra, M., Aburto, M. R. & Acker-Palmer, A. Blood-brain barrier dynamics to maintain brain homeostasis. Trends Neurosci. 44, 393–405 (2021).33423792
125. Bhattacharya A Kaushik DK Lozinski BM Yong VW Beyond barrier functions: Roles of pericytes in homeostasis and regulation of neuroinflammation J. Neurosci. Res. 2020 98 2390 2405 32815569
Bhattacharya, A., Kaushik, D. K., Lozinski, B. M. & Yong, V. W. Beyond barrier functions: Roles of pericytes in homeostasis and regulation of neuroinflammation. J. Neurosci. Res. 98, 2390–2405 (2020).32815569
126. Fong CW Permeability of the blood–brain barrier: molecular mechanism of transport of drugs and physiologically important compounds J. Membr. Biol. 2015 248 651 669 25675910
Fong, C. W. Permeability of the blood–brain barrier: molecular mechanism of transport of drugs and physiologically important compounds. J. Membr. Biol. 248, 651–669 (2015).25675910
127. Galea I The blood–brain barrier in systemic infection and inflammation Cell. Mol. Immunol. 2021 18 2489 2501 34594000
Galea, I. The blood–brain barrier in systemic infection and inflammation. Cell. Mol. Immunol. 18, 2489–2501 (2021).34594000
128. Sonar SA Lal G Blood–brain barrier and its function during inflammation and autoimmunity J. Leukoc. Biol. 2018 103 839 853 29431873
Sonar, S. A. & Lal, G. Blood–brain barrier and its function during inflammation and autoimmunity. J. Leukoc. Biol. 103, 839–853 (2018).29431873
129. Harilal S Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules Brain Res. Bull. 2020 160 121 140 32315731
Harilal, S. et al. Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules. Brain Res. Bull. 160, 121–140 (2020).32315731
130. Yang X Wang Q Cao E Structure of the human cation–chloride cotransporter NKCC1 determined by single-particle electron cryo-microscopy Nat. Commun. 2020 11 1016 32081947
Yang, X., Wang, Q. & Cao, E. Structure of the human cation–chloride cotransporter NKCC1 determined by single-particle electron cryo-microscopy. Nat. Commun. 11, 1016 (2020).32081947
131. Sweeney MD Zhao Z Montagne A Nelson AR Zlokovic BV Blood-brain barrier: from physiology to disease and back Physiol. Rev. 2019 99 21 78 30280653
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R. & Zlokovic, B. V. Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019).30280653
132. DeMaio A Mehrotra S Sambamurti K Husain S The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases J. Neuroinflammation 2022 19 251 36209107
DeMaio, A., Mehrotra, S., Sambamurti, K. & Husain, S. The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases. J. Neuroinflammation 19, 251 (2022).36209107
133. Yang J Luly KM Green JJ Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2022 15 e1853 36193561
Yang, J., Luly, K. M. & Green, J. J. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 15, e1853 (2022).36193561
134. Pardridge WM CSF, blood-brain barrier, and brain drug delivery Expert Opin. Drug Deliv. 2016 13 963 975 27020469
Pardridge, W. M. CSF, blood-brain barrier, and brain drug delivery. Expert Opin. Drug Deliv. 13, 963–975 (2016).27020469
135. Fowler MJ Intrathecal drug delivery in the era of nanomedicine Adv. Drug Deliv. Rev. 2020 165-166 77 95 32142739
Fowler, M. J. et al. Intrathecal drug delivery in the era of nanomedicine. Adv. Drug Deliv. Rev. 165-166, 77–95 (2020).32142739
136. Porensky PN Burghes AH Antisense oligonucleotides for the treatment of spinal muscular atrophy Hum. Gene Ther. 2013 24 489 498 23544870
Porensky, P. N. & Burghes, A. H. Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum. Gene Ther. 24, 489–498 (2013).23544870
137. Lonser RR Sarntinoranont M Morrison PF Oldfield EH Convection-enhanced delivery to the central nervous system J. Neurosurg. 2015 122 697 706 25397365
Lonser, R. R., Sarntinoranont, M., Morrison, P. F. & Oldfield, E. H. Convection-enhanced delivery to the central nervous system. J. Neurosurg. 122, 697–706 (2015).25397365
138. Mehta AM Sonabend AM Bruce JN Convection-enhanced delivery Neurotherapeutics 2017 14 358 371 28299724
Mehta, A. M., Sonabend, A. M. & Bruce, J. N. Convection-enhanced delivery. Neurotherapeutics 14, 358–371 (2017).28299724
139. Gurke J Hybrid fabrication of multimodal intracranial implants for electrophysiology and local drug delivery Mater. Horiz. 2022 9 1727 1734 35474130
Gurke, J. et al. Hybrid fabrication of multimodal intracranial implants for electrophysiology and local drug delivery. Mater. Horiz. 9, 1727–1734 (2022).35474130
140. Campbell A Wu C Chronically implanted intracranial electrodes: Tissue reaction and electrical changes Micromachines 2018 9 430 30424363
Campbell, A. & Wu, C. Chronically implanted intracranial electrodes: Tissue reaction and electrical changes. Micromachines 9, 430 (2018).30424363
141. Lozano AM Deep brain stimulation: current challenges and future directions Nat. Rev. Neurol. 2019 15 148 160 30683913
Lozano, A. M. et al. Deep brain stimulation: current challenges and future directions. Nat. Rev. Neurol. 15, 148–160 (2019).30683913
142. Cagnan H Denison T McIntyre C Brown P Emerging technologies for improved deep brain stimulation Nat. Biotechnol. 2019 37 1024 1033 31477926
Cagnan, H., Denison, T., McIntyre, C. & Brown, P. Emerging technologies for improved deep brain stimulation. Nat. Biotechnol. 37, 1024–1033 (2019).31477926
143. Liu Y Microneedle-mediated vascular endothelial growth factor delivery promotes angiogenesis and functional recovery after stroke J. Control. Release 2021 338 610 622 34481025
Liu, Y. et al. Microneedle-mediated vascular endothelial growth factor delivery promotes angiogenesis and functional recovery after stroke. J. Control. Release 338, 610–622 (2021).34481025
144. Abdelkader H Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants Adv. Drug Deliv. Rev. 2021 177 113957 34481032
Abdelkader, H. et al. Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants. Adv. Drug Deliv. Rev. 177, 113957 (2021).34481032
145. Shapira-Furman T Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer J. Control. Release 2019 295 93 101 30605703
Shapira-Furman, T. et al. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. J. Control. Release 295, 93–101 (2019).30605703
146. Wang Z Silk microneedle patch capable of on-demand multidrug delivery to the brain for glioblastoma treatment Adv. Mater. 2022 34 2106606
Wang, Z. et al. Silk microneedle patch capable of on-demand multidrug delivery to the brain for glioblastoma treatment. Adv. Mater. 34, 2106606 (2022).
147. Hladky SB Barrand MA Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier Fluids Barriers CNS 2018 15 30 30340614
Hladky, S. B. & Barrand, M. A. Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier. Fluids Barriers CNS 15, 30 (2018).30340614
148. Hersh AM Alomari S Tyler BM Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology Int. J. Mol. Sci. 2022 23 4153 35456971
Hersh, A. M., Alomari, S. & Tyler, B. M. Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int. J. Mol. Sci. 23, 4153 (2022).35456971
149. Brasnjevic I Steinbusch HWM Schmitz C Martinez Martinez P Delivery of peptide and protein drugs over the blood–brain barrier Prog. Neurobiol. 2009 87 212 251 19395337
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C. & Martinez Martinez, P. Delivery of peptide and protein drugs over the blood–brain barrier. Prog. Neurobiol. 87, 212–251 (2009).19395337
150. Gu Y Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway Neuropharmacology 2013 75 407 415 23973310
Gu, Y. et al. Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway. Neuropharmacology 75, 407–415 (2013).23973310
151. Han L Increased nanoparticle delivery to brain tumors by autocatalytic oriming for improved treatment and imaging ACS Nano 2016 10 4209 4218 26967254
Han, L. et al. Increased nanoparticle delivery to brain tumors by autocatalytic oriming for improved treatment and imaging. ACS Nano 10, 4209–4218 (2016).26967254
152. Miao T Nanoparticles surmounting blood-brain tumor barrier through both transcellular and paracellular pathways to target brain metastases Adv. Funct. Mater. 2019 29 1900259
Miao, T. et al. Nanoparticles surmounting blood-brain tumor barrier through both transcellular and paracellular pathways to target brain metastases. Adv. Funct. Mater. 29, 1900259 (2019).
153. Al Hajj M Wicha MS Benito Hernandez A Morrison SJ Clarke MF Prospective identification of tumorigenic breast cancer cells Proc. Natl Acad. Sci. USA 2003 100 3983 3988 12629218
Al Hajj, M., Wicha, M. S., Benito Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).12629218
154. van den Broek SL Shalgunov V Herth MM Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy Biomater. Adv. 2022 141 213125 36182833
van den Broek, S. L., Shalgunov, V. & Herth, M. M. Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy. Biomater. Adv. 141, 213125 (2022).36182833
155. Al Ahmady ZS Selective brain entry of lipid nanoparticles in haemorrhagic stroke is linked to biphasic blood-brain barrier disruption Theranostics 2022 12 4477 4497 35832077
Al Ahmady, Z. S. et al. Selective brain entry of lipid nanoparticles in haemorrhagic stroke is linked to biphasic blood-brain barrier disruption. Theranostics 12, 4477–4497 (2022).35832077
156. Liu Z Effect of baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats Int. J. Pharm. 2015 489 131 138 25895718
Liu, Z. et al. Effect of baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats. Int. J. Pharm. 489, 131–138 (2015).25895718
157. Tsuji A Tamai I Carrier-mediated or specialized transport of drugs across the blood–brain barrier Adv. Drug Deliv. Rev. 1999 36 277 290 10837720
Tsuji, A. & Tamai, I. Carrier-mediated or specialized transport of drugs across the blood–brain barrier. Adv. Drug Deliv. Rev. 36, 277–290 (1999).10837720
158. Pardridge WM CNS drug design based on principles of blood-brain barrier transport J. Neurochem. 1998 70 1781 1792 9572261
Pardridge, W. M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70, 1781–1792 (1998).9572261
159. Henkin RI Intranasal delivery to the brain Nat. Biotechnol. 2011 29 480 21654661
Henkin, R. I. Intranasal delivery to the brain. Nat. Biotechnol. 29, 480 (2011).21654661
160. Agrawal M Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs J. Control. Release 2018 281 139 177 29772289
Agrawal, M. et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J. Control. Release 281, 139–177 (2018).29772289
161. Gänger S Schindowski K Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa Pharmaceutics 2018 10 116 30081536
Gänger, S. & Schindowski, K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 10, 116 (2018).30081536
162. Chatterjee B Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges Int. J. Pharm. 2019 565 258 268 31095983
Chatterjee, B. et al. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int. J. Pharm. 565, 258–268 (2019).31095983
163. Godfrey L Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia J. Control. Release 2018 270 135 144 29191784
Godfrey, L. et al. Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. J. Control. Release 270, 135–144 (2018).29191784
164. Kanazawa T Akiyama F Kakizaki S Takashima Y Seta Y Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles Biomaterials 2013 34 9220 9226 23992922
Kanazawa, T., Akiyama, F., Kakizaki, S., Takashima, Y. & Seta, Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 34, 9220–9226 (2013).23992922
165. Khatri KD Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy Curr. Neuropharmacol. 2022 20 1
Khatri, K. D. et al. Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy. Curr. Neuropharmacol. 20, 1 (2022).
166. Kozlovskaya L Abou-Kaoud M Stepensky D Quantitative analysis of drug delivery to the brain via nasal route J. Control. Release 2014 189 133 140 24997277
Kozlovskaya, L., Abou-Kaoud, M. & Stepensky, D. Quantitative analysis of drug delivery to the brain via nasal route. J. Control. Release 189, 133–140 (2014).24997277
167. Nabi B Rehman S Khan S Baboota S Ali J Ligand conjugation: An emerging platform for enhanced brain drug delivery Brain Res. Bull. 2018 142 384 393 30086350
Nabi, B., Rehman, S., Khan, S., Baboota, S. & Ali, J. Ligand conjugation: An emerging platform for enhanced brain drug delivery. Brain Res. Bull. 142, 384–393 (2018).30086350
168. Anthony DP Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases Life Sci. 2021 274 119326 33711385
Anthony, D. P. et al. Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases. Life Sci. 274, 119326 (2021).33711385
169. Prabhu S A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: Tumor-specific homing directed by nestin Nanoscale 2017 9 10919 10932 28731079
Prabhu, S. et al. A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: Tumor-specific homing directed by nestin. Nanoscale 9, 10919–10932 (2017).28731079
170. Kang S Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma Theranostics 2020 10 4308 4322 32292496
Kang, S. et al. Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics 10, 4308–4322 (2020).32292496
171. Liu C A dual-mediated liposomal drug delivery system targeting the brain: Rational construction, integrity evaluation across the blood-brain barrier, and the transporting mechanism to glioma cells Int. J. Nanomed. 2017 12 2407 2425
Liu, C. et al. A dual-mediated liposomal drug delivery system targeting the brain: Rational construction, integrity evaluation across the blood-brain barrier, and the transporting mechanism to glioma cells. Int. J. Nanomed. 12, 2407–2425 (2017).
172. Ruan S Acid-responsive transferrin dissociation and GLUT mediated exocytosis for increased blood–brain barrier transcytosis and programmed glioma targeting delivery Adv. Funct. Mater. 2018 28 1802227
Ruan, S. et al. Acid-responsive transferrin dissociation and GLUT mediated exocytosis for increased blood–brain barrier transcytosis and programmed glioma targeting delivery. Adv. Funct. Mater. 28, 1802227 (2018).
173. Lei T A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease Acta Pharm. Sin. B 2021 11 4032 4044 35024324
Lei, T. et al. A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease. Acta Pharm. Sin. B 11, 4032–4044 (2021).35024324
174. He X Acid-responsive dual-targeted nanoparticles encapsulated aspirin rescue the Immune activation and phenotype in autism spectrum disorder Adv. Sci. 2022 9 e2104286
He, X. et al. Acid-responsive dual-targeted nanoparticles encapsulated aspirin rescue the Immune activation and phenotype in autism spectrum disorder. Adv. Sci. 9, e2104286 (2022).
175. Scherer T Sakamoto K Buettner C Brain insulin signalling in metabolic homeostasis and disease Nat. Rev. Endocrinol. 2021 17 468 483 34108679
Scherer, T., Sakamoto, K. & Buettner, C. Brain insulin signalling in metabolic homeostasis and disease. Nat. Rev. Endocrinol. 17, 468–483 (2021).34108679
176. Nagao H Unique ligand and kinase-independent roles of the insulin receptor in regulation of cell cycle, senescence and apoptosis Nat. Commun. 2023 14 57 36599833
Nagao, H. et al. Unique ligand and kinase-independent roles of the insulin receptor in regulation of cell cycle, senescence and apoptosis. Nat. Commun. 14, 57 (2023).36599833
177. Boucher J Tseng Y-H Kahn CR Insulin and insulin-like growth factor-1 receptors Act as ligand-specific amplitude modulators of a common pathway regulating gene transcription J. Biol. Chem. 2010 285 17235 17245 20360006
Boucher, J., Tseng, Y.-H. & Kahn, C. R. Insulin and insulin-like growth factor-1 receptors Act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J. Biol. Chem. 285, 17235–17245 (2010).20360006
178. Ulbrich K Knobloch T Kreuter J Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB) J. Drug Target. 2011 19 125 132 20387992
Ulbrich, K., Knobloch, T. & Kreuter, J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target. 19, 125–132 (2011).20387992
179. Thorne RG Pronk GJ Padmanabhan V Frey WH Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration Neuroscience 2004 127 481 496 15262337
Thorne, R. G., Pronk, G. J., Padmanabhan, V. & Frey, W. H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481–496 (2004).15262337
180. Goldstein JL Brown MS Anderson RGW Russell DW Schneider WJ Receptor-mediated endocytosis: concepts emerging from the LDL receptor system Annu. Rev. Cell Biol. 1985 1 1 39 2881559
Goldstein, J. L., Brown, M. S., Anderson, R. G. W., Russell, D. W. & Schneider, W. J. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol. 1, 1–39 (1985).2881559
181. Ying X Angiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy Angew. Chem. Int. Ed. 2014 53 12436 12440
Ying, X. et al. Angiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy. Angew. Chem. Int. Ed. 53, 12436–12440 (2014).
182. Wang Y Electroresponsive nanoparticles improve antiseizure effect of phenytoin in generalized tonic-clonic seizures Neurotherapeutics 2016 13 603 613 27137202
Wang, Y. et al. Electroresponsive nanoparticles improve antiseizure effect of phenytoin in generalized tonic-clonic seizures. Neurotherapeutics 13, 603–613 (2016).27137202
183. Thirumurugan S Angiopep-2-decorated titanium-alloy core-shell magnetic nanoparticles for nanotheranostics and medical imaging Nanoscale 2022 14 14789 14800 36184995
Thirumurugan, S. et al. Angiopep-2-decorated titanium-alloy core-shell magnetic nanoparticles for nanotheranostics and medical imaging. Nanoscale 14, 14789–14800 (2022).36184995
184. Israel LL Signature effects of vector-guided systemic nano bioconjugate delivery across blood-brain barrier of normal, Alzheimer’s, and tumor mouse models ACS Nano 2022 16 11815 11832 35961653
Israel, L. L. et al. Signature effects of vector-guided systemic nano bioconjugate delivery across blood-brain barrier of normal, Alzheimer’s, and tumor mouse models. ACS Nano 16, 11815–11832 (2022).35961653
185. Ebrahimnejad P Taleghani AS Asare-Addo K Nokhodchi A An updated review of folate-functionalized nanocarriers: a promising ligand in cancer Drug Discov. Today 2022 27 471 489 34781032
Ebrahimnejad, P., Taleghani, A. S., Asare-Addo, K. & Nokhodchi, A. An updated review of folate-functionalized nanocarriers: a promising ligand in cancer. Drug Discov. Today 27, 471–489 (2022).34781032
186. Zhuang X Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression Mol. Ther. 2016 24 96 105 26444082
Zhuang, X. et al. Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol. Ther. 24, 96–105 (2016).26444082
187. Wang Y Increased brain uptake of pterostilbene loaded folate modified micellar delivery system Drug Deliv. 2022 29 3071 3086 36131589
Wang, Y. et al. Increased brain uptake of pterostilbene loaded folate modified micellar delivery system. Drug Deliv. 29, 3071–3086 (2022).36131589
188. Kuplennik N Lang K Steinfeld R Sosnik A Folate receptor α-modified nanoparticles for targeting of the central nervous system ACS Appl. Mater. Interfaces 2019 11 39633 39647 31532618
Kuplennik, N., Lang, K., Steinfeld, R. & Sosnik, A. Folate receptor α-modified nanoparticles for targeting of the central nervous system. ACS Appl. Mater. Interfaces 11, 39633–39647 (2019).31532618
189. Liu H Su YY Jiang XC Gao JQ Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system Drug Deliv. Transl. Res. 2023 13 716 737 36417162
Liu, H., Su, Y. Y., Jiang, X. C. & Gao, J. Q. Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. Drug Deliv. Transl. Res. 13, 716–737 (2023).36417162
190. Fang RH Kroll AV Gao W Zhang L Cell membrane coating nanotechnology Adv. Mater. 2018 30 1706759
Fang, R. H., Kroll, A. V., Gao, W. & Zhang, L. Cell membrane coating nanotechnology. Adv. Mater. 30, 1706759 (2018).
191. Zeng Y Cell membrane coated-nanoparticles for cancer immunotherapy Acta Pharm. Sin. B 2022 12 3233 3254 35967284
Zeng, Y. et al. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharm. Sin. B 12, 3233–3254 (2022).35967284
192. Xia Y Engineering macrophages for cancer immunotherapy and drug delivery Adv. Mater. 2020 32 e2002054 32856350
Xia, Y. et al. Engineering macrophages for cancer immunotherapy and drug delivery. Adv. Mater. 32, e2002054 (2020).32856350
193. Fang RH Gao W Zhang L Targeting drugs to tumours using cell membrane-coated nanoparticles Nat. Rev. Clin. Oncol. 2023 20 33 48 36307534
Fang, R. H., Gao, W. & Zhang, L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat. Rev. Clin. Oncol. 20, 33–48 (2023).36307534
194. Li J Cell-membrane-coated nanoparticles for targeted drug delivery to the brain for the Treatment of neurological diseases Pharmaceutics 2023 15 621 36839943
Li, J. et al. Cell-membrane-coated nanoparticles for targeted drug delivery to the brain for the Treatment of neurological diseases. Pharmaceutics 15, 621 (2023).36839943
195. Tan S Wu T Zhang D Zhang Z Cell or cell membrane-based drug delivery systems Theranostics 2015 5 863 881 26000058
Tan, S., Wu, T., Zhang, D. & Zhang, Z. Cell or cell membrane-based drug delivery systems. Theranostics 5, 863–881 (2015).26000058
196. Lee JY Red blood cell membrane bioengineered Zr-89 labelled hollow mesoporous silica nanosphere for overcoming phagocytosis Sci. Rep. 2019 9 7419 31092899
Lee, J. Y. et al. Red blood cell membrane bioengineered Zr-89 labelled hollow mesoporous silica nanosphere for overcoming phagocytosis. Sci. Rep. 9, 7419 (2019).31092899
197. Chai Z A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery J. Control. Release 2017 264 102 111 28842313
Chai, Z. et al. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J. Control. Release 264, 102–111 (2017).28842313
198. Zou Y Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine Adv. Mater. 2018 30 1803717
Zou, Y. et al. Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine. Adv. Mater. 30, 1803717 (2018).
199. Tapeinos C Cell membrane-coated magnetic nanocubes with a homotypic targeting ability increase intracellular temperature due to ROS scavenging and act as a versatile theranostic system for glioblastoma multiforme Adv. Healthc. Mater. 2019 8 1900612
Tapeinos, C. et al. Cell membrane-coated magnetic nanocubes with a homotypic targeting ability increase intracellular temperature due to ROS scavenging and act as a versatile theranostic system for glioblastoma multiforme. Adv. Healthc. Mater. 8, 1900612 (2019).
200. Zhu JY Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes Nano Lett. 2016 16 5895 5901 27513184
Zhu, J. Y. et al. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 16, 5895–5901 (2016).27513184
201. Liu S Neutrophil-biomimetic “nanobuffer” for remodeling the microenvironment in the infarct core and protecting neurons in the penumbra via neutralization of detrimental factors to treat ischemic stroke ACS Appl. Mater. Interfaces 2022 14 27743 27761 35695238
Liu, S. et al. Neutrophil-biomimetic “nanobuffer” for remodeling the microenvironment in the infarct core and protecting neurons in the penumbra via neutralization of detrimental factors to treat ischemic stroke. ACS Appl. Mater. Interfaces 14, 27743–27761 (2022).35695238
202. Oroojalian F Beygi M Baradaran B Mokhtarzadeh A Shahbazi MA Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy Small 2021 17 2006484
Oroojalian, F., Beygi, M., Baradaran, B., Mokhtarzadeh, A. & Shahbazi, M. A. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy. Small 17, 2006484 (2021).
203. Liang T Recent advances in macrophage-mediated drug delivery systems Int. J. Nanomed. 2021 16 2703 2714
Liang, T. et al. Recent advances in macrophage-mediated drug delivery systems. Int. J. Nanomed. 16, 2703–2714 (2021).
204. Yin T Engineered macrophage-membrane-coated nanoparticles with enhanced PD-1 expression induce immunomodulation for a synergistic and targeted antiglioblastoma activity Nano Lett. 2022 22 6606 6614 35948420
Yin, T. et al. Engineered macrophage-membrane-coated nanoparticles with enhanced PD-1 expression induce immunomodulation for a synergistic and targeted antiglioblastoma activity. Nano Lett. 22, 6606–6614 (2022).35948420
205. Han Y Macrophage membrane-coated nanocarriers co-modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer’s disease mice Bioact. Mater. 2021 6 529 542 32995678
Han, Y. et al. Macrophage membrane-coated nanocarriers co-modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer’s disease mice. Bioact. Mater. 6, 529–542 (2021).32995678
206. Chu D Dong X Shi X Zhang C Wang Z Neutrophil-based drug delivery systems Adv. Mater. 2018 30 e1706245 29577477
Chu, D., Dong, X., Shi, X., Zhang, C. & Wang, Z. Neutrophil-based drug delivery systems. Adv. Mater. 30, e1706245 (2018).29577477
207. Pitchaimani A Nguyen TDT Aryal S Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy Biomaterials 2018 160 124 137 29407341
Pitchaimani, A., Nguyen, T. D. T. & Aryal, S. Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy. Biomaterials 160, 124–137 (2018).29407341
208. Deng G Natural-killer-cell-inspired nanorobots with aggregation-induced emission characteristics for near-Infrared-II fluorescence-guided glioma theranostics ACS Nano 2020 14 11452 11462 32820907
Deng, G. et al. Natural-killer-cell-inspired nanorobots with aggregation-induced emission characteristics for near-Infrared-II fluorescence-guided glioma theranostics. ACS Nano 14, 11452–11462 (2020).32820907
209. Kiessling M Herchenhan E Eggert HR Cerebrovascular and metabolic effects on the rat brain of focal Nd:YAG laser irradiation J. Neurosurg. 1990 73 909 917 2230973
Kiessling, M., Herchenhan, E. & Eggert, H. R. Cerebrovascular and metabolic effects on the rat brain of focal Nd:YAG laser irradiation. J. Neurosurg. 73, 909–917 (1990).2230973
210. Tao W Farokhzad OC Theranostic nanomedicine in the NIR-II window: classification, fabrication, and biomedical applications Chem. Rev. 2022 122 5405 5407 35317560
Tao, W. & Farokhzad, O. C. Theranostic nanomedicine in the NIR-II window: classification, fabrication, and biomedical applications. Chem. Rev. 122, 5405–5407 (2022).35317560
211. Xu C Pu K Second near-infrared photothermal materials for combinational nanotheranostics Chem. Soc. Rev. 2021 50 1111 1137 33245316
Xu, C. & Pu, K. Second near-infrared photothermal materials for combinational nanotheranostics. Chem. Soc. Rev. 50, 1111–1137 (2021).33245316
212. Wu X Tether-free photothermal deep-brain stimulation in freely behaving mice via wide-field illumination in the near-infrared-II window Nat. Biomed. Eng. 2022 6 754 770 35314800
Wu, X. et al. Tether-free photothermal deep-brain stimulation in freely behaving mice via wide-field illumination in the near-infrared-II window. Nat. Biomed. Eng. 6, 754–770 (2022).35314800
213. Li B Photothermal modulation of depression-related ion channel function through conjugated polymer nanoparticles Adv. Funct. Mater. 2021 31 2010757
Li, B. et al. Photothermal modulation of depression-related ion channel function through conjugated polymer nanoparticles. Adv. Funct. Mater. 31, 2010757 (2021).
214. Chen W Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy Adv. Mater. 2018 30 1703458
Chen, W. et al. Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy. Adv. Mater. 30, 1703458 (2018).
215. Wu D Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy Sci. Adv. 2022 8 eabm3381 35020438
Wu, D. et al. Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy. Sci. Adv. 8, eabm3381 (2022).35020438
216. Choi M Ku T Chong K Yoon J Choi C Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability Proc. Natl Acad. Sci. USA 2011 108 9256 9261 21576460
Choi, M., Ku, T., Chong, K., Yoon, J. & Choi, C. Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability. Proc. Natl Acad. Sci. USA 108, 9256–9261 (2011).21576460
217. Jin L Fast-acting black-phosphorus-assisted depression therapy with low toxicity Adv. Mater. 2020 32 1906050
Jin, L. et al. Fast-acting black-phosphorus-assisted depression therapy with low toxicity. Adv. Mater. 32, 1906050 (2020).
218. Li X Reversibly modulating the blood-brain barrier by laser stimulation of molecular-targeted nanoparticles Nano Lett. 2021 21 9805 9815 34516144
Li, X. et al. Reversibly modulating the blood-brain barrier by laser stimulation of molecular-targeted nanoparticles. Nano Lett. 21, 9805–9815 (2021).34516144
219. Clement GT Hynynen K A non-invasive method for focusing ultrasound through the human skull Phys. Med. Biol. 2002 47 1219 12030552
Clement, G. T. & Hynynen, K. A non-invasive method for focusing ultrasound through the human skull. Phys. Med. Biol. 47, 1219 (2002).12030552
220. Ellens, N. P. K. & Hynynen, K. Power Ultrasonics (eds J A. Gallego-Juárez & K. F. Graff) Ch. 22 (Woodhead Publishing, 2015).
221. Lynn JG Putnam TJ Histology of cerebral lesions produced by focused ultrasound Am. J. Pathol. 1944 20 637 649 19970769
Lynn, J. G. & Putnam, T. J. Histology of cerebral lesions produced by focused ultrasound. Am. J. Pathol. 20, 637–649 (1944).19970769
222. Aryal M Arvanitis CD Alexander PM McDannold N Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system Adv. Drug Deliv. Rev. 2014 72 94 109 24462453
Aryal, M., Arvanitis, C. D., Alexander, P. M. & McDannold, N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv. Drug Deliv. Rev. 72, 94–109 (2014).24462453
223. Gorick CM Applications of focused ultrasound-mediated blood-brain barrier opening Adv. Drug Deliv. Rev. 2022 191 114583 36272635
Gorick, C. M. et al. Applications of focused ultrasound-mediated blood-brain barrier opening. Adv. Drug Deliv. Rev. 191, 114583 (2022).36272635
224. Liu Y Microbubbles in combination with focused ultrasound for the delivery of quercetin-modified sulfur nanoparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat Alzheimer’s disease Nanoscale 2020 12 6498 6511 32154811
Liu, Y. et al. Microbubbles in combination with focused ultrasound for the delivery of quercetin-modified sulfur nanoparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat Alzheimer’s disease. Nanoscale 12, 6498–6511 (2020).32154811
225. Gorick CM Sonoselective transfection of cerebral vasculature without blood-brain barrier disruption Proc. Natl Acad. Sci. USA 2020 117 5644 5654 32123081
Gorick, C. M. et al. Sonoselective transfection of cerebral vasculature without blood-brain barrier disruption. Proc. Natl Acad. Sci. USA 117, 5644–5654 (2020).32123081
226. Liu S A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis Nature 2021 598 641 645 34646018
Liu, S. et al. A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis. Nature 598, 641–645 (2021).34646018
227. Zhang J Electroacupuncture: a new approach to open the blood-brain barrier in rats recovering from middle cerebral artery occlusion Acupunct. Med. 2018 36 377 385 29903719
Zhang, J. et al. Electroacupuncture: a new approach to open the blood-brain barrier in rats recovering from middle cerebral artery occlusion. Acupunct. Med. 36, 377–385 (2018).29903719
228. Zhang S The barrier and interface mechanisms of the brain barrier, and brain drug delivery Brain Res. Bull. 2022 190 69 83 36162603
Zhang, S. et al. The barrier and interface mechanisms of the brain barrier, and brain drug delivery. Brain Res. Bull. 190, 69–83 (2022).36162603
229. Bellettato CM Scarpa M Possible strategies to cross the blood-brain barrier Ital. J. Pediatr. 2018 44 131 30442184
Bellettato, C. M. & Scarpa, M. Possible strategies to cross the blood-brain barrier. Ital. J. Pediatr. 44, 131 (2018).30442184
230. Li W BBB pathophysiology–independent delivery of siRNA in traumatic brain injury Sci. Adv. 2021 7 eabd6889 33523853
Li, W. et al. BBB pathophysiology–independent delivery of siRNA in traumatic brain injury. Sci. Adv. 7, eabd6889 (2021).33523853
231. Zhang X He T Chai Z Samulski RJ Li C Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration Biomaterials 2018 176 71 83 29860139
Zhang, X., He, T., Chai, Z., Samulski, R. J. & Li, C. Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176, 71–83 (2018).29860139
232. Obermeier B Daneman R Ransohoff RM Development, maintenance and disruption of the blood-brain barrier Nat. Med. 2013 19 1584 1596 24309662
Obermeier, B., Daneman, R. & Ransohoff, R. M. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19, 1584–1596 (2013).24309662
233. Wang D Tai PWL Gao G Adeno-associated virus vector as a platform for gene therapy delivery Nat. Rev. Drug Discov. 2019 18 358 378 30710128
Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019).30710128
234. Wang D A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates Mol. Ther.-Methods Clin. Dev. 2018 9 234 246 29766031
Wang, D. et al. A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates. Mol. Ther.-Methods Clin. Dev. 9, 234–246 (2018).29766031
235. Goertsen D AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset Nat. Neurosci. 2022 25 106 115 34887588
Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106–115 (2022).34887588
236. Yao Y Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates Nat. Biomed. Eng. 2022 6 1257 1271 36217021
Yao, Y. et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates. Nat. Biomed. Eng. 6, 1257–1271 (2022).36217021
237. Coureuil M Lécuyer H Bourdoulous S Nassif X A journey into the brain: insight into how bacterial pathogens cross blood-brain barriers Nat. Rev. Microbiol. 2017 15 149 159 28090076
Coureuil, M., Lécuyer, H., Bourdoulous, S. & Nassif, X. A journey into the brain: insight into how bacterial pathogens cross blood-brain barriers. Nat. Rev. Microbiol. 15, 149–159 (2017).28090076
238. Sun R Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy Nat. Commun. 2022 13 5127 36050316
Sun, R. et al. Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy. Nat. Commun. 13, 5127 (2022).36050316
239. Chung TD Effects of acute and chronic oxidative stress on the blood-brain barrier in 2D and 3D in vitro models Fluids Barriers CNS 2022 19 33 35551622
Chung, T. D. et al. Effects of acute and chronic oxidative stress on the blood-brain barrier in 2D and 3D in vitro models. Fluids Barriers CNS 19, 33 (2022).35551622
240. Wardill HR Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction Int. J. Cancer 2016 139 2635 2645 27367824
Wardill, H. R. et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. Int. J. Cancer 139, 2635–2645 (2016).27367824
241. Lehner C Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases Antioxid. Redox Signal. 2011 15 1305 1323 21294658
Lehner, C. et al. Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid. Redox Signal. 15, 1305–1323 (2011).21294658
242. Kim Y Effects of natural polyphenols on oxidative stress-mediated blood-brain barrier dysfunction Antioxidants 2022 11 197 35204080
Kim, Y. et al. Effects of natural polyphenols on oxidative stress-mediated blood-brain barrier dysfunction. Antioxidants 11, 197 (2022).35204080
243. Ballance WC Qin EC Chung HJ Gillette MU Kong H Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseases Biomaterials 2019 217 119292 31279098
Ballance, W. C., Qin, E. C., Chung, H. J., Gillette, M. U. & Kong, H. Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseases. Biomaterials 217, 119292 (2019).31279098
244. Nash AM Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors Sci. Adv. 2022 8 eabm1032 35235346
Nash, A. M. et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci. Adv. 8, eabm1032 (2022).35235346
245. Barenholz Y Doxil® — the first FDA-approved nano-drug: lessons learned J. Control. Release 2012 160 117 134 22484195
Barenholz, Y. Doxil® — the first FDA-approved nano-drug: lessons learned. J. Control. Release 160, 117–134 (2012).22484195
246. Anselmo AC Mitragotri S Nanoparticles in the clinic: an update Bioeng. Transl. Med. 2019 4 e10143 31572799
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 4, e10143 (2019).31572799
247. Anselmo AC Mitragotri S Nanoparticles in the clinic Bioeng. Transl. Med. 2016 1 10 29 29313004
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1, 10–29 (2016).29313004
248. Allen TM Cullis PR Liposomal drug delivery systems: From concept to clinical applications Adv. Drug Deliv. Rev. 2013 65 36 48 23036225
Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013).23036225
249. Shah S Dhawan V Holm R Nagarsenker MS Perrie Y Liposomes: advancements and innovation in the manufacturing process Adv. Drug Deliv. Rev. 2020 154-155 102 122 32650041
Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S. & Perrie, Y. Liposomes: advancements and innovation in the manufacturing process. Adv. Drug Deliv. Rev. 154-155, 102–122 (2020).32650041
250. Crommelin DJA van Hoogevest P Storm G The role of liposomes in clinical nanomedicine development. What now? Now what? J. Control. Release 2020 318 256 263 31846618
Crommelin, D. J. A., van Hoogevest, P. & Storm, G. The role of liposomes in clinical nanomedicine development. What now? Now what? J. Control. Release 318, 256–263 (2020).31846618
251. Guimarães D Cavaco-Paulo A Nogueira E Design of liposomes as drug delivery system for therapeutic applications Int. J. Pharm. 2021 601 120571 33812967
Guimarães, D., Cavaco-Paulo, A. & Nogueira, E. Design of liposomes as drug delivery system for therapeutic applications. Int. J. Pharm. 601, 120571 (2021).33812967
252. Antimisiaris SG Overcoming barriers by local drug delivery with liposomes Adv. Drug Deliv. Rev. 2021 174 53 86 33539852
Antimisiaris, S. G. et al. Overcoming barriers by local drug delivery with liposomes. Adv. Drug Deliv. Rev. 174, 53–86 (2021).33539852
253. Zhang Z Brain-targeted drug delivery by manipulating protein corona functions Nat. Commun. 2019 10 3561 31395892
Zhang, Z. et al. Brain-targeted drug delivery by manipulating protein corona functions. Nat. Commun. 10, 3561 (2019).31395892
254. Zhang Y Brain-targeted delivery of obidoxime, using aptamer-modified liposomes, for detoxification of organophosphorus compounds J. Control. Release 2021 329 1117 1128 33096123
Zhang, Y. et al. Brain-targeted delivery of obidoxime, using aptamer-modified liposomes, for detoxification of organophosphorus compounds. J. Control. Release 329, 1117–1128 (2021).33096123
255. Kucharz K Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles Nat. Commun. 2021 12 4121 34226541
Kucharz, K. et al. Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. Nat. Commun. 12, 4121 (2021).34226541
256. Zhu Y Feijen J Zhong Z Dual-targeted nanomedicines for enhanced tumor treatment Nano Today 2018 18 65 85
Zhu, Y., Feijen, J. & Zhong, Z. Dual-targeted nanomedicines for enhanced tumor treatment. Nano Today 18, 65–85 (2018).
257. Shi D Mi G Shen Y Webster TJ Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in vitro blood–brain barrier Nanoscale 2019 11 15057 15071 31369016
Shi, D., Mi, G., Shen, Y. & Webster, T. J. Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in vitro blood–brain barrier. Nanoscale 11, 15057–15071 (2019).31369016
258. Lakkadwala S dos Santos Rodrigues B Sun C Singh J Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma J. Control. Release 2019 307 247 260 31252036
Lakkadwala, S., dos Santos Rodrigues, B., Sun, C. & Singh, J. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. J. Control. Release 307, 247–260 (2019).31252036
259. Ozdas MS Non-invasive molecularly-specific millimeter-resolution manipulation of brain circuits by ultrasound-mediated aggregation and uncaging of drug carriers Nat. Commun. 2020 11 4929 33004789
Ozdas, M. S. et al. Non-invasive molecularly-specific millimeter-resolution manipulation of brain circuits by ultrasound-mediated aggregation and uncaging of drug carriers. Nat. Commun. 11, 4929 (2020).33004789
260. Fernandes M Novel concept of exosome-like liposomes for the treatment of Alzheimer’s disease J. Control. Release 2021 336 130 143 34126168
Fernandes, M. et al. Novel concept of exosome-like liposomes for the treatment of Alzheimer’s disease. J. Control. Release 336, 130–143 (2021).34126168
261. Zhang W Mehta A Tong Z Esser L Voelcker NH Development of polymeric nanoparticles for blood–brain barrier transfer—strategies and challenges Adv. Sci. 2021 8 2003937
Zhang, W., Mehta, A., Tong, Z., Esser, L. & Voelcker, N. H. Development of polymeric nanoparticles for blood–brain barrier transfer—strategies and challenges. Adv. Sci. 8, 2003937 (2021).
262. Lagreca E Recent advances in the formulation of PLGA microparticles for controlled drug delivery Prog. Biomater. 2020 9 153 174 33058072
Lagreca, E. et al. Recent advances in the formulation of PLGA microparticles for controlled drug delivery. Prog. Biomater. 9, 153–174 (2020).33058072
263. Semete B In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems Nanomed. -Nanotechnol. 2010 6 662 671
Semete, B. et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed. -Nanotechnol. 6, 662–671 (2010).
264. Del Grosso A Brain-targeted enzyme-loaded nanoparticles: a breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease Sci. Adv. 2019 5 eaax7462 31799395
Del Grosso, A. et al. Brain-targeted enzyme-loaded nanoparticles: a breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease. Sci. Adv. 5, eaax7462 (2019).31799395
265. Wu D Thermo-sensitive micelles extend therapeutic potential for febrile seizures Signal Transduct. Target. Ther. 2021 6 296 34385416
Wu, D. et al. Thermo-sensitive micelles extend therapeutic potential for febrile seizures. Signal Transduct. Target. Ther. 6, 296 (2021).34385416
266. Wang Y Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance Nat. Biomed. Eng. 2021 5 1048 1058 34045730
Wang, Y. et al. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nat. Biomed. Eng. 5, 1048–1058 (2021).34045730
267. Lu Y Microthrombus-targeting micelles for neurovascular remodeling and enhanced microcirculatory perfusion in acute ischemic stroke Adv. Mater. 2019 31 1808361
Lu, Y. et al. Microthrombus-targeting micelles for neurovascular remodeling and enhanced microcirculatory perfusion in acute ischemic stroke. Adv. Mater. 31, 1808361 (2019).
268. Lu Y Microenvironment remodeling micelles for alzheimer’s disease therapy by early modulation of activated microglia Adv. Sci. 2019 6 1801586
Lu, Y. et al. Microenvironment remodeling micelles for alzheimer’s disease therapy by early modulation of activated microglia. Adv. Sci. 6, 1801586 (2019).
269. Lam FC Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles Nat. Commun. 2018 9 1991 29777137
Lam, F. C. et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat. Commun. 9, 1991 (2018).29777137
270. Zhou Y Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy Sci. Adv. 2020 6 eabc7031 33036977
Zhou, Y. et al. Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy. Sci. Adv. 6, eabc7031 (2020).33036977
271. Li J Mooney DJ Designing hydrogels for controlled drug delivery Nat. Rev. Mater. 2016 1 16071 29657852
Li, J. & Mooney, D. J. Designing hydrogels for controlled drug delivery. Nat. Rev. Mater. 1, 16071 (2016).29657852
272. Picone P Nose-to-brain delivery of insulin enhanced by a nanogel carrier J. Control. Release 2018 270 23 36 29196041
Picone, P. et al. Nose-to-brain delivery of insulin enhanced by a nanogel carrier. J. Control. Release 270, 23–36 (2018).29196041
273. Gadhave D Rasal N Sonawane R Sekar M Kokare C Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: Pharmacological and in vitro cytotoxicity studies Int. J. Biol. Macromol. 2021 167 906 920 33186648
Gadhave, D., Rasal, N., Sonawane, R., Sekar, M. & Kokare, C. Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: Pharmacological and in vitro cytotoxicity studies. Int. J. Biol. Macromol. 167, 906–920 (2021).33186648
274. Gadhave D Gupta A Khot S Tagalpallewar A Kokare C Nose-to-brain delivery of paliperidone palmitate poloxamer-guar gum nanogel: Formulation, optimization and pharmacological studies in rats Ann. Pharm. Fr. 2023 81 315 333 36037930
Gadhave, D., Gupta, A., Khot, S., Tagalpallewar, A. & Kokare, C. Nose-to-brain delivery of paliperidone palmitate poloxamer-guar gum nanogel: Formulation, optimization and pharmacological studies in rats. Ann. Pharm. Fr. 81, 315–333 (2023).36037930
275. Huang G Nose-to-brain delivery of drug nanocrystals by using Ca2+ responsive deacetylated gellan gum based in situ-nanogel Int. J. Pharm. 2021 594 120182 33346126
Huang, G. et al. Nose-to-brain delivery of drug nanocrystals by using Ca2+ responsive deacetylated gellan gum based in situ-nanogel. Int. J. Pharm. 594, 120182 (2021).33346126
276. Singh S Protease responsive nanogels for transcytosis across the blood−brain barrier and intracellular delivery of radiopharmaceuticals to brain tumor cells Adv. Healthc. Mater. 2021 10 2100812
Singh, S. et al. Protease responsive nanogels for transcytosis across the blood−brain barrier and intracellular delivery of radiopharmaceuticals to brain tumor cells. Adv. Healthc. Mater. 10, 2100812 (2021).
277. She D Hypoxia-degradable zwitterionic phosphorylcholine drug nanogel for enhanced drug delivery to glioblastoma Chem. Eng. J. 2021 408 127359
She, D. et al. Hypoxia-degradable zwitterionic phosphorylcholine drug nanogel for enhanced drug delivery to glioblastoma. Chem. Eng. J. 408, 127359 (2021).
278. Qi W Light-controlled precise delivery of NIR-responsive semiconducting polymer nanoparticles with promoted vascular permeability Adv. Healthc. Mater. 2021 10 2100569
Qi, W. et al. Light-controlled precise delivery of NIR-responsive semiconducting polymer nanoparticles with promoted vascular permeability. Adv. Healthc. Mater. 10, 2100569 (2021).
279. Curcio M Natural polysaccharide carriers in brain delivery: challenge and perspective Pharmaceutics 2020 12 1183 33291284
Curcio, M. et al. Natural polysaccharide carriers in brain delivery: challenge and perspective. Pharmaceutics 12, 1183 (2020).33291284
280. Agrawal M Stimuli-responsive In situ gelling system for nose-to-brain drug delivery J. Control. Release 2020 327 235 265 32739524
Agrawal, M. et al. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. J. Control. Release 327, 235–265 (2020).32739524
281. Kopeček J Yang J Polymer nanomedicines Adv. Drug Deliv. Rev. 2020 156 40 64 32735811
Kopeček, J. & Yang, J. Polymer nanomedicines. Adv. Drug Deliv. Rev. 156, 40–64 (2020).32735811
282. Geng H Binding to amyloid-β protein by photothermal blood-brain barrier-penetrating nanoparticles for inhibition and disaggregation of fibrillation Adv. Funct. Mater. 2021 31 2102953
Geng, H. et al. Binding to amyloid-β protein by photothermal blood-brain barrier-penetrating nanoparticles for inhibition and disaggregation of fibrillation. Adv. Funct. Mater. 31, 2102953 (2021).
283. Goddard ZR Marín MJ Russell DA Searcey M Active targeting of gold nanoparticles as cancer therapeutics Chem. Soc. Rev. 2020 49 8774 8789 33089858
Goddard, Z. R., Marín, M. J., Russell, D. A. & Searcey, M. Active targeting of gold nanoparticles as cancer therapeutics. Chem. Soc. Rev. 49, 8774–8789 (2020).33089858
284. Sharifi M Plasmonic gold nanoparticles: Optical manipulation, imaging, drug delivery and therapy J. Control. Release 2019 311-312 170 189 31472191
Sharifi, M. et al. Plasmonic gold nanoparticles: Optical manipulation, imaging, drug delivery and therapy. J. Control. Release 311-312, 170–189 (2019).31472191
285. Behroozi Z Distribution of gold nanoparticles into the brain: a systematic review and meta-analysis Nanotoxicology 2021 15 1059 1072 34591733
Behroozi, Z. et al. Distribution of gold nanoparticles into the brain: a systematic review and meta-analysis. Nanotoxicology 15, 1059–1072 (2021).34591733
286. Kwon SP Thrombin-activatable fluorescent peptide incorporated gold nanoparticles for dual optical/computed tomography thrombus imaging Biomaterials 2018 150 125 136 29035738
Kwon, S. P. et al. Thrombin-activatable fluorescent peptide incorporated gold nanoparticles for dual optical/computed tomography thrombus imaging. Biomaterials 150, 125–136 (2018).29035738
287. Meir R Popovtzer R Cell tracking using gold nanoparticles and computed tomography imaging WIREs Nanomed. Nanobiotechnol. 2018 10 e1480
Meir, R. & Popovtzer, R. Cell tracking using gold nanoparticles and computed tomography imaging. WIREs Nanomed. Nanobiotechnol. 10, e1480 (2018).
288. Arami H Remotely controlled near-infrared-triggered photothermal treatment of brain tumours in freely behaving mice using gold nanostars Nat. Nanotechnol. 2022 17 1015 1022 35995855
Arami, H. et al. Remotely controlled near-infrared-triggered photothermal treatment of brain tumours in freely behaving mice using gold nanostars. Nat. Nanotechnol. 17, 1015–1022 (2022).35995855
289. Xue Y Li X Li H Zhang W Quantifying thiol–gold interactions towards the efficient strength control Nat. Commun. 2014 5 4348 25000336
Xue, Y., Li, X., Li, H. & Zhang, W. Quantifying thiol–gold interactions towards the efficient strength control. Nat. Commun. 5, 4348 (2014).25000336
290. Oshra, B., Malka, S., Menachem, M. & Rachela, P. In Proc. SPIE, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI. 108911H (2019).
291. Zhang J Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in Alzheimer’s disease Colloid Surf. B 2021 200 111584
Zhang, J. et al. Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in Alzheimer’s disease. Colloid Surf. B 200, 111584 (2021).
292. Lee HE Amino-acid- and peptide-directed synthesis of chiral plasmonic gold nanoparticles Nature 2018 556 360 365 29670265
Lee, H. E. et al. Amino-acid- and peptide-directed synthesis of chiral plasmonic gold nanoparticles. Nature 556, 360–365 (2018).29670265
293. Cai J Polarization-sensitive optoionic membranes from chiral plasmonic nanoparticles Nat. Nanotechnol. 2022 17 408 416 35288671
Cai, J. et al. Polarization-sensitive optoionic membranes from chiral plasmonic nanoparticles. Nat. Nanotechnol. 17, 408–416 (2022).35288671
294. Hou K Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease Nat. Commun. 2020 11 4790 32963242
Hou, K. et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease. Nat. Commun. 11, 4790 (2020).32963242
295. Liu L Switchable nanoparticle for programmed gene-chem delivery with enhanced neuronal recovery and CT imaging for neurodegenerative disease treatment Mater. Horiz. 2019 6 1923 1929
Liu, L. et al. Switchable nanoparticle for programmed gene-chem delivery with enhanced neuronal recovery and CT imaging for neurodegenerative disease treatment. Mater. Horiz. 6, 1923–1929 (2019).
296. Feng Q Self-assembly of gold nanoparticles shows microenvironment-mediated dynamic switching and enhanced brain tumor targeting Theranostics 2017 7 1875 1889 28638474
Feng, Q. et al. Self-assembly of gold nanoparticles shows microenvironment-mediated dynamic switching and enhanced brain tumor targeting. Theranostics 7, 1875–1889 (2017).28638474
297. Gao X Guiding brain-tumor surgery via blood–brain-barrier-permeable gold nanoprobes with acid-triggered MRI/SERRS signals Adv. Mater. 2017 29 1603917
Gao, X. et al. Guiding brain-tumor surgery via blood–brain-barrier-permeable gold nanoprobes with acid-triggered MRI/SERRS signals. Adv. Mater. 29, 1603917 (2017).
298. Liu Y Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’s disease J. Colloid Interface Sci. 2019 552 388 400 31151017
Liu, Y. et al. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’s disease. J. Colloid Interface Sci. 552, 388–400 (2019).31151017
299. Schroeder V Savagatrup S He M Lin S Swager TM Carbon nanotube chemical sensors Chem. Rev. 2019 119 599 663 30226055
Schroeder, V., Savagatrup, S., He, M., Lin, S. & Swager, T. M. Carbon nanotube chemical sensors. Chem. Rev. 119, 599–663 (2019).30226055
300. Panwar N Nanocarbons for biology and medicine: sensing, imaging, and drug delivery Chem. Rev. 2019 119 9559 9656 31287663
Panwar, N. et al. Nanocarbons for biology and medicine: sensing, imaging, and drug delivery. Chem. Rev. 119, 9559–9656 (2019).31287663
301. Dasari Shareena TP McShan D Dasmahapatra AK Tchounwou PB A review on graphene-based nanomaterials in biomedical applications and risks in environment and health Nano-Micro Lett. 2018 10 53
Dasari Shareena, T. P., McShan, D., Dasmahapatra, A. K. & Tchounwou, P. B. A review on graphene-based nanomaterials in biomedical applications and risks in environment and health. Nano-Micro Lett. 10, 53 (2018).
302. Du J Xu N Fan J Sun W Peng X Carbon dots for in vivo bioimaging and theranostics Small 2019 15 1805087
Du, J., Xu, N., Fan, J., Sun, W. & Peng, X. Carbon dots for in vivo bioimaging and theranostics. Small 15, 1805087 (2019).
303. Sanginario A Miccoli B Demarchi D Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment Biosensors 2017 7 9 28212271
Sanginario, A., Miccoli, B. & Demarchi, D. Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment. Biosensors 7, 9 (2017).28212271
304. Teradal NL Jelinek R Carbon nanomaterials in biological studies and biomedicine Adv. Healthc. Mater. 2017 6 1700574
Teradal, N. L. & Jelinek, R. Carbon nanomaterials in biological studies and biomedicine. Adv. Healthc. Mater. 6, 1700574 (2017).
305. Bagheri B Carbon-based nanostructures for cancer therapy and drug delivery applications J. Mater. Chem. B 2022 10 9944 9967 36415922
Bagheri, B. et al. Carbon-based nanostructures for cancer therapy and drug delivery applications. J. Mater. Chem. B 10, 9944–9967 (2022).36415922
306. Ashrafizadeh M Carbon dots as versatile nanoarchitectures for the treatment of neurological disorders and their theranostic applications: a review Adv. Colloid Interfac. 2020 278 102123
Ashrafizadeh, M. et al. Carbon dots as versatile nanoarchitectures for the treatment of neurological disorders and their theranostic applications: a review. Adv. Colloid Interfac. 278, 102123 (2020).
307. Zhou Y Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood–brain barrier and inhibitors of β-amyloid Nanoscale 2019 11 22387 22397 31730144
Zhou, Y. et al. Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood–brain barrier and inhibitors of β-amyloid. Nanoscale 11, 22387–22397 (2019).31730144
308. Hettiarachchi SD Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors Nanoscale 2019 11 6192 6205 30874284
Hettiarachchi, S. D. et al. Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors. Nanoscale 11, 6192–6205 (2019).30874284
309. Tabish TA Narayan RJ Crossing the blood–brain barrier with graphene nanostructures Mater. Today 2021 51 393 401
Tabish, T. A. & Narayan, R. J. Crossing the blood–brain barrier with graphene nanostructures. Mater. Today 51, 393–401 (2021).
310. Liu J Dong J Zhang T Peng Q Graphene-based nanomaterials and their potentials in advanced drug delivery and cancer therapy J. Control. Release 2018 286 64 73 30031155
Liu, J., Dong, J., Zhang, T. & Peng, Q. Graphene-based nanomaterials and their potentials in advanced drug delivery and cancer therapy. J. Control. Release 286, 64–73 (2018).30031155
311. Wang K Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer’s disease Drug Deliv. 2021 28 580 593 33729067
Wang, K. et al. Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer’s disease. Drug Deliv. 28, 580–593 (2021).33729067
312. Tan MJ Flexible modulation of CO-release using various nuclearity of metal carbonyl clusters on graphene oxide for stroke remediation Adv. Healthc. Mater. 2018 7 1701113
Tan, M. J. et al. Flexible modulation of CO-release using various nuclearity of metal carbonyl clusters on graphene oxide for stroke remediation. Adv. Healthc. Mater. 7, 1701113 (2018).
313. Xiong S Targeted graphene oxide for drug delivery as a therapeutic nanoplatform against Parkinson’s disease Biomater. Sci. 2021 9 1705 1715 33427264
Xiong, S. et al. Targeted graphene oxide for drug delivery as a therapeutic nanoplatform against Parkinson’s disease. Biomater. Sci. 9, 1705–1715 (2021).33427264
314. Su S In vitro study of transportation of porphyrin immobilized graphene oxide through blood brain barrier Mat. Sci. Eng. C.-Mater. 2020 107 110313
Su, S. et al. In vitro study of transportation of porphyrin immobilized graphene oxide through blood brain barrier. Mat. Sci. Eng. C.-Mater. 107, 110313 (2020).
315. Burkhart A Expression of iron-related proteins at the neurovascular unit supports reduction and reoxidation of iron for transport through the blood-brain barrier Mol. Neurobiol. 2016 53 7237 7253 26687231
Burkhart, A. et al. Expression of iron-related proteins at the neurovascular unit supports reduction and reoxidation of iron for transport through the blood-brain barrier. Mol. Neurobiol. 53, 7237–7253 (2016).26687231
316. Liu G Transferrin modified graphene oxide for glioma-targeted drug delivery: In vitro and in vivo evaluations ACS Appl. Mater. Interfaces 2013 5 6909 6914 23883622
Liu, G. et al. Transferrin modified graphene oxide for glioma-targeted drug delivery: In vitro and in vivo evaluations. ACS Appl. Mater. Interfaces 5, 6909–6914 (2013).23883622
317. Kim D Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease Nat. Nanotechnol. 2018 13 812 818 29988049
Kim, D. et al. Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease. Nat. Nanotechnol. 13, 812–818 (2018).29988049
318. Sung S Graphene quantum dots-mediated theranostic penetrative delivery of drug and photolytics in deep tumors by targeted biomimetic nanosponges Nano Lett. 2019 19 69 81 30521346
Sung, S. et al. Graphene quantum dots-mediated theranostic penetrative delivery of drug and photolytics in deep tumors by targeted biomimetic nanosponges. Nano Lett. 19, 69–81 (2019).30521346
319. Henna TK Carbon nanostructures: The drug and the delivery system for brain disorders Int. J. Pharm. 2020 587 119701 32736018
Henna, T. K. et al. Carbon nanostructures: The drug and the delivery system for brain disorders. Int. J. Pharm. 587, 119701 (2020).32736018
320. Harsha PJ A novel PEGylated carbon nanotube conjugated mangiferin: An explorative nanomedicine for brain cancer cells J. Drug Deliv. Sci. Technol. 2019 53 101186
Harsha, P. J. et al. A novel PEGylated carbon nanotube conjugated mangiferin: An explorative nanomedicine for brain cancer cells. J. Drug Deliv. Sci. Technol. 53, 101186 (2019).
321. Tan JM Foo JB Fakurazi S Hussein MZ Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes Beilstein J. Nanotechnol. 2015 6 243 253 25671168
Tan, J. M., Foo, J. B., Fakurazi, S. & Hussein, M. Z. Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J. Nanotechnol. 6, 243–253 (2015).25671168
322. You Y Designing dual-functionalized carbon nanotubes with high blood–brain-barrier permeability for precise orthotopic glioma therapy Dalton Trans. 2019 48 1569 1573 30499579
You, Y. et al. Designing dual-functionalized carbon nanotubes with high blood–brain-barrier permeability for precise orthotopic glioma therapy. Dalton Trans. 48, 1569–1573 (2019).30499579
323. Rasras S Single-walled and multiwalled carbon nanotubes induce oxidative stress in isolated rat brain mitochondria Toxicol. Ind. Health 2019 35 497 506 31272286
Rasras, S. et al. Single-walled and multiwalled carbon nanotubes induce oxidative stress in isolated rat brain mitochondria. Toxicol. Ind. Health 35, 497–506 (2019).31272286
324. Facciolà A Carbon nanotubes and central nervous system: environmental risks, toxicological aspects and future perspectives Environ. Toxicol. Pharmacol. 2019 65 23 30 30500734
Facciolà, A. et al. Carbon nanotubes and central nervous system: environmental risks, toxicological aspects and future perspectives. Environ. Toxicol. Pharmacol. 65, 23–30 (2019).30500734
325. Israel LL Galstyan A Holler E Ljubimova JY Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain J. Control. Release 2020 320 45 62 31923537
Israel, L. L., Galstyan, A., Holler, E. & Ljubimova, J. Y. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. J. Control. Release 320, 45–62 (2020).31923537
326. Dadfar SM Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications Adv. Drug Deliv. Rev. 2019 138 302 325 30639256
Dadfar, S. M. et al. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 138, 302–325 (2019).30639256
327. Cardoso VF Advances in magnetic nanoparticles for biomedical applications Adv. Healthc. Mater. 2018 7 1700845
Cardoso, V. F. et al. Advances in magnetic nanoparticles for biomedical applications. Adv. Healthc. Mater. 7, 1700845 (2018).
328. Rajamani USGRMP Biodistribution, clearance and morphological alterations of intravenously administered iron oxide nanoparticles in male wistar rats Int. J. Nanomed. 2019 14 9677 9692
Rajamani, U. S. G. R. M. P. Biodistribution, clearance and morphological alterations of intravenously administered iron oxide nanoparticles in male wistar rats. Int. J. Nanomed. 14, 9677–9692 (2019).
329. Qiao R Receptor-mediated delivery of magnetic nanoparticles across the blood–brain barrier ACS Nano 2012 6 3304 3310 22443607
Qiao, R. et al. Receptor-mediated delivery of magnetic nanoparticles across the blood–brain barrier. ACS Nano 6, 3304–3310 (2012).22443607
330. Enteshari Najafabadi R Kazemipour N Esmaeili A Beheshti S Nazifi S Using superparamagnetic iron oxide nanoparticles to enhance bioavailability of quercetin in the intact rat brain BMC Pharmacol. Toxicol. 2018 19 59 30253803
Enteshari Najafabadi, R., Kazemipour, N., Esmaeili, A., Beheshti, S. & Nazifi, S. Using superparamagnetic iron oxide nanoparticles to enhance bioavailability of quercetin in the intact rat brain. BMC Pharmacol. Toxicol. 19, 59 (2018).30253803
331. Aguilera G Carboxymethyl cellulose coated magnetic nanoparticles transport across a human lung microvascular endothelial cell model of the blood–brain barrier Nanoscale Adv. 2019 1 671 685 36132237
Aguilera, G. et al. Carboxymethyl cellulose coated magnetic nanoparticles transport across a human lung microvascular endothelial cell model of the blood–brain barrier. Nanoscale Adv. 1, 671–685 (2019).36132237
332. Nosrati H Glutathione (GSH) peptide conjugated magnetic nanoparticles as blood–brain barrier shuttle for MRI-monitored brain delivery of paclitaxel ACS Biomater. Sci. Eng. 2019 5 1677 1685
Nosrati, H. et al. Glutathione (GSH) peptide conjugated magnetic nanoparticles as blood–brain barrier shuttle for MRI-monitored brain delivery of paclitaxel. ACS Biomater. Sci. Eng. 5, 1677–1685 (2019).
333. Zhang Y Glioblastoma therapy using codelivery of cisplatin and glutathione peroxidase targeting siRNA from iron oxide nanoparticles ACS Appl. Mater. Interfaces 2020 12 43408 43421 32885649
Zhang, Y. et al. Glioblastoma therapy using codelivery of cisplatin and glutathione peroxidase targeting siRNA from iron oxide nanoparticles. ACS Appl. Mater. Interfaces 12, 43408–43421 (2020).32885649
334. Zhong Y Low-intensity focused ultrasound-responsive phase-transitional nanoparticles for thrombolysis without vascular damage: a synergistic nonpharmaceutical strategy ACS Nano 2019 13 3387 3403 30855938
Zhong, Y. et al. Low-intensity focused ultrasound-responsive phase-transitional nanoparticles for thrombolysis without vascular damage: a synergistic nonpharmaceutical strategy. ACS Nano 13, 3387–3403 (2019).30855938
335. Xu H-L Glioma-targeted delivery of a theranostic liposome integrated with quantum dots, superparamagnetic iron oxide, and cilengitide for dual-imaging guiding cancer surgery Adv. Healthc. Mater. 2018 7 1701130
Xu, H.-L. et al. Glioma-targeted delivery of a theranostic liposome integrated with quantum dots, superparamagnetic iron oxide, and cilengitide for dual-imaging guiding cancer surgery. Adv. Healthc. Mater. 7, 1701130 (2018).
336. Liu F Vessel-targeting nanoclovers enable noninvasive delivery of magnetic hyperthermia–chemotherapy combination for brain cancer treatment Nano Lett. 2021 21 8111 8118 34597054
Liu, F. et al. Vessel-targeting nanoclovers enable noninvasive delivery of magnetic hyperthermia–chemotherapy combination for brain cancer treatment. Nano Lett. 21, 8111–8118 (2021).34597054
337. Sukumar UK Intranasal delivery of targeted polyfunctional gold–iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide Biomaterials 2019 218 119342 31326657
Sukumar, U. K. et al. Intranasal delivery of targeted polyfunctional gold–iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials 218, 119342 (2019).31326657
338. Manzano M Vallet-Regí M Mesoporous silica nanoparticles for drug delivery Adv. Funct. Mater. 2020 30 1902634
Manzano, M. & Vallet-Regí, M. Mesoporous silica nanoparticles for drug delivery. Adv. Funct. Mater. 30, 1902634 (2020).
339. Kankala RK Nanoarchitectured structure and surface biofunctionality of mesoporous silica nanoparticles Adv. Mater. 2020 32 1907035
Kankala, R. K. et al. Nanoarchitectured structure and surface biofunctionality of mesoporous silica nanoparticles. Adv. Mater. 32, 1907035 (2020).
340. Mo J He L Ma B Chen T Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood–brain barrier ACS Appl. Mater. Interfaces 2016 8 6811 6825 26911360
Mo, J., He, L., Ma, B. & Chen, T. Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood–brain barrier. ACS Appl. Mater. Interfaces 8, 6811–6825 (2016).26911360
341. Díaz-García D Design of mesoporous silica nanoparticles for the treatment of amyotrophic lateral sclerosis (ALS) with a therapeutic cocktail based on leptin and pioglitazone ACS Biomater. Sci. Eng. 2022 8 4838 4849 36240025
Díaz-García, D. et al. Design of mesoporous silica nanoparticles for the treatment of amyotrophic lateral sclerosis (ALS) with a therapeutic cocktail based on leptin and pioglitazone. ACS Biomater. Sci. Eng. 8, 4838–4849 (2022).36240025
342. Kuang J iRGD modified chemo-immunotherapeutic banoparticles for enhanced ommunotherapy against glioblastoma Adv. Funct. Mater. 2018 28 1800025
Kuang, J. et al. iRGD modified chemo-immunotherapeutic banoparticles for enhanced ommunotherapy against glioblastoma. Adv. Funct. Mater. 28, 1800025 (2018).
343. Janjua TI Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma Nanoscale 2021 13 16909 16922 34533167
Janjua, T. I. et al. Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma. Nanoscale 13, 16909–16922 (2021).34533167
344. Sun A Protective effect of lipoic acid modification on brain dysfunctions of mice induced by mesoporous silica nanoparticles Chem. Eng. J. 2021 415 128957
Sun, A. et al. Protective effect of lipoic acid modification on brain dysfunctions of mice induced by mesoporous silica nanoparticles. Chem. Eng. J. 415, 128957 (2021).
345. Zhu J Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB Biochem. Biophys. Res. Commun. 2021 534 902 907 33162028
Zhu, J. et al. Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB. Biochem. Biophys. Res. Commun. 534, 902–907 (2021).33162028
346. Singh AK Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation ACS Biomater. Sci. Eng. 2021 7 3737 3753 34297529
Singh, A. K. et al. Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation. ACS Biomater. Sci. Eng. 7, 3737–3753 (2021).34297529
347. Wu M MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma Nat. Commun. 2018 9 4777 30429468
Wu, M. et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat. Commun. 9, 4777 (2018).30429468
348. Liu N Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism Theranostics 2022 12 6646 6664 36185606
Liu, N. et al. Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism. Theranostics 12, 6646–6664 (2022).36185606
349. Turan O Treatment of glioblastoma using multicomponent silica nanoparticles Adv. Ther. 2019 2 1900118
Turan, O. et al. Treatment of glioblastoma using multicomponent silica nanoparticles. Adv. Ther. 2, 1900118 (2019).
350. Liu J Liew SS Wang J Pu K Bioinspired and biomimetic delivery platforms for cancer vaccines Adv. Mater. 2022 34 2103790
Liu, J., Liew, S. S., Wang, J. & Pu, K. Bioinspired and biomimetic delivery platforms for cancer vaccines. Adv. Mater. 34, 2103790 (2022).
351. Chang M Nanobiomimetic medicine Adv. Funct. Mater. 2022 32 2204791
Chang, M. et al. Nanobiomimetic medicine. Adv. Funct. Mater. 32, 2204791 (2022).
352. Chen L Recent progress in targeted delivery vectors based on biomimetic nanoparticles Signal Transduct. Target. Ther. 2021 6 225 34099630
Chen, L. et al. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct. Target. Ther. 6, 225 (2021).34099630
353. Hu CMJ Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform Proc. Natl Acad. Sci. USA 2011 108 10980 10985 21690347
Hu, C. M. J. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980–10985 (2011).21690347
354. Zhang Y Sun T Jiang C Biomacromolecules as carriers in drug delivery and tissue engineering Acta Pharm. Sin. B 2018 8 34 50 29872621
Zhang, Y., Sun, T. & Jiang, C. Biomacromolecules as carriers in drug delivery and tissue engineering. Acta Pharm. Sin. B 8, 34–50 (2018).29872621
355. Tran PHL Exosomes and nanoengineering: a match made for orecision therapeutics Adv. Mater. 2020 32 1904040
Tran, P. H. L. et al. Exosomes and nanoengineering: a match made for orecision therapeutics. Adv. Mater. 32, 1904040 (2020).
356. Edwardson TGW Hilvert D Virus-inspired function in engineered protein cages J. Am. Chem. Soc. 2019 141 9432 9443 31117660
Edwardson, T. G. W. & Hilvert, D. Virus-inspired function in engineered protein cages. J. Am. Chem. Soc. 141, 9432–9443 (2019).31117660
357. Herrmann IK Wood MJA Fuhrmann G Extracellular vesicles as a next-generation drug delivery platform Nat. Nanotechnol. 2021 16 748 759 34211166
Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021).34211166
358. Li Z Chemically and biologically engineered bacteria-based delivery systems for emerging diagnosis and advanced therapy Adv. Mater. 2021 33 2102580
Li, Z. et al. Chemically and biologically engineered bacteria-based delivery systems for emerging diagnosis and advanced therapy. Adv. Mater. 33, 2102580 (2021).
359. Gregory JV Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy Nat. Commun. 2020 11 5687 33173024
Gregory, J. V. et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat. Commun. 11, 5687 (2020).33173024
360. Galstyan A Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy Nat. Commun. 2019 10 3850 31462642
Galstyan, A. et al. Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat. Commun. 10, 3850 (2019).31462642
361. Yang T Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer AAPS J. 2017 19 475 486 27882487
Yang, T. et al. Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer. AAPS J. 19, 475–486 (2017).27882487
362. Wang J Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy Biomaterials 2021 273 120784 33848731
Wang, J. et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomaterials 273, 120784 (2021).33848731
363. Song Y M2 microglia-derived exosomes protect the mouse brain from ischemia-reperfusion injury via exosomal miR-124 Theranostics 2019 9 2910 2923 31244932
Song, Y. et al. M2 microglia-derived exosomes protect the mouse brain from ischemia-reperfusion injury via exosomal miR-124. Theranostics 9, 2910–2923 (2019).31244932
364. Xue J Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence Nat. Nanotechnol. 2017 12 692 700 28650441
Xue, J. et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 12, 692–700 (2017).28650441
365. Hou J Accessing neuroinflammation sites: monocyte/neutrophil-mediated drug delivery for cerebral ischemia Sci. Adv. 2019 5 eaau8301 31531392
Hou, J. et al. Accessing neuroinflammation sites: monocyte/neutrophil-mediated drug delivery for cerebral ischemia. Sci. Adv. 5, eaau8301 (2019).31531392
366. Lu G Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma Nat. Commun. 2022 13 4214 35864093
Lu, G. et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat. Commun. 13, 4214 (2022).35864093
367. Jia Y Phototheranostics: active targeting of orthotopic glioma using biomimetic oroteolipid nanoparticles ACS Nano 2019 13 386 398 30576599
Jia, Y. et al. Phototheranostics: active targeting of orthotopic glioma using biomimetic oroteolipid nanoparticles. ACS Nano 13, 386–398 (2019).30576599
368. Geng X Active-targeting NIR-II phototheranostics in multiple tumor models using platelet-camouflaged nanoprobes ACS Appl. Mater. Interfaces 2020 12 55624 55637 33269904
Geng, X. et al. Active-targeting NIR-II phototheranostics in multiple tumor models using platelet-camouflaged nanoprobes. ACS Appl. Mater. Interfaces 12, 55624–55637 (2020).33269904
369. Ye Z Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme ACS Appl. Mater. Interfaces 2018 10 12341 12350 29564886
Ye, Z. et al. Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme. ACS Appl. Mater. Interfaces 10, 12341–12350 (2018).29564886
370. Ge X Xia Z Guo S Recent advances on black phosphorus for biomedicine and biosensing Adv. Funct. Mater. 2019 29 1900318
Ge, X., Xia, Z. & Guo, S. Recent advances on black phosphorus for biomedicine and biosensing. Adv. Funct. Mater. 29, 1900318 (2019).
371. Xiong S Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson’s disease Biomaterials 2020 260 120339 32861017
Xiong, S. et al. Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson’s disease. Biomaterials 260, 120339 (2020).32861017
372. Yang S The colossal role of H-MnO2-PEG in ischemic stroke Nanomed. -Nanotechnol. 2021 33 102362
Yang, S. et al. The colossal role of H-MnO2-PEG in ischemic stroke. Nanomed. -Nanotechnol. 33, 102362 (2021).
373. Gao Y NIR-assisted MgO-based polydopamine nanoparticles for targeted treatment of Parkinson’s disease through the blood-brain barrier Adv. Healthc. Mater. 2022 11 e2201655 36153843
Gao, Y. et al. NIR-assisted MgO-based polydopamine nanoparticles for targeted treatment of Parkinson’s disease through the blood-brain barrier. Adv. Healthc. Mater. 11, e2201655 (2022).36153843
374. Li M Synthesis of double interfering biodegradable nano-MgO micelle composites and their effect on Parkinson’s disease ACS Biomater. Sci. Eng. 2021 7 1216 1229 33560819
Li, M. et al. Synthesis of double interfering biodegradable nano-MgO micelle composites and their effect on Parkinson’s disease. ACS Biomater. Sci. Eng. 7, 1216–1229 (2021).33560819
375. Feng L TiO2-nanowired delivery of DL-3-n-butylphthalide (DL-NBP) attenuates blood-brain barrier disruption, brain edema formation, and neuronal damages following concussive head injury Mol. Neurobiol. 2018 55 350 358 28856586
Feng, L. et al. TiO2-nanowired delivery of DL-3-n-butylphthalide (DL-NBP) attenuates blood-brain barrier disruption, brain edema formation, and neuronal damages following concussive head injury. Mol. Neurobiol. 55, 350–358 (2018).28856586
376. Zou Y Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy Sci. Adv. 2022 8 eabm8011 35442747
Zou, Y. et al. Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci. Adv. 8, eabm8011 (2022).35442747
377. Lerman MJ Lembong J Gillen G Fisher JP 3D printing in cell culture systems and medical applications Appl. Phys. Rev. 2018 5 041109 32550961
Lerman, M. J., Lembong, J., Gillen, G. & Fisher, J. P. 3D printing in cell culture systems and medical applications. Appl. Phys. Rev. 5, 041109 (2018).32550961
378. Jagtiani E Yeolekar M Naik S Patravale V In vitro blood brain barrier models: an overview J. Control. Release 2022 343 13 30 35026351
Jagtiani, E., Yeolekar, M., Naik, S. & Patravale, V. In vitro blood brain barrier models: an overview. J. Control. Release 343, 13–30 (2022).35026351
379. Wu J Wang C Sun J Xue Y Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways ACS Nano 2011 5 4476 4489 21526751
Wu, J., Wang, C., Sun, J. & Xue, Y. Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways. ACS Nano 5, 4476–4489 (2011).21526751
380. Arami H Khandhar A Liggitt D Krishnan KM In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles Chem. Soc. Rev. 2015 44 8576 8607 26390044
Arami, H., Khandhar, A., Liggitt, D. & Krishnan, K. M. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem. Soc. Rev. 44, 8576–8607 (2015).26390044
381. Wang X Zhong X Li J Liu Z Cheng L Inorganic nanomaterials with rapid clearance for biomedical applications Chem. Soc. Rev. 2021 50 8669 8742 34156040
Wang, X., Zhong, X., Li, J., Liu, Z. & Cheng, L. Inorganic nanomaterials with rapid clearance for biomedical applications. Chem. Soc. Rev. 50, 8669–8742 (2021).34156040
382. Boehnke N Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery Science 2022 377 eabm5551 35862544
Boehnke, N. et al. Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery. Science 377, eabm5551 (2022).35862544
383. Zhu Y Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy J. Control. Release 2021 330 641 657 33359582
Zhu, Y. et al. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. J. Control. Release 330, 641–657 (2021).33359582
384. dos Santos Rodrigues B Oue H Banerjee A Kanekiyo T Singh J Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection J. Control. Release 2018 286 264 278 30071253
dos Santos Rodrigues, B., Oue, H., Banerjee, A., Kanekiyo, T. & Singh, J. Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection. J. Control. Release 286, 264–278 (2018).30071253
385. Xu S Modulating autophagic flux via ROS-responsive targeted micelles to restore neuronal proteostasis in Alzheimer’s disease Bioact. Mater. 2022 11 300 316 34977433
Xu, S. et al. Modulating autophagic flux via ROS-responsive targeted micelles to restore neuronal proteostasis in Alzheimer’s disease. Bioact. Mater. 11, 300–316 (2022).34977433
386. Yang P Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer’s disease Biomaterials 2020 238 119844 32062148
Yang, P. et al. Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer’s disease. Biomaterials 238, 119844 (2020).32062148
387. Chen T Small-sized mPEG–PLGA nanoparticles of schisantherin A with sustained release for enhanced brain uptake and anti-Parkinsonian activity ACS Appl. Mater. Interfaces 2017 9 9516 9527 28247754
Chen, T. et al. Small-sized mPEG–PLGA nanoparticles of schisantherin A with sustained release for enhanced brain uptake and anti-Parkinsonian activity. ACS Appl. Mater. Interfaces 9, 9516–9527 (2017).28247754
388. Song E Surface chemistry governs cellular tropism of nanoparticles in the brain Nat. Commun. 2017 8 15322 28524852
Song, E. et al. Surface chemistry governs cellular tropism of nanoparticles in the brain. Nat. Commun. 8, 15322 (2017).28524852
389. Sánchez-López E Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization J. Nanobiotechnol. 2018 16 32
Sánchez-López, E. et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization. J. Nanobiotechnol. 16, 32 (2018).
390. Temizyürek A Blood-brain barrier targeted delivery of lacosamide-conjugated gold nanoparticles: Improving outcomes in absence seizures Epilepsy Res. 2022 184 106939 35785634
Temizyürek, A. et al. Blood-brain barrier targeted delivery of lacosamide-conjugated gold nanoparticles: Improving outcomes in absence seizures. Epilepsy Res. 184, 106939 (2022).35785634
391. Yi Y Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells J. Control. Release 2019 295 268 277 30639386
Yi, Y. et al. Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells. J. Control. Release 295, 268–277 (2019).30639386
392. Coluccia D Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound Nanomedicine 2018 14 1137 1148 29471172
Coluccia, D. et al. Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine 14, 1137–1148 (2018).29471172
393. Guo Q Shen X-T Li Y-Y Xu S-Q Carbon nanotubes-based drug delivery to cancer and brain Curr. Med. Sci. 2017 37 635 641
Guo, Q., Shen, X.-T., Li, Y.-Y. & Xu, S.-Q. Carbon nanotubes-based drug delivery to cancer and brain. Curr. Med. Sci. 37, 635–641 (2017).
394. Ren J The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2 Biomaterials 2012 33 3324 3333 22281423
Ren, J. et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33, 3324–3333 (2012).22281423
395. Hsieh T-Y Neurotensin-conjugated reduced graphene oxide with multi-stage near-infrared-triggered synergic targeted neuron gene transfection In vitro and in vivo for neurodegenerative disease therapy Adv. Healthc. Mater. 2016 5 3016 3026 27805786
Hsieh, T.-Y. et al. Neurotensin-conjugated reduced graphene oxide with multi-stage near-infrared-triggered synergic targeted neuron gene transfection In vitro and in vivo for neurodegenerative disease therapy. Adv. Healthc. Mater. 5, 3016–3026 (2016).27805786
396. Bielecki PA Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors Nanoscale Horiz. 2021 6 156 167 33400743
Bielecki, P. A. et al. Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors. Nanoscale Horiz. 6, 156–167 (2021).33400743
397. Niu W A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy Nano Lett. 2021 21 1484 1492 33475372
Niu, W. et al. A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy. Nano Lett. 21, 1484–1492 (2021).33475372
398. He W Preferential targeting cerebral ischemic lesions with cancer cell-inspired nanovehicle for ischemic stroke treatment Nano Lett. 2021 21 3033 3043 33755480
He, W. et al. Preferential targeting cerebral ischemic lesions with cancer cell-inspired nanovehicle for ischemic stroke treatment. Nano Lett. 21, 3033–3043 (2021).33755480
399. Wang C Camouflaging nanoparticles with brain metastatic tumor cell membranes: a new strategy to traverse blood–brain barrier for imaging and therapy of brain tumors Adv. Funct. Mater. 2020 30 1909369
Wang, C. et al. Camouflaging nanoparticles with brain metastatic tumor cell membranes: a new strategy to traverse blood–brain barrier for imaging and therapy of brain tumors. Adv. Funct. Mater. 30, 1909369 (2020).
400. Alvarez-Erviti L Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat. Biotechnol. 2011 29 341 345 21423189
Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).21423189
401. El-Andaloussi S Exosome-mediated delivery of siRNA in vitro and in vivo Nat. Protoc. 2012 7 2112 2126 23154783
El-Andaloussi, S. et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7, 2112–2126 (2012).23154783
402. Yang C Glioma-derived exosomes hijack the blood-brain barrier to facilitate nanocapsule delivery via LCN2 J. Control. Release 2022 345 537 548 35341902
Yang, C. et al. Glioma-derived exosomes hijack the blood-brain barrier to facilitate nanocapsule delivery via LCN2. J. Control. Release 345, 537–548 (2022).35341902
403. Xu F Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer’s disease treatment Adv. Mater. 2022 34 e2207107 36193769
Xu, F. et al. Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer’s disease treatment. Adv. Mater. 34, e2207107 (2022).36193769
404. Kojima R Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment Nat. Commun. 2018 9 1305 29610454
Kojima, R. et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat. Commun. 9, 1305 (2018).29610454
405. Yuan D Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain Biomaterials 2017 142 1 12 28715655
Yuan, D. et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 142, 1–12 (2017).28715655
406. Tian T Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy Biomaterials 2018 150 137 149 29040874
Tian, T. et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials 150, 137–149 (2018).29040874
407. Cheng G “Swiss Army Knife” black phosphorus-based nanodelivery platform for synergistic antiparkinsonian therapy via remodeling the brain microenvironment J. Control. Release 2023 353 752 766 36526020
Cheng, G. et al. “Swiss Army Knife” black phosphorus-based nanodelivery platform for synergistic antiparkinsonian therapy via remodeling the brain microenvironment. J. Control. Release 353, 752–766 (2023).36526020
408. Li Z Neodymium (3+)-coordinated black phosphorus quantum dots with retrievable NIR/X-Ray pptoelectronic switching effect for anti-glioblastoma Small 2022 18 e2105160 34821027
Li, Z. et al. Neodymium (3+)-coordinated black phosphorus quantum dots with retrievable NIR/X-Ray pptoelectronic switching effect for anti-glioblastoma. Small 18, e2105160 (2022).34821027
